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Summary/Abstract 
Members of the CUL4-RBX1-DDB1 (CRL4) E3 ubiquitin ligase family 
regulate multiple cellular processes including development, transcription, and 
DNA repair. CRL4 type ligases are modularly assembled with specialized 
substrate receptors (DCAFs), which recruit a specific substrate and thereby 
confer specificity. Tight regulation of the versatile CRL4 network is crucial to 
maintain the integrity of important cellular pathways, as deregulation and 
mutations are often associated with human disease and cancer. A number of 
regulatory factors for the CRL system have been identified, including the 
COP9 signalosome (CSN), which has emerged as the major cullin regulator. 
CSN is a large protease that cleaves the isopeptide bond between a cullin 
and the ubiquitin-like modifier Nedd8, thereby controlling CRL4 activity. 
 
One of the best characterized DCAFs is the DNA damage binding protein 2 
(DDB2), which, as part of the CRL4DDB2 ligase, orchestrates the initial steps of 
nucleotide excision repair (NER). In the first part of my thesis, I applied 
structural, biochemical and functional methods to elucidate the molecular 
architecture, targeting, and regulation of this important ligase complex. I 
demonstrate that CRL4DDB2 is recruited to UV-induced lesions in chromatin 
and provide the structures of the fully assembled CUL4A/B-RBX1-DDB1-
DDB2 ligase complexes bound to damaged DNA substrates. These studies 
reveal the intrinsic mobility of the ligase arm that creates an ubiquitination 
zone around the substrate binding site. The distance observed between the 
E2 binding site and the DNA binding site, together with the mobility of the 
ligase, preclude direct ligase activation through DNA damage binding. 
Instead, we found that CSN mediates CRL4DDB2 inhibition in a CSN5 
independent fashion and this inhibition is relieved upon the binding of 
damaged DNA to the DDB2 receptor. We show that the CRL4CSA ligase, 
involved in transcription coupled repair, shares common architectural features 
with CRL4DDB2. And that the CSB protein substrate is sufficient to relieve CSN 
mediated CRL4CSA inhibition. Our data argues in favor of a general 
mechanism in which CRL4DCAF(WD40) ligases are inhibited by CSN, and in turn, 
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activation of the ligase is induced by substrate binding to, together with CSN 
displacement from, the ligase.  
 
The ubiquitin proteasome system (UPS) controls timely degradation of 
short-lived proteins, including prominent oncogenes and tumor suppressors 
such as p53, β-catenin or c-myc. Targeting the UPS has emerged as a 
promising anti-cancer strategy and the FDA approval of bortezomib as the 
“first in class” proteasome inhibitor reflects this. However, global inhibition of 
the proteasome induces dramatic effects on protein homeostasis and high 
levels of cell toxicity, promoting efforts to target the UPS upstream of the 
proteasome, particularly through specific CRLs. 
Despite being known to cause multiple birth defects, thalidomide 
(contergan) and its more potent derivative lenalidomide (revlimid) are FDA 
approved and widely used in the treatment of multiple myeloma. While the 
more recent discovery of the CRL4CRBN ubiquitin ligase as a primary cellular 
target of thalidomide has been a milestone in understanding thalidomide 
teratogenicity, a detailed molecular understanding of thalidomide action 
remains to be elucidated. In the second part of my thesis, I provide the X-ray 
structure of the DDB1-CRBN heterodimer in complex with the small molecule 
inhibitors thalidomide, lenalidomide and pomalidomide. The structure provides 
a molecular rationale for thalidomide action and, for the first time, a structural 
rationale for specifically targeting a CRL4 E3 ubiquitin ligase. 
. 
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Chapter 1: General Introduction 
The spatiotemporally regulated degradation of proteins by posttranslational 
modification with ubiquitin is an essential and ubiquitous eukaryotic process, 
discovered in the early 1980s (Ciechanover et al., 1980; Hershko et al., 1980). 
Ubiquitin emerged as an important posttranslational modification throughout 
virtually all cellular processes, with the number of ubiquitin conjugating 
enzymes surpassing the diversity observed for kinases (de Bie and 
Ciechanover, 2011). Moreover, it has become evident that cellular protein 
turnover is a wide spread, highly specific and regulated process. Cullin-RING 
E3 ligase (CRL) form the largest superfamily of ubiquitin E3 ligases and play 
central roles in virtually all cellular processes, including the early steps of 
mammalian nucleotide excision repair (NER) (Sugasawa et al., 2005). The 
enzymatic principles of ubiquitin transfer by Cullin-RING ubiquitin ligases 
(CRL) are well understood, while a detailed understanding of regulatory 
mechanisms is still emerging. Regulators of CRL ligases have been 
discovered and studied, including the COP9 signalosome (CSN), a master 
regulator of cullins, yet little is known about its ability to differentially regulate 
the multitude of cullins present in cells. 
We studied the detailed molecular architecture of the CUL4A/B-RBX1-
DDB1-DDB2 (CRL4DDB2) ubiquitin ligase complex examining the molecular 
basis underlying its targeting to damaged DNA and CSN mediated regulation. 
We employed structural, biochemical and cellular approaches to elucidate the 
mechanism of CRL4DDB2 activation. We further studied the related CRL4CSA 
ubiquitin ligase, which binds to a protein substrate instead of DNA, to 
understand the generality of the observed findings. 
Thalidomide, a drug with a long and tragic history, has been identified as 
targeting the cereblon protein (CRBN), which is part of the CRL4CRBN ubiquitin 
ligase complex. In the second part of my thesis I worked towards a structural 
and functional understanding of this “prototype” CRL4 ligase inhibitor. 
The following general introduction will provide background information on 
the ubiquitin proteasome system (UPS) with a focus on cullin-RING ligases. I 
will also provide an overview of the CRL4 ligase family and finally describe 
current efforts to modulate the CRL system. 
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A detailed introduction to the CRL4DDB2 and CRL4CSA ligase complexes, 
their role in nucleotide excision repair (NER) and further roles of CRL4s can 
be found in Chapter 2: Detecting UV-lesions in the genome: The modular 
CRL4 ubiquitin ligase does it best (published manuscript). 
 
The Ubiquitin Proteasome System 
The peptide bond as the backbone of proteins is of remarkable stability: the 
spontaneous hydrolysis of a single bond in a polypeptide chain is anticipated 
to occur with a half-life of several hundred years under physiological 
conditions (Wolfenden and Snider, 2001). While, in general, the stability of 
proteins is desirable, cells need mechanisms for the controlled turnover of 
proteins to allow regulation, or quality control. This is achieved by proteases, 
which catalyze the reaction of a nucleophilic attack, where the nucleophile is 
either a amino acid or a water molecule, on the peptide bond and are rarely 
energy dependent due to the thermodynamically favorable reaction that they 
catalyze. Efforts to understand the energy dependence of intracellular 
proteolysis lead to the discovery of ubiquitin as a 76 amino acid polypeptide 
that is, via energy dependence, joined to the acceptor lysine of a substrate 
through an isopeptide bond (Ciehanover et al., 1978; Ciechanover et al., 
1980; Hershko et al., 1980; Hershko and Ciechanover, 1998). The transfer of 
ubiquitin to the substrate, termed ubiquitination or ubiquitylation, occurs as a 
sequential reaction catalyzed by the ubiquitin activating (E1), the ubiquitin 
conjugating (E2) and the ubiquitin ligase (E3) enzymes (Hershko et al., 1983), 
poly-ubiquitination can than lead to recruitment of the 26S proteasome and 
ATP dependent degradation. Since the first discovery of ubiquitin, it has 
become evident that proteolysis of cellular proteins is a complex, timed, and 
tightly regulated process and that the ubiquitin proteasome system (UPS) 
accounts for the majority of cellular protein turnover. As of today, we know 
that ubiquitination is not solely a signal for degradation, but also plays 
important roles in signaling, mediating protein-protein interactions, or as an 
epigenetic mark. In fact, histone H2A was the first protein discovered to be 
modified by ubiquitin through an isopeptide bond (Goldknopf et al., 1975), 
while preceding the groundbreaking discovery of the UPS by Nobel laureates 
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Aaron Ciechanover, Avram Hershko and Irwin Rose. Moreover, work in the 
early 1980s on a temperature-sensitive mouse cell line, ts85, provided 
evidence that the UPS is the principal mechanism for controlled turnover of 
short-lived proteins (Marunouchi et al., 1980; Ciechanover et al., 1984; Finley 
et al., 1984), as well providing an initial link to cell cycle control. The role of 
ubiquitin dependent cyclin turnover, together with numerous other important 
cellular processes, is now a well-established functional role of the UPS. 
 
 
Figure 1.1: The Ubiquitin Proteasome System: The cascade of enzymatic reactions in the 
Ubiquitin Proteasome System (Hershko and Ciechanover, 1998).  
 
Ubiquitin and ubiquitin conjugation: Thioester chemistry 
Ubiquitin is one of the most highly conserved eukaryotic proteins, with only 
three amino acid substitutions from yeast to man (Ozkaynak et al., 1984). 
Mammals have four genes that encode for the ubiquitin polypeptide, and 
ubiquitin is either expressed as a precursor of four (Ubb gene) or nine (Ubc 
gene) ubiquitins in one polypeptide chain in a head-to-tail arrangement, or as 
a fusion to the ribosomal subunits UBL40 and UBS27 (Kimura and Tanaka, 
2010). Proteolytic cleavage is required to generate functional monomeric 
ubiquitin with a C-terminal glycine residue that then can be, through the 
catalytic activity of the E1 enzyme, adenylated, resulting in an acyl-phosphate 
linkage with AMP (Figure 1.1). The ubiquitin-AMP is then attacked by the 
catalytic cysteine of the E1 enzyme and a thioester linkage is formed between 
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the E1 Cysteine and the C-terminus of ubiquitin, releasing AMP (Lee and 
Schindelin, 2008). The thioester-bound ubiquitin is then, by trans-
thioesterification, transferred to the catalytic cysteine of an E2 enzyme. The 
last step of the cascade is catalyzed by an E3 enzyme and transfers the 
ubiquitin from the E2 cysteine to the ε-amino group of an acceptor lysine in 
the target protein. The increasing number and specialization of enzymes 
provides substrate specificity throughout the ubiquitin cascade, the ubiquitin 
E1s, UBA1 and UBA6, are responsible for ubiquitin activation, tens of E2 
enzymes and hundreds of E3’s confer substrate specificity. Ubiquitin does not 
only attach to an acceptor lysine in the target protein, but can also be targeted 
to one of the seven lysines within another ubiquitin, leading to the formation of 
a poly-ubiquitin chain. Chain formation can occur as a homogenous chain 
linked through seven acceptor lysines, while more complex structures such as 
branched chains and linear chain formation (involving the N-terminus of an 
acceptor ubiquitin) have also been described (Komander and Rape, 2012). 
The linkage of a poly-ubiquitin chain determines the fate of the substrate 
protein: Lys48-linked chains of sufficient length have been associated with 
proteasomal degradation, while Lys63-linked chains have generally been 
associated with non-proteasome-related functions, such as protein trafficking 
or signaling. Less is known about linear chains involved in NF-κB signaling 
(Walczak et al., 2012), Lys11 linked chains associated with the Anaphase 
Promoting Complex/Cyclosome (APC/C) (Jin et al., 2008), and much less 
about other linkages or more complex structures. Despite the formation of 
poly-ubiquitin chains, mono-ubiquitination occurs at defined acceptor lysines, 
such as PRC1 mediated ubiquitination of histone H2A (Lys119), and plays 
important roles throughout cellular processes. 
Substrate specificity and chain formation are commonly determined by the 
nature of the E3 ligase and may be influenced by the E2 conjugating enzyme.  
 
E3 Ligases: Two major families 
E3 ligases deliver the substrate lysine at close proximity to the ubiquitin 
loaded E2, thereby facilitating the transfer of the ubiquitin to the acceptor 
lysine. E3 ligases do not share a common architecture, but exist as single 
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proteins or multi-protein complexes; some participate in the ubiquitination 
reaction by transiently interacting with the ubiquitin, while others never 
physically interact with ubiquitin. This variety makes it hard to identify ubiquitin 
E3 ligases based on sequence homology. The precise number of these 
ligases in humans is still unknown but expected to exceed the roughly 500 
protein kinases present in the human genome (Deshaies and Joazeiro, 2009). 
In the following paragraphs I will provide an overview of the two major 
ubiquitin E3 ligase families. 
 
HECT E3 ligase 
HECT (Homologues to E6AP C-terminus) domain containing ubiquitin E3s are 
unique among the ubiquitin ligases, as they involve thioester-intermediates 
between the catalytic Cysteine of the HECT domain and the C-terminus of 
ubiquitin prior to transfer to the acceptor lysine (Dye and Schulman, 2007). 
HECT E3 ligases have evolved to facilitate the formation of poly-ubiquitin 
chains such as K48-linked (E6AP), and K29-linked (KIAA10), while also 
directly monoubiquitinating a specific substrate (Rsp5). In mammals, there are 
roughly 30 HECT domain ubiquitin ligases, and the conserved HECT domain 
is usually located at the C-terminus, while the N-terminus is commonly 
involved in substrate binding. The HECT domain itself consists of a bi-loped 
structure (Figure 1.2), where the N-terminal domain contacts the E2, and the 
C-terminal domain contains the reactive cysteine (Huang et al., 1999). In 
contrast to the HECT domain E3 ligases, RING domain containing E3 ligases 
represent the largest family of E3 ligases, and their activity does not involve a 
direct interaction with ubiquitin. 
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Figure 1.2: Crystal structure of the HECT E3 ligase E6AP complexed to UbcH7. (A and 
B) The C-lobe, depicted in green, and the N-lobe in red, of the HECT E3 ligase (E6AP) in 
conjunction with the ubiquitin E2 (UbcH7) in blue, all of which form a U-shaped structure. The 
active site cysteines are depicted in yellow (Huang et al., 200). From a comparison of multiple 
HECT-containing structures, a hinge point between the C- and N-lope has been anticipated 
and is thought to position the active site cysteine. 
 
RING type E3 ligases 
RING ubiquitin ligases represent the largest family of E3 ligases. Several 
hundred human genes encode for members of this ligase family (Deshaies 
and Joazeiro, 2009). The protein Ring1 (Really interesting new gene 1) has 
been the eponym for the family, and the first to be described as a RING 
domain containing protein. It then took several years to establish the role of 
the RING motif as a crucial part of the ubiquitin ligase. Many important 
concepts of the RING domain function have been established through the 
discovery and characterization of Rbx1, as ubiquitin ligase activity bearing 
part of the Skp1-Cullin-F-box (SCF) ubiquitin ligase complex (Kamura et al., 
1999; Ohta et al., 1999; Seol et al., 1999; Tan et al., 1999). Moreover, the 
functional (Joazeiro et al., 1999) as well as structural studies (Zheng et al., 
2000) on c-Cbl RING mediated ubiquitin ligase activity deepened the 
understanding of the RING motif, containing the ubiquitin ligase function. 
Unlike HECT domain proteins, the ubiquitin ligase activity of RING proteins is 
comprised of binding to and the activation of an E2 conjugating enzyme 
without the intermediate transfer of the ubiquitin to the ligase. The canonical 
RING domain is defined by two zinc ions coordinated by eight conserved 
cysteine or histidine residues (Dye and Schulman, 2007), while numerous 
variations exist (Deshaies and Joazeiro, 2009). 
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RING domain E3 ligases have been implicated in regulating a variety of 
cellular processes, including cell cycle progression, signal transduction, DNA 
repair and replication, and even viral infections. RING finger ligases exist as 
monomeric enzymes that, in the case of c-Cbl with a Src-homology 2 (SH2) 
domain, bind directly the substrate, and with the RING finger domain the E2 
enzyme (Zheng et al., 2000). In contrast, the RING finger proteins can also be 
part of large multi-protein ubiquitin ligase complexes, such as the 1.5 MDa 
Anaphase Promoting Complex/Cyclosome (APC/C), where the RING finger 
protein Apc11 is required for ubiquitin ligase activity (Thornton and Toczyski, 
2006). While the work on SCF has significantly contributed to the 
understanding of RING finger mediated ubiquitination, SCF has also been the 
founding member for the largest group of ubiquitin ligases: the Cullin-RING 
ubiquitin ligase (CRL) superfamily. 
 
 
Figure 1.3: Modular architecture of the cullin-RING ligase family. Canonical Cullin-RING 
ligases share a general architecture consisting of the scaffolding Cullin protein (Cul1-5), the 
small RING finger protein comprising the E2 binding site (Rbx1,2) and either a adaptor 
protein (Skp1, EloB/C, and DDB1) in conjunction with a substrate receptor (F-box, BC/SOCS-
box, and DCAF) or a BTB protein conferring substrate specificity (O’Connel and Harper, 
2007). 
 
Cullin-RING Ligases 
The superfamily of Cullin-RING ubiquitin ligases (CRL) represents the 
largest group of E3 ligases (Petroski and Deshaies, 2005), where the highly 
conserved cullin protein family contributes, as a scaffold protein that binds the 
small RING finger protein Rbx1 (Kamura et al., 1999; Ohta et al., 1999; Seol 
et al., 1999; Tan et al., 1999), to the assembly of as many as 400 distinct 
CRLs. The human genome codes for six canonical cullin proteins, Cul1, Cul2, 
Cul3, Cul4A, Cul4B, and Cul5 that, in conjunction with the RING finger 
proteins Rbx1 and Rbx2, provide the backbone for different subfamilies of 
CRLs, CRL1-5 (Figure 1.3). The genes Cul7, PARC, and the Apc2 subunit of 
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the APC/C share a homology domain with the canonical cullins but differ 
elsewhere, and are considered atypical cullins (Zachariae et al., 1998; Skaar 
et al., 2007). The overall assembly of CRLs follows a common scheme; the 
cullin protein binds with its C-terminus, the RING protein, and with its N-
terminus interacts either, as in the case of Cul3, directly with a substrate 
receptor protein (BTP protein), or for CRL1, 2, 4 and 5, an additional linker 
protein (Skp1, ElonginB/C or DDB1) connects the cullin with a specific 
substrate receptor protein. The substrate receptors are diverse and belong to 
specific families for every cullin: Cul1 associates with F-box proteins (>70 
different proteins), Cul2/5 with the BC-box (>50 different proteins), Cul3 with 
the BTB proteins (>200 different proteins) and Cul4A/B with the DCAF 
substrate receptor proteins (>30 different proteins) (Jackson and Xiong, 
2009). These substrate receptors confer specificity to the CRL and employ 
various protein-protein interaction domains to specifically bind to a substrate 
(Schulman et al., 2000; Hao et al., 2007; Scrima et al., 2008; Zhuang et al., 
2009). A prerequisite to recognition as a substrate is often a posttranslational 
modification, such as phosphorylation (Wu et al., 2003), hydroxylation (Min, 
2002) or methylation (Lee et al., 2012a).  
Figure 1.4: Comparison of Cullin to adaptor binding. A) overlay of the BTB domain from 
Elongin C (PDB: 1VCB), SPOP (PDB: 4EOZ) and Skp1 (PDB: 1LDK) colored in orange, 
magenta and blue, respectively, together with their respective Cul3 (SPOP) and Cul1 (Skp1) 
cullin colored in cyan and green, respectively. B) The BPB WD40 β-propeller domain of DDB1 
in magenta, bound to the N-terminal domain of Cul4A in gray (PDB: 2HYE). (Zheng et al., 
2002; Angers et al., 2006; Stebbins et al., 1999; Errington et al., 2012).  
 
The structure of the founding member of the CRL superfamily, SCFSkp2 
(Zheng et al., 2002) established an architectural and assembly logic to be 
found throughout the CRL family. The cullin forms a rigid arch-shaped scaffold 
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that, with a globular C-terminal domain, binds to Rbx1, while the elongated 
helical N-terminal domain binds to the adaptor protein Skp1 (Figure 1.5). In 
the structure of SCFSkp2, Skp1 is bound to the F-box motif of Skp2. Skp2 
mediates cell cycle progression by recruiting the Cdk inhibitor p27 for 
ubiquitination and subsequent degradation. The adaptor protein complex 
ElonginB/C shares sequence homology with Skp1 and serves as the common 
adaptor for CRL2 and CRL5 ligase complexes. Crystal structures revealed 
that Skp1 and ElonginC essentially consist of a Bric-a-brac, Tramtrack, and 
Broad complex (BTB) domain and that the substrate receptor family of BC-
box containing proteins is recruited to ElonginB/C, resulting in an overall 
structural assembly of CRL2/5 ligases similar to that of SCF (Zimmerman et 
al., 2010). Moreover, the CRL3 subfamily employs BTB family proteins that 
combine the role of a substrate receptor and adaptor protein but still share a 
structural homology in the way they interact with Cul3. Characteristic BTB 
family proteins employ MATH, Kelch or ZnF domains to mediate substrate 
binding, while dimerization has been observed as a common feature among 
BTB proteins (Zhuang et al., 2009; Canning et al., 2013). While CRL1, 2, 3 
and 5 all employ a BTB fold to mediate the binding of a cullin to the 
adaptor/substrate receptor complex, the adaptor of the CRL4 family is distinct 
and structurally unrelated (Figure 1.4). 
 
The CUL4 subfamily of CRLs 
In contrast to the rather small BTB motif that serves as the common 
structural entity within the adaptors for CRL1, 2, 3 and 5, CRL4 ligases 
employ the 127kDa Damaged DNA binding protein 1 (DDB1) as an adaptor to 
bridge Cul4 and the substrate receptors, so-called DCAFs for DDB1 and Cul4 
associated factors (Angers et al., 2006) (Figure 1.4).  
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Figure 1.5: Structure of SCFSkp2. A Model of the entire SCFSkp2 complex, depicted as ribbon 
diagram, was generated by superimposing the structures of SCFFbox(Skp2) (PDB: 1LDK) and 
Skp1-Skp2 (PDB: 1FQV). Cul1, Rbx1, Skp1 and Skp2 are colored in green, red, blue and 
magenta, respectively. (Zheng et al., 2000; Schulman et al., 2000).   
 
In addition to endogenous substrate receptors, viral proteins have been 
shown to bind to a Cul4 ligase and redirect it to degrade targets that would 
otherwise interfere with viral infection or function (Martin-Lluesma et al., 2008; 
Sharifi et al., 2012). The V protein of simian virus 5 (SV5v) has been found to 
recruit STAT proteins to the CRL4 ligase and drive the ubiquitination and 
degradation of STAT1 (Horvath, 2004), though the structure of the CUL4A-
RBX1-DDB1-SV5v complex provided the first insights into the molecular 
architecture of this CRL family (Angers et al., 2006) (Figure 1.6). The adaptor 
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protein DDB1 comprises three canonical 7-bladed WD40 β-propellers in a 
triangular shape (BPA-BPC), stabilized by a helical C-terminal domain (CTD) 
(Li et al., 2006). The interaction between Cul4 and DDB1 is mediated by the 
BPB domain of DDB1 and two N-terminal α-helices of Cul4, corresponding to 
those used by Cul1 to bind Skp1 (Angers et al., 2006). The NTD and large 
parts of the CTD of Cul4 resemble the overall structure of Cul1, while the 
winged-helix B (WHB) domain and the orientation of Rbx1 show structural 
differences (Zheng et al., 2002; Angers et al., 2006). Despite the lack of 
sequence or structural similarity between DDB1 and Skp1, the relative 
arrangement of Rbx1 to the substrate receptor is comparable, positioning 
Rbx1 and a putative substrate in a similar orientation. Angers et al. further 
identified a group of putative endogenous CRL4 substrate receptors, including 
DDB2 and CSA, which are largely characterized by a WD40 β-propeller and a 
DxR motif, and were named DCAF for DDB1 and Cul4 associated factors, 
further DCAF members were identified through numerous studies (Angers et 
al., 2006; Bennett et al., 2010; He et al., 2006; Higa et al., 2006; Jin et al., 
2006). In vitro binding experiments demonstrated that increasing amounts of 
purified SV5v protein could compete of the binding of an endogenous DCAF 
protein to DDB1, suggesting a competitive binding mode and similar 
interfaces used by SV5v and endogenous DCAFs. The structure of the first 
endogenous DCAF bound to DDB1, the DDB1-DDB2 protein complex (Scrima 
et al., 2008), detailed for the first time how an endogenous DCAF can bind to 
the DDB1 protein. Strikingly, it employs a helix-loop-helix motif to bind to the 
very same binding pocket in the cavity between the BPA and BPC domain of 
DDB1, as does the helical interacting motif of SV5v. The structure of DDB1-
DDB2 further revealed that, in addition to the HLH motif, and similar to SV5v, 
the DDB2 interaction with DDB1 is mediated through a hydrophobic surface 
patch (Scrima et al., 2008). Co-crystal structures of DDB1 with interacting 
peptides of the proteins HBx, WHX, WDTC1, DDB2, WDR21A, WDR22, 
IQWD1, H326 and WDR40 (Li et al., 2010) revealed that all characterized 
viral and endogenous DCAFs share a similar helical motif mediating 
interaction with DDB1. While these findings propose a common architecture 
(similar to that of DDB2) for DCAFs containing a WD40 β-propeller and a 
preceding helical binding motif, the precise structural constraints and 
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hallmarks are as yet unresolved. Moreover, prediction of helical motifs has not 
been possible for all DCAF proteins, and the questions of whether or not non-
WD40 DCAFs exist and how they might interact with DDB1 remain 
unanswered. 
Figure 1.6: Crystal structure of the CRL4SV5v protein complex. a,b) Rbx1, Cul4, DDB1 and 
SV5v are depicted as ribbon diagram in red, green, blue and magenta, respectively. The BPB 
domain of DDB1 is depicted in blue and the Zn atoms of Rbx1 and SV5v are highlighted as 
yellow spheres (Angers et al., 2006).  
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Furthermore, the CRL4 ligase is the only CRL that, in mammals, 
possesses two isoforms, Cul4A and Cul4B. In contrast to Cul4A, Cul4B has 
an extended N-terminus (190 amino acids) preceding the cullin homology 
domain, while the cullin domain shows a sequence identity of 83% over 753 
residues. While Cul4A and Cul4B appear to be largely redundant (Liu et al., 
2009), Cul4B has been linked to a number of distinct cellular functions and 
diseases, such as a mild form of X-linked mental retardation (Tarpey et al., 
2007), or the degradation of the estrogen receptor (ER-α) (Ohtake et al., 
2007). The precise molecular determinants for the specific roles played by 
Cul4A or Cul4B, as well as the structural homology between the two isoforms, 
await further investigation. 
Despite the fact that only few DCAFs have assigned cellular functions, 
CRL4 ligases have been associated with a number of important cellular 
processes. CRL4DDB2 and CRL4CSA are associated with the early steps of 
nucleotide excision repair, as outlined in Chapter 3. CRL4Cdt2 is an essential 
CRL4 ligase involved in regulating S/G2 cell cycle transition through timed 
degradation of the replication licensing factor (Cdt1) (Havens and Walter, 
2011). Other targets of CRL4Cdt2 include p21 (Abbas et al., 2008; Nishitani et 
al., 2008) and the histone methyltransferase SET8/Pr-SET7 (Abbas et al., 
2010). The VprBP/DCAF1 protein, as part of the CRL4DCAF1 ligase complex, 
has been associated with the tumor suppressor Merlin (Huang and Chen, 
2008) and is involved in HIV-1 infection through the Vpr mediated degradation 
of UNG2 and SAMHD1 (Ahn et al., 2010; 2012). Other putative targets of 
Cul4 include c-Jun (Wertz et al., 2004), Dacapo/p27Kip1, CyclinE (Higa et al., 
2006) or the checkpoint protein CHK1 (Leung-Pineda et al., 2009), although 
the responsible DCAFs and the underlying mechanisms are unresolved. The 
prominence of cellular events regulated by CRL ubiquitin ligases requires a 
tight control of these cellular machines. 
 
Cullin regulation 
Instrumental to the regulation of important cellular pathways, cullins 
themselves are subject to a diversity of regulatory events. A number of 
proteins and protein complexes have been identified as cullin binding 
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partners. Upon certain cellular or extracellular signals, such as UV-light, low 
oxygen levels, cell cycle events, or pathogenic infections, CRLs have been 
shown to be activated or modulated in their activity. In the following 
paragraphs, I will review the major protein complexes that have been 
implicated in general cullin regulation. In addition, specific regulators have 
been associated with an individual or a subset of cullins such as Glomulin 
(Duda et al., 2012), a protein that binds to Rbx1, occupies the E2 binding site, 
and has been associated with SCFFbw7 inhibition. Another binding partner that 
reproducibly co-purifies with certain CRL4 complexes is the small protein 
DDA1 (DDB1 and DET1 associated factor 1), a protein shown to bind the 
BPC of DDB1 while its functional role remains elusive (Pick et al., 2007; Olma 
et al., 2009). 
 
Autocatalytic conjugation of Nedd8 activates the cullin 
For the canonical cullins, it has been shown that the autocatalytic 
conjugation of the ubiquitin-Like Protein (UBL) Nedd8 to a conserved lysine 
residue in the winged-helix B (WHB) domain of a cullin activates the ligase 
(Furukawa et al., 2000; Pan et al., 2004). Structural studies (Duda et al., 
2008) have revealed that the attachment of Nedd8 induces a conformational 
change within the globular CTD of the cullin and frees the RING domain of 
Rbx1 to swing out and adopt multiple conformations. The conformational 
freedom of Rbx1 leads to increased catalytic activity (Duda et al., 2008; 2011) 
and is thought to bridge the gap between the E2 binding site and the 
substrate, observed in the crystal structure of SCFSkp2 (Zheng et al., 2002). 
The fundamental principal of Nedd8 conjugation is similar to the ubiquitin 
cascade, though it employs the Nedd8 specific E1 enzyme UBA3/NAE1, the 
E2 enzymes UBE2M (Ubc12), and UBE2F together with the E3 activity of 
Rbx1 or Rbx2 (Huang et al., 2009). More recently it has been shown that the 
yeast cullin Cdc53 requires the presence of an additional Nedd8 specific E3, 
namely the Dcn1 protein in yeast (Scott et al., 2010), which, in conjunction 
with the E3 activity of the yeast Rbx1 orthologue Hrt1, facilitates efficient 
neddylation of Cdc53. The extent to which this mechanism is conserved in 
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mammals and its role among the different cullin families has not been fully 
resolved. 
 Nedd8 mediated activation of CRLs is counteracted by the proteolytic 
cleavage of the Nedd8 modification through a large multi-protein isopeptidase 
complex, the COP9 signalosome (CSN). 
 
The COP9 Signalosome: Counteracting Cullin activation 
The COP9 signalosome (CSN) was originally discovered based on its role 
in the regulation of photomorphogenesis in the mustard weed Arabidopsis 
Thaliana (Wei and Deng, 1992; Wei et al., 1994; Chamovitz et al., 1996; Kwok 
et al., 1996). CSN is a large 350 kDa protein complex comprised of subunits 
csn1 to csn8 (Wei and Deng, 1999) and all or most subunits are conserved 
from yeast to man. Genetic studies have linked CSN to a variety of cellular 
processes within a number of model systems, such as photomorphogenesis 
in A. Thaliana (Osterlund et al., 1999), embryonic development in Drosophila 
Melanogaster (Doronkin et al., 2002) or DNA replication in 
Schizosaccharomyces pombe (Mundt et al., 1999; 2002). The discovery that 
CSN interacts with the cullin-RING ubiquitin ligase complex SCFTIR1 
(Schwechheimer et al., 2001) and that it promotes cleavage of Nedd8 from 
the S. Pombe Cul1 orthologue, shed light on the biochemical function of CSN 
(Lyapina, 2001). The CSN5/Jab1 subunit of CSN was subsequently described 
as a metalloprotease containing a JAMM/MPN+ motif (Cope et al., 2002) and 
implicated in harboring the catalytic deneddylation activity of CSN. CSN 
shares significant structural homology with the components of the 19S 
proteasome lid and the eukaryotic translation initiation factor (eIF3) (Pick et 
al., 2009). The 19S lid and CSN share a common architecture containing 6 
subunits  (CSN1, CSN2, CSN3, CSN4, CSN7a/7b and CSN8) that harbor a 
PCI (Proteasome, COP9 signalosome, Initiation factor) domain at their C-
terminus, and 2 subunits (CSN5 and CSN6) containing a MPN (Mpr1-Pad1-N 
terminal) domain at their N-terminus. The PCI domain is important for the 
assembly of the CSN complex, whereas the MPN domain with the catalytic 
JAMM/MPN+ motif in the CSN5 subunit is responsible for metallo-
isopeptidase activity (Kapelari et al., 2000; Lyapina, 2001; Cope et al., 2002; 
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Fang et al., 2008; Sharon et al., 2009). The CSN5 subunit is also present in 
an isolated free form. The individual CSN5 subunit is catalytically inactive and 
gets allosterically activated only while embedded in the holocomplex (Cope et 
al., 2002; Sharon et al., 2009). The JAMM metalloprotease of the proteasome 
lid subunit Rpn11, in contrast to CSN5, cleaves poly-ubiquitin chains (Verma 
et al., 2002). CSN is further commonly associated with a conventional 
deubiquitinating enzyme (DUB) Ubp12 (Groisman et al., 2003; Zhou et al., 
2003) that is thought to act in concert with the deneddylation activity of CSN5 
to inhibit the ubiquitination activity of CRLs. It has now become widely 
appreciated that CSN regulates all canonical cullins through the control of 
neddylation in vivo. Despite its role as a negative regulator of CRL activity, 
functional CSN is also required to sustain CRL function in vivo (Schmidt et al., 
2009; Wang et al., 2010). Genetic studies demonstrated that the inhibitory 
role of CSN on CRL activity protects substrate receptors from detrimental 
autocatalytic ubiquitination (Zhou et al., 2003; He et al., 2005; Wee et al., 
2005; Cope and Deshaies, 2006), a potential explanation why CSN would be 
indispensable for full CRL function. 
Though we now understand the biochemical properties of CSN, CSN has 
been implicated in the regulation of all canonical cullins and this, given that 
the human genome encodes for hundreds of distinct substrate receptors, 
raises the question: How can CSN differentially and independently regulate 
two different CRLs according to a specific stimulus?  
 
CAND1 
The CAND1 (Cullin-Associated and Neddylation-Dissociated 1) binds 
specifically to free cullin-rbx complexes and inhibits neddylation and CRL 
assembly, thereby keeping the cullin in an inactive form. The structure of 
CAND1 bound to Cul1-Rbx1 reveals that the heat-repeat protein CAND1 
wraps around the cullin, and blocks the N-terminal binding interface for CRL 
assembly, as well as the neddylation site (Goldenberg et al., 2004). It had 
been proposed that CAND1 sequesters non-neddylated cullins to prepare 
them for new CRL assembly in a deneddylation-CAND1-CRL assembly cycle 
(Schmidt et al., 2009). A recent proteomic study, however, did not further 
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support a critical role for CAND1 in CRL assembly (Bennett et al., 2010) and 
further investigation will be required to elucidate the precise role of CAND1 in 
CRL reorganization and regulation. 
 
Modulating the Ubiquitin Proteasome system with small molecules 
The ubiquitin proteasome system (UPS) regulates a wide variety of cellular 
processes, including protein turnover, DNA damage response, transcription, 
and cell signaling. Alterations and mutations within the UPS are associated 
with countless human diseases, such as cancer and neurodegenerative 
disorders, making the UPS a potential pool for promising drug targets. Within 
the hierarchical enzymatic cascade of the UPS, a maximum of two E1 
enzymes charge several E2 enzymes that, in conjunction with one out of 
hundreds of E3 ligases, provides substrate specificity (Figure 1.7). It is 
noteworthy that the first successful approach to target the UPS for therapeutic 
intervention was the proteasome inhibitor bortezomib (Velcade; Millennium 
Pharmaceuticals, Cambridge US), which acts the far most downstream in the 
UPS (Adams, 2004). Bortezomib is a peptide boronic acid inhibitor (Adams et 
al., 1998) of the proteasome and was later approved by the FDA to treat 
refractory or relapsed multiple myeloma. Although targeting the proteasome 
lacks any specificity for a specific ubiquitinated substrate, bortezomib provides 
a sufficient therapeutic window together with manageable side effects to be 
effective in cancer treatment (Aghajanian et al., 2002; Orlowski and Dees, 
2003). It is commonly believed that the therapeutic window occurs because 
heavily dividing tumor cells generate larger amounts of aberrant proteins to be 
degraded by the UPS and are therefore more susceptible to proteasome 
inhibition and the resulting change in cellular protein homeostasis (Adams, 
2004). Despite the lack in specificity, bortezomib has provided clinical proof 
that targeting the UPS can be a successful approach in treating malignancies 
and that more specific drugs could ultimately be used to provide promising 
new medicines. Another compound currently in clinical trials is MLN4924 
(Millennium Pharmaceuticals, Cambridge US). MLN4924 targets the Nedd8-
specific E1 enzyme NAE1, which controls the activity of the CRL ligase family 
(Soucy et al., 2009). MLN4924 acts by forming a stable NEDD8-MLN4924 
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adduct—catalyzed by the UBA3/NAE1 enzyme—that resembles the NEDD8 
adenylate but that cannot be further processed by the enzyme. It remains 
stably bound, thereby inhibiting the E1 (Brownell et al., 2010). 
Figure 1.7: Potential drug targets within the Ubiquitin Proteasome System (UPS). (a) 
Targeting the E1 enzyme will result in pan-UPS inhibition. (b) Targeting the E2 enzyme has 
been successful in the case of Cdc34 (Ceccarelli et al., 2011) and will provide more specificity 
then E1 inhibition. To gain true specificity to a certain target pathway or protein, targeting a 
specific E3 ligase (c) will be required. The final step of the UPS is (d, e) ATP dependent 
degradation of the poly-ubiquitinated substrate, which is inhibited by the FDA approved small 
molecule Bortezomib (Nalepa et al., 2006). 
 
The nature of the enzymes involved in ubiquitin conjugation represents a 
challenge for drug development. While the E1 (as well as the proteasome) 
represents a more conventional enzyme having either an ATP binding pocket, 
or being a protease-like enzyme to be targeted by small molecules, targeting 
a specific ubiquitin ligase, such as a CRL, requires the development of 
protein–protein interaction inhibitors; most of the E3s lack obvious small 
molecule-binding pockets. Despite these difficulties, efforts to find such small 
molecules have resulted in a number of compounds targeting specific E3 
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ligases within the UPS. The protein–protein interaction of the RING finger 
ubiquitin ligase Mdm2 with p53 (Kussie et al., 1996; Chi et al., 2005), one of 
the most prominent tumor suppressors, has been one of the first to be 
successfully targeted by a small molecule. A class of compounds, nutlins (cis-
imidazoline-derivatives), was found by screening a chemical compound library 
for the ability to block the p53-Mdm2 interface (Vassilev et al., 2004). Nutlins 
have been shown to be competitive inhibitors that bind to the binding groove 
on Mdm2 and block binding of p53. Recent efforts to target CRL ligases have 
resulted in tool compounds directed to the yeast CRL ligases SCFCdc4 (Orlicky 
et al., 2010) and SCFMet30 (Aghajan et al., 2010). While these attempts are still 
far from the clinics, the compound SCF-I2, which inhibits SCFCdc4, in particular 
provides proof that it is principally possible to target specific SCF substrate 
receptors (Orlicky et al., 2010). Interestingly, SCF-I2 does not bind the 
substrate binding site but rather targets a pocket induced between blades 5 
and 6 of the Cdc4 WD40 β-propeller and acts as an allosteric inhibitor of 
phosphodegron binding. 
Another small molecule, thalidomide (Thalomid, Contergan), was approved 
by the FDA in 2006 to treat multiple myeloma and leprosy’s, and it later turned 
out to inhibit a specific CRL4 ligase complex. 
 
Thalidomide and derivatives: Specific CRL4CRBN inhibitors? 
Thalidomide was developed in the 1950s by the German pharmaceutical 
company Grünenthal and was first marketed as a mild sedative better known 
as Contergan in Germany. While it was never approved by the FDA as a 
sedative due to safety concerns, the drug quickly reached over 40 countries. 
The tragedy commonly associated with thalidomide became apparent in the 
early 1960s, when thalidomide taken by pregnant women was found to be 
responsible for multiple and severe birth defects (Knobloch and Rüther, 
2008). More than 10,000 children were born with birth defects, such as 
malformations of the limbs, ears, or internal organs, before the drug was 
discontinued in 1961. However, studies to unravel the mechanism of 
teratogenicity continued, and physicians have uncovered several clinical 
effects such as efficacy in the treatment of leprosy (SHESKIN, 1965), 
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rheumatoid arthritis (Gutiérrez-Rodríguez, 1984), and chronic graft-versus-
host disease (McCarthy et al., 1989; Vogelsang et al., 1992). The discovery 
that thalidomide inhibits TNF-α production (Sampaio et al., 1991; 
Makonkawkeyoon et al., 1993) and possesses anti-angiogenic activity 
(D'Amato et al., 1994) suggested an anti-cancer potential and stimulated 
research in this direction. Thalidomide was first shown to be effective for the 
treatment of refractory multiple myeloma (Singhal et al., 1999) and was 
approved as a treatment by the FDA in 2006. Thalidomide is a derivative of 
glutamic acid composed of two imide rings: glutarimide and phtalimide. The 
drug has two isomeric forms, S-thalidomide and R-thalidomide, which rapidly 
interconvert under physiological conditions (Bosch et al., 2008), and are 
subject to non-enzymatic and enzymatic breakdown, resulting in numerous 
metabolites (Ando et al., 2002; Bosch et al., 2008). Advances in the use of 
thalidomide as an anti-cancer drug have led to the development of new 
derivatives with the aim of increasing the potency of TNF-α inhibition and 
making the side effects less severe. This resulted in a class of compounds 
called immunomodulatory drugs (IMiDs). In particular, lenalidomide (CC-5013, 
revlimid) and pomalidomide (CC-4047) have proven to be effective in several 
multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin’s leukemia, 
and solid tumor directed pre-clinical and clinical trials (Bartlett et al., 2004). 
The FDA has now approved lenalidomide to treat multiple myeloma and 5q-
MDS (deletion of chromosome arm 5q associated myelodisplastic syndrome). 
Despite the apparent success in clinical use, the precise mode of action 
associated with thalidomide teratogenicity and anti-cancer potential remains 
elusive and has led to a variety of proposed models for thalidomide action 
(Stephens, 1988; Quach et al., 2010). While a majority of the hypotheses lack 
sufficient experimental support, the oxidative stress hypothesis and the anti-
angiogenic hypothesis have gained support as being involved in the 
teratogenicity of thalidomide, despite the fact that the precise mechanism 
remains elusive. 
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Oxidative stress hypothesis 
Thalidomide has been shown to induce elevation of reactive oxygen 
species (ROS) (Wells et al., 1997; Parman et al., 1999), resulting in oxidized 
DNA and limb malformations in rabbits. It was demonstrated that this is 
counteracted by phenyl-N-tert-butylnitrone (PNB), a chemical that traps free 
radicals. Fgf8 and Fgf10 are essential regulators of limb development and 
their expression is inhibited by thalidomide, which is suppressed by PNB 
(Hansen et al., 2002; Ito et al., 2011). It was later shown by Knobloch et al. 
(2007) that thalidomide-induced ROS result in the upregulation of bone 
morphogenic proteins (BMPs) and programmed cell death. BMPs negatively 
regulate Fgf, Wnt, and Akt signaling (Ito et al., 2011); Wnt and Akt signaling 
are important for cell proliferation and survival. This results in a model where 
thalidomide-induced ROS attenuate the level of BMPs, thereby negatively 
affecting Fgf, Wnt, and Akt signaling to drive programmed cell death (Ito et al., 
2011). 
 
Anti-angiogenesis hypothesis 
Following the discovery that thalidomide inhibits Fgf2-induced 
angiogenesis (D'Amato et al., 1994), the authors hypothesized that the 
inhibition of angiogenesis caused limb defects by disrupting blood vessel 
formation crucial to limb development. It was further suggested that the anti-
angiogenic properties of thalidomide would cause the downregulation of 
Fg8/Fgf10 and cell death, in turn causing impaired limb development 
(Therapontos et al., 2009). However, Ito and colleagues found that in 
zebrafish, Fgf8 downregulation, together with malformation of the pectoral 
fins, precedes the formation of blood vessels (Ito et al., 2010). This suggests 
that, at least in zebrafish, the order of events is different and that additional 
knowledge of the precise molecular mechanisms underlying anti-angiogenesis 
is necessary to understand the effect on limb development. A tremendous 
achievement in understanding thalidomide action came with the discovery of 
the protein cereblon (CRBN) as a primary cellular target of thalidomide.  
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CRBN: A primary target of thalidomide 
Using a carboxyl-type derivative of thalidomide coupled to magnetic beads 
(Figure 1.8), Ito et al. (2010) were able to identify the protein cereblon 
(CRBN) as direct target of thalidomide. CRBN was readily purified from 
various human cell lines, including HeLa, 293T, HUVEC, U266, and Jurkat, 
and was found to be the only direct binding partner of thalidomide under these 
conditions (Ito et al., 2010). Together with CRBN, the DNA damage binding 
protein 1 (DDB1) was co-purified, and CRBN turned out to be part of a Cul4-
Rbx1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase complex. CRBN is a 442 
amino acid protein that was originally discovered as being mutated in a mild 
form of mental retardation (MR) (Higgins et al., 2004). It has been shown that 
CRBN directly interacts with a large-conductance calcium-activated potassium 
channel (BKCa) (Jo et al., 2005) and a voltage-gated chloride channel 
(Hohberger and Enz, 2009). Moreover, CRBN was found to interact with 
proteasome subunit beta type 4 (PSMB4) (Lee et al., 2012b) and AMP-
activated protein kinase subunit α1 (AMPKα1) (Lee et al., 2011) by yeast two-
hybrid screens. However, little is known about the cellular and physiological 
functions of CRBN, other than that it is a subunit of the CRL4CRBN ubiquitin 
ligase. 
Figure 1.8: Thalidomide coupling on magnetic beads. (A) Chemical structure of 
thalidomide and (B) thalidomide-derivative to be (C) coupled to FG magnetic beads (Ito et al., 
2010). 
 
Following the discovery of CRBN as a direct target of thalidomide, Ito et al. 
(2010) also found that CRBN is autoubiquitinated in vivo and that 
autoubiquitination is inhibited by thalidomide. In an attempt to validate the role 
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of CRBN teratogenicity, the authors investigated the effect of thalidomide on 
the embryonic development of chickens (Gallus gallus) and zebrafish (Danio 
rerio). In chicken and zebrafish embryos, limb development and the 
development of pectoral fins, respectively, was severely impaired upon 
thalidomide treatment (Ito et al., 2010). The CRBN dependence of this 
phenotype was further confirmed by the observation that a CRBN mutant 
deficient in thalidomide binding while maintaining its ability to form a functional 
ligase (CRBNYW/AA) renders embryos expressing this mutant insensitive to 
thalidomide teratogenicity (Ito et al., 2010). This finding was corroborated by 
the observation that the knockdown of endogenous CRBN in zebrafish using 
antisense morpholino oligonucleotides resulted in the malformation of pectoral 
fins, similar to thalidomide treatment (Ito et al., 2010), and reduction of Fgf8 
expression. Similar experiments performed using chicken embryos suggest 
that the role of CRBN in fin and limb development is conserved (Ito et al., 
2010). A potential connection between the previously outlined oxidative stress 
hypothesis and the role of CRBN is suggested by the common 
downregulation of Fgf8 and Fgf10. If functional CRBN were required in a 
pathway controlling levels of ROS, then ROS levels would in turn be elevated 
in the presence of thalidomide, resulting in reduced levels of Fgf8 and Fgf10. 
However, there is no experimental evidence of CRBN being involved in the 
control of reactive oxygen detoxification. Further research about the direct 
versus indirect targets of CRL4CRBN ubiquitination activity will be required to 
shed light on CRBN functions. 
A comprehensive study has also confirmed that CRBN is essential for the 
anti-myeloma effects of thalidomide, lenalidomide, and pomalidomide (Lopez-
Girona et al., 2012). The authors reported that in addition to thalidomide, 
lenalidomide and pomalidomide also directly interact with CRBN and that 
CRBN is required for their anti-proliferative potency. Moreover, the acquired 
resistance of a H929 myeloma cell line to thalidomide treatment has been 
linked to loss of CRBN expression. Overexpression of functional CRBN, but 
not CRBNYW/AA mutant protein, in those cells restored thalidomide sensitivity 
(Lopez-Girona et al., 2012). More detailed structural and functional data on 
CRBN will be required to decipher IMiD action on this CRL4 ligase complex. 
Further research about downstream targets would allow a better 
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understanding of how CRBN is involved in teratogenicity and of the anti-
proliferative effects of thalidomide and its derivatives. 
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Aim of This Thesis 
The global branch of mammalian nucleotide excision repair (GGR) has 
been extensively studied, yet, so far, little is known about the detailed 
molecular architecture and function of the involved cullin-RING ubiquitin ligase 
CRL4DDB2. 
Previous work demonstrated the important role for DDB2 in efficient repair 
of photo-dimers in vivo (Scrima 2008, Nishi 2009). DDB2 is further part of the 
CUL4-RBX1-DDB1-DDB2 (CRL4DDB2) ligase complex (Sugasawa 2005), 
involved in ubiquitination of XPC, DDB2, histones H3, H4 and H2A (Guerrero-
Santoro 2008; Kapetanaki 2006; Wang 2006), and thereby bridging NER to 
the ubiquitin proteasome system.  
A first aim of the present study is to employ structural and functional 
methodology to elucidate the molecular architecture of the 280kDa CRL4DDB2 
ligase complex bound to its DNA substrate and to understand its targeting to 
photo-dimers in chromatin. While CRL4DDB2 shows constitutive activity in vitro, 
its ubiquitination activity appears tightly regulated in vivo. Characterizing the 
biochemical and biophysical interplay of CRL4DDB2 with the COP9 
signalosome (CSN), a master regulator of cullin activity, will address how the 
ligase complex is activated upon DNA damage recognition. 
While CRL4DDB2 is a special ligase that recognizes a damaged DNA 
substrate, rather then a protein substrate, we further set out to characterize 
CSN mediated CRL4 regulation of other members of the family. Being 
involved in transcription coupled repair and targeting the CSB protein for 
ubiquitination, we chose the CRL4CSA ligase to further detail CRL4 regulation.  
The cullin family represents the largest subgroup of E3 ubiquitin ligases 
and is involved in numerous human diseases. Recent advances in the 
treatment of malignancies using the proteasome inhibitor velcade/bortezomib 
and the Nedd8 E1 inhibitor MLN4924 shed light on the potential of modulating 
the ubiquitin proteasome system (UPS) in cancer therapy. The drug 
thalidomide (Contergan), developed in the 1950’s, and its derivative 
lenalidomide (Revlimid) have been FDA approved for treatment of multiple 
myeloma and a study from Ito and colleagues demonstrated that thalidomide 
binds the protein cereblon (CRBN), which is part of the CRL4CRBN ligase 
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complex. The second aim of the present thesis is, to understand how this 
small molecule inhibitors target and act on the CRL4CRBN ligase. X-ray 
crystallography and biochemical methods will be used to elucidate how these 
inhibitors bind to CRBN and how they modulate the activity of the CRL4CRBN 
ligase complex.  
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Chapter 2: The molecular basis of CRL4DDB2/CSA 
ubiquitin ligase architecture, targeting and activation. 
(published manuscript) 
 
Eric S. Fischer1,8*, Andrea Scrima1,7*, Kerstin Böhm1, Syota Matsumoto2, 
Gondichatnahalli M. Lingaraju1, Mahamadou Faty1, Takeshi Yasuda3, Simone 
Cavadini1, Mitsuo Wakasugi4, Fumio Hanaoka5, Shigenori Iwai6, Heinz Gut1, 
Kaoru Sugasawa2, Nicolas H Thomä1† 
1 Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, 
Switzerland 
2 Biosignal Research Center, and Graduate School of Science, Kobe University, 1-1 
Rokkodai, Nada-ku, Kobe 657-8501, Japan 
3 National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, 
Japan 
4 Laboratory of Human Molecular Genetics, Graduate School of Natural Science and 
Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan 
5 Faculty of Science, Gakushuin University, 1-5-1 Meijro, Toshima-ku, Tokyo 171-8588, 
Japan 
6 Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama, 
Toyonaka, Osaka 560-8531 Japan 
7 Present address: Department of Molecular Structural Biology, Helmholtz-Centre for Infection 
Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany 
8 Universität Basel, Petersplatz 10, CH-4003 Basel, Switzerland 
 
Cell 2011, Volume 147, pg 1024-1039 
 
Summary: The DDB1-CUL4-RBX1 (CRL4) ubiquitin ligase family regulates a diverse set of 
cellular pathways through dedicated substrate receptors (DCAFs). The DCAF DDB2 detects 
UV-induced pyrimidine dimers in the genome and facilitates nucleotide excision repair. We 
provide the molecular basis for DDB2 receptor-mediated cyclobutane pyrimidine dimer 
recognition in chromatin. The structures of the fully assembled DDB1-DDB2-CUL4A/B-RBX1 
(CRL4DDB2) ligases reveal that the mobility of the ligase arm creates a defined ubiquitination 
zone around the damage, which precludes direct ligase activation by DNA lesions. Instead, 
the COP9 signalosome (CSN) mediates the CRL4DDB2 inhibition in a CSN5 independent, non-
enzymatic, fashion. In turn, CSN inhibition is relieved upon DNA damage binding to the DDB2 
module within CSN-CRL4DDB2. The Cockayne syndrome A DCAF complex crystal structure 
shows that CRL4DCAF(WD40) ligases share common architectural features. Our data support a 
general mechanism of ligase activation, which is induced by CSN displacement from 
CRL4DCAF on substrate binding to the DCAF. 
 
author contributions: ESF designed and performed the experiments in figures 3, 4, 5, 7, S2, 
S3, S4 and S5. AS designed and performed the experiments in figures 1, 2 and S1. KB, AS 
and EF designed and performed the experiments in figures 6, S6 and S7. SM designed and 
performed the experiments in figures 5a-c. GML purified and provided recombinant COP9 
signalosome. MF purified the CAND1-CUL4B protein for crystallization. TY designed and 
performed the experiments in figures 2b-e. SC analyzed CRL4-CSN complexes by EM. MW 
tested DDB1 mutants for complementation in Chicken DT40 cells. FM contributed to the 
design of experiments in figures 2b-e. SI provided synthetic DNA oligos containing 6-4PP or 
CPD lesions. HG helped with data collection and structure determination. KS designed the 
experiments in figures 2b-e and 5a-c, NHT designed the experiments and wrote the 
manuscript together with ESF, AS and KB. 
 34 
 
The molecular basis of CRL4DDB2/CSA 
ubiquitin ligase architecture, targeting,  
and activation 
 
Eric S. Fischer1,8*, Andrea Scrima1,7*, Kerstin Böhm1, Syota Matsumoto2, 
Gondichatnahalli M. Lingaraju1, Mahamadou Faty1, Takeshi Yasuda3, 
Simone Cavadini1, Mitsuo Wakasugi4, Fumio Hanaoka5, Shigenori Iwai6, 
Heinz Gut1, Kaoru Sugasawa2, Nicolas H Thomä1† 
 
 
1 Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, 
Switzerland 
2 Biosignal Research Center, and Graduate School of Science, Kobe University, 1-1 
Rokkodai, Nada-ku, Kobe 657-8501, Japan 
3 National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, 
Japan 
4 Laboratory of Human Molecular Genetics, Graduate School of Natural Science and 
Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan 
5 Faculty of Science, Gakushuin University, 1-5-1 Meijro, Toshima-ku, Tokyo 171-8588, 
Japan 
6 Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama, 
Toyonaka, Osaka 560-8531 Japan 
7 Present address: Department of Molecular Structural Biology, Helmholtz-Centre for 
Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany 
8 Universität Basel, Petersplatz 10, CH-4003 Basel, Switzerland 
 
 
 
† to whom correspondence should be addressed: nicolas.thoma@fmi.ch 
* both authors have contributed equally 
 
 
Keywords: Xeroderma pigmentosum, Cockayne syndrome, CSA, DDB2, 
CRL4, CSN, COP9, CDT2, CSB, DCAF1, cullin, chromatin and damage 
repair.   
 
 
 
 
 35 
Summary 
The DDB1-CUL4-RBX1 (CRL4) ubiquitin ligase family regulates a diverse 
set of cellular pathways through dedicated substrate receptors (DCAFs). The 
DCAF DDB2 detects UV-induced pyrimidine dimers in the genome and 
facilitates nucleotide excision repair. We provide the molecular basis for 
DDB2 receptor-mediated cyclobutane pyrimidine dimer recognition in 
chromatin. The structures of the fully assembled DDB1-DDB2-CUL4A/B-
RBX1 (CRL4DDB2) ligases reveal that the mobility of the ligase arm creates a 
defined ubiquitination zone around the damage, which precludes direct ligase 
activation by DNA lesions. Instead, the COP9 signalosome (CSN) mediates 
the CRL4DDB2 inhibition in a CSN5 independent, non-enzymatic, fashion. In 
turn, CSN inhibition is relieved upon DNA damage binding to the DDB2 
module within CSN-CRL4DDB2. The Cockayne syndrome A DCAF complex 
crystal structure shows that CRL4DCAF(WD40) ligases share common 
architectural features. Our data support a general mechanism of ligase 
activation, which is induced by CSN displacement from CRL4DCAF on 
substrate binding to the DCAF. 
     
 
Introduction 
The evolutionarily conserved CUL4 E3 ligase family, in concert with its 
DDB1 adaptor, regulates a diverse set of cellular processes including 
development, transcription, replication and DNA repair (Jackson and Xiong, 
2009). Specificity is conferred by a set of more than 50 WD40 containing 
substrate receptors, also referred to as DCAFs (DDB1 CUL4 Associated 
Factors) (Angers et al., 2006; Bennett et al., 2010; He et al., 2006; Higa et al., 
2006; Jin et al., 2006). A large fraction of these targeting modules is directed 
towards chromatin-associated proteins. One of the best characterized 
substrate receptors is the damaged DNA binding protein 2 (DDB2), which 
binds to UV-induced DNA pyrimidine dimers. The DDB2 receptor is part of the 
DDB1-DDB2-CUL4-RBX1 E3 ligase complex (CRL4DDB2) (Scrima et al., 
2011). This bi-functional damage detection and ubiquitin ligase complex 
serves in the repair of UV-induced DNA lesions in chromatin. 
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Exposure of the genomic DNA to ultraviolet light (UV) results in the 
formation of covalent crosslinks between neighboring pyrimidine nucleotides. 
These pyrimidine dimers, if left unrepaired, stall transcription by RNA 
polymerase II (RNAPII). Unrepaired lesions require error-prone translesion 
polymerases in S phase (Friedberg, 2001), which potentially introduce 
oncogenic mutations. Cyclobutane pyrimidine dimers (CPD) and (6-4) 
pyrimidine-pyrimidone photoproducts (6-4PP) are the two major photo lesions, 
accounting for approximately 75 % and 25 % of genomic UV-lesions, 
respectively (Mitchell et al., 1989). Compared to 6-4PP, CPDs cause relatively 
minor thermodynamic duplex destabilization (Jing et al., 1998), and are found 
frequently obscured by organization into nucleosomes (Gale and Smerdon, 
1988). These biophysical and cellular properties render CPDs the most 
difficult photo-lesion to detect. CPDs are thereby highly mutagenic and major 
facilitators of skin carcinogenesis (Hoeijmakers, 2009). 
The mammalian global genome repair branch of nucleotide excision repair 
(NER) surveys the genome for lesions and actively repairs pyrimidine dimers 
(Aboussekhra et al., 1995). NER thereby functions as a central pathway in 
safeguarding metazoan cells against sun-induced skin carcinogenesis. XPC-
RAD23-Centrin2 acts as a lesion surveillance complex, recruiting the core 
NER machinery to damaged sites (Volker et al., 2001). Assembly of the NER 
complex results in rapid damage excision and repair synthesis, with repair 
generally proceeding in a fast and error free fashion. While XPC is required 
for global genome NER, it has little or no affinity for CPD lesions, and does 
not recognize 6-4PP in the context of chromatin (Batty et al., 2000; Sugasawa 
et al., 2001; Yasuda et al., 2005). Recently, XPC recruitment to chromatin 
was shown to be facilitated by the DDB1-DDB2 (UV-DDB) complex (Nishi et 
al., 2009). In the absence of DDB2, XPC remains localized to 6-4PP and to a 
lesser extent to CPDs, albeit with substantially delayed kinetics (Sugasawa, 
2010). The precise mechanism of XPC recruitment to sites of UV damage, in 
the absence of DDB2 is unclear. DDB2 binds to CPD and 6-4PP pyrimidine 
dimers with the highest reported affinity and specificity of all metazoan 
damage recognition factors (Payne and Chu, 1994; Wittschieben et al., 2005). 
Mutations in DDB2 give rise to XP complementation group E (Tang and Chu, 
2002). In DDB2-deficient XPE cells, CPD repair is largely abolished, while 6-
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4PP repair is affected to a lesser extent (Hwang et al., 1998; Moser et al., 
2005; Tang et al., 2000). The structural basis of 6-4PP recognition by DDB1-
DDB2 is known (Scrima et al., 2008) but it is currently unclear how DDB2 
recognizes CPD lesions, which are chemically distinct from the 6-4PP and 
frequently encapsulated in nucleosomes (Gale and Smerdon, 1988).  
DDB1-DDB2 appears constitutively bound to CUL4 which targets XPC and 
DDB2 for ubiquitination (Sugasawa et al., 2005). In addition, histones H2A, 
H3 and H4 surrounding the lesion are ubiquitinated in a UV-dependent 
fashion (Guerrero-Santoro et al., 2008; Kapetanaki et al., 2006; Wang et al., 
2006). DDB2 autoubiquitination leads to the loss of DNA damage binding and 
rapid DDB2 degradation (Sugasawa et al., 2005). XPC ubiquitination, in 
contrast, retains the complex at the site of UV damage without immediate 
proteasomal degradation. The differential response of XPC and DDB2 upon 
ubiquitination has been linked to a ubiquitin-dependent damage handover 
from CRL4DDB2 to XPC (Sugasawa et al., 2005). CRL4DDB2 is found in 
complex with the COP9 signalosome (CSN) (Hannss and Dubiel, 2011). CSN 
is an 8-subunit isopeptidase complex, which via the proteolytic activity of its 
CSN5 subunit removes the ubiquitin-like NEDD8 from cullins. NEDD8 is 
considered as an activator and its removal renders the ligase complex 
inactive (Furukawa et al., 2000). Recruitment of CRL4DDB2 to sites of DNA 
damage in chromatin appears to correlate with CSN release (Groisman et al., 
2003; Takedachi et al., 2010). The molecular mechanism triggering 
CRL4DDB2 activation in response to damage binding is currently unresolved. 
While the DDB2 substrate receptor recruits CRL4DDB2 to DNA damage, 
other CRL4 substrate receptors are recruited by protein epitopes. Prominent 
examples include DCAF1, CDT2 and the Cockayne syndrome A (CSA) 
protein (Lee and Zhou, 2007). All CRL4 substrate receptors are linked to 
CUL4 through the DDB1 adaptor. CSA is functionally unrelated to DDB2 and 
serves in the transcription coupled branch of NER. CRL4CSA is recruited to 
sites of CSB and stalled RNA polymerase II, where it facilitates DNA repair 
and the subsequent transcription restart (Tornaletti, 2009). Reported CRL4CSA 
ubiquitination targets include the Cockayne syndrome B protein (CSB), a 
SWI/SNF ATPase (Troelstra et al., 1992). CRL4DDB2 and CRL4CSA, as well as 
other cullin-RING type ligases are inhibited by CSN (Bennett et al., 2010). It is 
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currently unclear how CSN inhibition is retained at the majority of cellular 
cullin ligase complexes, while CSN specifically dissociates from those ligases 
that undergo activation in response to a given stimulus (i.e.: CSN mediated 
dissociation and activation of CRL4DDB2 and CRL4CSA in response to UV). 
Here we provide the molecular basis for CRL4DDB2 recruitment to CPD 
lesions in chromatin, and characterize how the damage recognition process 
results in ubiquitin ligase activation, a process mediated by CSN. We present 
the structure of the DDB1-CSA complex, which in conjunction with 
biochemical data presented argues in favor of conserved architectural and 
regulatory principles amongst CRL4 ligases.  
 
Results 
CPD recognition by DDB2 involves β-hairpin insertion and lesion flipping 
The DDB2 damage detection module has previously been postulated to 
undergo conformational changes upon binding of a pyrimidine dimer resulting 
in CRL4DDB2 activation in vivo (Takedachi et al., 2010). We therefore focused 
on the structure of the DDB1-DDB2 complex bound to CPD-containing 
duplexes, its physiological substrate. DDB1-DDB2 has the highest reported 
affinity for CPD lesions among metazoan damage recognition factors. Its 
absolute affinity, however, was not sufficient to allow successful crystallization 
in the presence of CPD duplexes. We then engineered DDB1-DDB2 crystal 
contacts disfavoring crystallization of the DNA-free (apo) state, biasing 
crystallization towards CPD co-complexes. This was done by mutating DDB1 
contacts that occur only in the apo-DDB1-DDB2 crystal lattice, as DDB1 is not 
involved in DNA binding (Figure S1). This approach led to the structures of 
DDB1-DDB2 bound to four different cis-syn CPD-containing DNA duplexes, 
observed in different space groups and crystal packing arrangements (Figure 
1; Figure S1). Due to the overall structural similarity among these DNA co-
complex structures, the discussion focuses on the 3.0 Å resolution structure of 
DDB1-DDB2 bound to a 13mer duplex having a 5’ overhang on both strands 
(CPD#1). 
Consistent with the DDB1-DDB2 6-4PP complex (Scrima et al., 2008), the 
CPD-containing duplex is exclusively held by the DDB2 WD40 propeller. The 
DNA traverses the central cavity of the WD40 propeller along the axis defined 
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by DDB2 blades 7 and 4, pointing away from DDB1 (Figure 1). A DDB2 β-
hairpin, comprising Phe371, Gln372 and His373 is inserted into the minor 
groove of the duplex at the site of the CPD. Insertion of this damage-
recognition finger (Scrima et al., 2008) proceeds with duplex unwinding of 
~12.6° (Figure S1d), widening of the minor groove to ~18 Å (Table S2) and 
extrusion of the CPD into an extra-helical, flipped out conformation. The 
observed kink angle of the cis-syn CPD DNA in the highest resolution CPD 
complex is ~45°. 
 
The DDB2 binding interface is specifically tailored towards CPD recognition 
The 6-4PP structure previously revealed few contacts between DDB2 and 
the extruded 6-4PP (Scrima et al., 2008). The 6-4PP has the pyrimidine-
pyrimidone rings angled at ~90° and can therefore not fully engage the DDB2 
damage recognition pocket (Figure 1c and d). The boat-shaped cis-syn CPD, 
in contrast, provides a high degree of surface complementarity through 
packing with its hydrophobic carbons (at C5 and C6 positions) against the 
hydrophobic core of the DDB2 pocket (Figure 1). This interaction is stabilized 
by DDB2 residues Trp239, Ile213, Gly192 and the Cα of Arg214. The four 
hydrophilic carbonyl groups of the CPD (at the C2/C4 positions), located on 
the opposing face, are solvent exposed and contact water molecules. The 
carboxylic group of Asp237 contacts the D+2 pyrimidine nitrogen at N3. The 
overall arrangement results in a larger contact area of 327 Å2 for the CPD 
moiety versus 265 Å2 for the 6-4PP.  
Comparison with existing structures of protein-free CPD duplexes indicated 
that the DNA conformation seen in the DDB2-CPD complex (Figure 1) closely 
resembles previously observed protein-free cis-syn CPD duplexes (Figure 
S1). DDB2, through its pyrimidine dimer binding pocket and overall DNA 
shape complementarity thereby specifically supports CPD recognition. 
 
The DDB1-DDB2 complex does not change its conformation in response to 
damage binding 
The DDB2 6-4PP, THF (Scrima et al., 2008) and CPD structures illustrate 
that the DNA is intrinsically flexible and can adapt to DDB2 despite 
differences in the DNA sequence (see Figure S1). The plasticity of the DNA is 
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contrasted with the rigidity of DDB2. In all DNA bound and DNA free 
structures available, DDB2 including its ß-hairpin does not change its 
conformation. Thus, DDB2 serves as a rigid damage recognition unit. As a 
consequence DDB2 binding to its physiological CPD substrate does not 
trigger conformational changes that could serve as the signal in ligase 
activation (see below). 
 
DDB2 mediated detection of CPD lesions in chromatin 
The DDB2 DNA binding interface has previously been proposed to allow 
readout of lesions embedded in nucleosomes (Scrima et al., 2008). This is of 
notable biological importance, as the majority of CPDs appear encapsulated 
in nucleosomes (Gale and Smerdon, 1988). The DNA curvature observed 
when bound to DDB2 matches the nucleosomal curvature (Scrima et al., 
2008) which was proposed to facilitate pyrimidine dimer readout through the 
minor groove. In order to test whether the DDB2 interface is compatible with 
nucleosomal damage detection, damage-containing nucleosomes were 
initially prepared by UV irradiation of DNA prior to the assembly of core 
particles (Supplemental experimental procedures). Electrophoretic mobility 
shift assays (EMSA) (Supplemental experimental procedures) demonstrated 
that DDB1-DDB2 is able to specifically recognize irradiated, linker free, 
mononucleosomes (Figure 2a). We subsequently prepared nucleosomes 
containing a chemically synthesized 6-4PP or CPD lesion (Figure 2b and c). 
Driven by nucleosome positioning sequence consisting of alternating A/T- and 
G/C-rich regions, these lesions were located at the sites where the minor 
groove is oriented away from the surface of the histone octamer (Yasuda et 
al., 2005). DDB1-DDB2 recognizes a single 6-4PP embedded in the 
nucleosome (Figure 2b lanes 10-12) and comparable binding can be 
observed in the presence of the equal amount of 6-4PP-containing naked 
DNA (Figure 2b, lanes 13-16). Binding was also detected for the CPD-
containing nucleosomes (Figure 2c). CPD nucleosome binding was weaker 
than that of the 6-4PP (Figure 2d and e), in line with its intrinsically lower helix 
destabilization (Jin et al., 1998). Binding of CPD-containing nucleosomes was 
comparable, however, with DDB2 affinities observed for naked CPD-
containing DNA. The DDB2 DNA binding interface in addition to being 
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optimized for CPD recognition, also confers compatibility for detecting CPDs 
and 6-4PPs in nucleosomes.  
Measurements of cellular diffusion rates identified the CRL4DDB2 complex 
as the functional macromolecular entity in DDB2 mediated DNA damage 
recognition (Luijsterburg et al., 2007). We therefore examined binding of the 
fully assembled CRL4DDB2 complex to irradiated nucleosomes (Figure 2f). 
Analogous to our findings with DDB1-DDB2, we observed that the CRL4DDB2 
complex is able to specifically recognize lesions in nucleosomes, suggesting 
that the presence of CUL4 is compatible with damage recognition in 
chromatin. In an effort to understand the interplay between damage binding 
and ligase activation, we subsequently focused on the structure of the 
CRL4DDB2 complex bound to damaged DNA duplexes. 
 
Structures of DDB1-DDB2-CUL4A/B-RBX1 bound to damage-containing 
duplexes 
We first determined the structure of DDB1-DDB2-CUL4A-RBX1 
(CRL4ADDB2) bound to a 12 bp DNA duplex containing a tetrahydrofuran 
(THF) lesion, a well characterized DDB2 substrate (Wittschieben et al., 2005). 
The structure of this 290 kDa nucleoprotein complex was refined by rigid body 
refinement to 5.9 Å resolution with an Rwork of 26.9 % (Rfree of 27 %) as 
outlined in Supplemental experimental procedures. Fragments from 
previously available high resolution structures of CUL4A (Angers et al., 2006), 
DDB1, DDB2 and DNA (Scrima et al., 2008) were positioned using iterative 
cycles of molecular replacement searches (Supplemental experimental 
procedures). The location of these individual rigid bodies was validated with 
anomalous dispersion methods using a selenomethionine (SeMet) labeled 
CRL4ADDB2 complex. Phases derived from molecular replacement were used 
for calculation of anomalous difference Fourier electron density maps, which 
allowed identification of peaks for 50 % of the 55 expected Se at 3.0 σ (90 % 
at 2.0 σ). All peaks were located within 5 Å of their predicted position (Figure 
S2d). Calculation of composite omit maps with CNS (Brunger et al., 1998) 
further corroborated the correct placement of the different domains of the 
large complex (Figure S2c). Well defined 2mFobs-DFcalc density was 
observed for CUL4A, DDB1 (BPB, BPC&BPA), DDB2 (helix-loop-helix motif 
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and WD40 propeller) and the 24 nucleotides of the DNA duplex. While density 
was present for the segment of RBX1 residues 19–39 that integrates into the 
CUL4A C-terminal β-sandwich (Angers et al., 2006), no density was observed 
for the remainder. 
Figure 3 shows the structure of CRL4ADDB2 complex bound to a damage-
containing duplex. CRL4ADDB2 assumes an overall U-shaped assembly, with 
two extended arms of nearly equal length. The thicker arm is contributed by 
DDB1-DDB2 (extreme dimensions 75 Å x 45 Å), while the thinner arm 
comprises CUL4A (75 Å x 23 Å). The connection between them is made by 
the N-terminus of CUL4A (aa 39–96) in conjunction with the DDB1-BPB 
domain (Angers et al., 2006). The DDB1-DDB2 and CUL4A extended arms 
are angled at about 50°. The overall complex assumes an approximately 
square arrangement (160 Å x 140 Å). The largely helical CUL4A fold is 
attached exclusively to the BPB WD40 propeller of DDB1 (Figure 3). The 
observed distances between the CUL4A arm and the remainder of the DDB1 
(BPC+BPA) propellers are generally more than 15-20 Å. The distance 
between CUL4A and the DNA duplex is around 50 Å. This arrangement 
excludes specific interactions between CUL4A and the DNA, or CUL4A and 
the BPA and BPC propellers of DDB1 (Figure 3). 
 
The CUL4A and CUL4B ligases are structurally indistinguishable 
Since human cells possess two CUL4 isoforms, CUL4A and CUL4B 
(Jackson and Xiong, 2009) with DDB1-DDB2 reported to exist in complex with 
both of them (Groisman et al., 2003; Wang et al., 2006), we determined the 
crystal structure of CUL4B-RBX1 bound to DDB1-DDB2 in the presence of a 
second 12 bp THF containing duplex DNA (7.4 Å resolution). While the cullin 
fold of CUL4B (aa 192–913) has high sequence identity to CUL4A (84 % over 
722 residues), the CUL4B N-terminus is unique to CUL4B. CUL4B 1–191 aa 
N-terminus was predicted to be mostly unstructured and was removed prior to 
co-expression of the CRL4DDB2 complex. 
In the absence of known structures of CUL4B, we first determined the 
structure of CUL4B (in complex with CAND1) at 3.8Å resolution 
(Supplemental experimental procedures). Analysis of CUL4A and CUL4B 
folds revealed superimposable structures (rmsd of 1.54 Å over 677 residues) 
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rendering the two homologues structurally indistinguishable (see Figure 4c 
and Figure S3 for the mapping of CUL4B mutations resulting in X-linked 
mental retardation). 
 
The CUL4 E3 ligase freely rotates around a rotation axis defined by DDB1 
and the damage 
The structure of the DDB1-DDB2-CUL4B-RBX1 (CRL4BDDB2) complex was 
solved following a similar strategy, as outlined for CRL4ADDB2 (Supplemental 
experimental procedures). The overall architecture of the two CRL4BDDB2 
complexes, observed in the asymmetric unit was comparable with CRL4ADDB2 
(Figure 4). Clear density for RBX1, again was only visible for 19–39 aa in both 
molecules of CRL4BDDB2. Comparison of the CRL4ADDB2 with the two 
CRL4BDDB2 molecules revealed the DDB1-BPB domain in three different 
rotational states. As the BPB domain is the anchor point of the CUL4 ligase, 
its mobility directly translates into the mobility of the entire ligase arm. Within 
the three molecules observed in our study (Figure 4a and b), CUL4 rotates 
around 60° along an axis defined by the damage and DDB1 (BPB propeller) 
(Figure 4). Minimal distances observed between CUL4B and DNA, and 
between CUL4B and DDB1 (BPC), for the two CUL4B molecules were 
between 25–35 Å and 5–27 Å, respectively. The cullin fold with its kink of 
~80° between cullin repeats 1 and 2 is shaped to allow rotation over BPC 
blades 2 and 3 towards the DDB1 C-terminus without steric clashes with 
DDB1 (Figure 4).  
 
The DDB1 BPB domain mobility structurally insulates the CUL4 ligase from 
the DDB2 module 
Examination of the 11 available medium/high resolution DDB1 molecules 
obtained in crystallographic studies (Angers et al., 2006; Li et al., 2006; Li et 
al., 2010; Scrima et al., 2008) suggest a total BPB domain rotation range of at 
least 150° (Figure 4d). Analysis of the expected energetics of rotation, as 
calculated by differences in solvation energy for the individual DDB1 (BPB) 
vs. DDB1 (BPC-BPA) interfaces (Krissinel and Henrick, 2007) predicts that 
the observed rotations are iso-energetic (Figure 4e). As a consequence, 
CRL4DDB2 is expected to rotate up to 150° establishing a ubiquitination zone 
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restricted to 60–80 Å, Upon modification with the small ubiquitin-like modifier 
NEDD8 and resultant release of RBX1, the ubiquitination zone increases to 
30-110 Å (Duda et al., 2008) (Figure 4d).  
The overall modular architecture of CRL4DDB2 implies that CUL4 cannot be 
directly activated through conformational changes induced by DDB2 damage 
binding. The mobility of the ligase arm further insulates CUL4 from DDB2. 
Activation of the ligase in response to DNA damage therefore requires 
additional factors. We next focused on known regulators and their role in 
CRL4DDB2 regulation.  
 
The DDB2-N-terminus is autoubiquitinated and regulates DDB2 levels after 
UV irradiation 
The CRL4DDB2 complex, in vivo, undergoes DDB2 autoubiquitination and 
degradation following UV irradiation. In contrast, the recombinant CRL4DDB2 
complex undergoes DDB2 autoubiquitination irrespective of the presence and 
absence of DNA damage. The DDB2 subunit has previously been shown to 
undergo polyubiquitination at multiple sites (Sugasawa et al., 2005). Using 
mass spectrometry, in conjunction with a ubiquitin variant lacking lysine 
residues required for polyubiquitination, we identified the human DDB2 Lys 
residues 5, 11, 35, 40 and 151 as the main targets for CRL4DDB2 
autoubiquitination in vitro (Figure S4a to d). The majority of these sites (Lys5, 
11, 35 and 40) are located within the unstructured DDB2 N-terminus. When 
determining the human DDB1-DDB2 complex structure DDB2 aa 1–59 were 
absent from the electron density maps, and were removed for subsequent 
structural studies. In vitro, deletion of the DDB2 N-terminus, 1–40 aa 
(DDB2ΔN), ablated the majority of ubiquitin acceptor sites (Figure 5a). On the 
basis of random-polymer-theory (Creighton, 1992) the very N-terminus of 
DDB2 is estimated to have a root-mean-square distance of about 90 Å from 
the beginning of the DDB2 structure (aa 1-66). The DDB2 N-terminus is 
thereby located on the edge of the active ubiquitination zone of the ligase. 
Next, we assessed the effect of these lysine residues in cells, in response 
to UV damage. A normal human fibroblast cell line, WI38 VA13, was used to 
stably express HA-tagged wild type DDB2 or a construct in which 7 N-terminal 
lysines (at positions 4, 5, 11, 22, 35, 36, and 40) were mutated to arginines 
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(DDB27KR). DDB27KR remained associated with DDB1 and CUL4 in a manner 
identical to that seen for wild type DDB2 (Figure 5b). After blocking translation 
by cycloheximide treatment and UV irradiation, DDB27KR showed remarkable 
stability compared to the wild type DDB2; cellular wild type DDB2 levels 
mostly disappeared 1 h after UV, whereas DDB27KR levels remained 
unchanged for 5 h (Figure 5c). Differences in total levels of wild type DDB2 
and DDB27KR are visible as early as 30min post UV, at a time when CSN has 
previously been shown to dissociate from the complex (Groisman et al., 
2003). Wild type and DDB27KR were not degraded in response to UV in the 
presence of MG132, an inhibitor of the proteasome (Rapić-Otrin et al., 2002) 
(Figure 5c). The lysine residues at the DDB2 N-terminus (aa 5-40), which are 
targeted by CRL4DDB2 for autoubiquitination in vitro, hence regulate the overall 
cellular concentration of DDB2 in response to UV.  
  
The COP9 signalosome mediates activation between DDB2 and the ubiquitin 
ligase 
DDB2 is autoubiquitinated by CRL4DDB2 in cis irrespective of the presence 
or absence of DNA damage in vitro. In vivo, however, DDB2 ubiquitination 
and degradation proceeds in a DNA damage specific fashion. CSN has been 
implicated in CUL4 inhibition through deneddylation, and is known to 
dynamically associate with CRL4DDB2 complexes (Groisman et al., 2003). 
Dissociation of the CSN from CRL4DDB2 had previously been observed in the 
presence of nucleosomes (Takedachi et al., 2010). We first examined the 
effect of CSN on CRL4DDB2 autoubiquitination. DDB2, within the CRL4DDB2 
complex, was readily ubiquitinated in the presence of an E1 (UBA1) and E2 
(UbcH5A), as previously observed (Sugasawa et al., 2005). DDB2 
autoubiquitination, however, was severely inhibited in the presence of CSN 
(Figure 5d, lanes 4 and 6). The inhibitory effect of CSN was observed in the 
presence of wild type CSN5, or using a CSN5 catalytic mutant deficient in 
deneddylation (CSNASM). We then carried out ubiquitination reactions in the 
presence of irradiated DNA plasmids. Under these conditions CSN, or 
CSNASM, no longer protected DDB2 from undergoing autoubiquitination 
(Figure 5d, lanes 5 and 7). We then examined the DNA specificity of 
activation. Short duplexes between 15 and 24bp in length containing either 
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THF, 6-4PP or CPD (Figure 5e) were sufficient to overcome CSN inhibition 
and triggered DDB2 autoubiquitination. Duplexes containing undamaged 
DNA, on the other hand, did not relieve protection (Figure 5e, lane 6). 
Analogously, a DDB2 mutant defective in damage DNA binding DDB2K244E 
(Wittschieben et al., 2005) was unable to relieve CSN inhibition (Figure 5f). 
EMSA and equilibrium size exclusion chromatography indicated that 
CRL4DDB2 dissociated from the CSN-CRL4DDB2 in the presence of small 
damage-containing DNA duplexes (Figure S5). We thereby conclude that 
substrate binding to the DDB2 subunit of CRL4DDB2 triggers CSN release, 
relieves inhibition and results in an active ligase complex. The DDB2 N-
terminus subsequently becomes subjected to CRL4DDB2 autoubiquitination, 
which triggers cellular DDB2 degradation in response to UV irradiation. 
Previous studies reported a deubiquitination (DUB) enzyme, UBP12, 
associated with CSN preparation immunopurified from human cells (Zhou et 
al., 2003). Our recombinant CSN, overexpressed and purified to homogeneity 
from insect cells (Enchev et al., 2010) (Figure S4) did not show any 
discernable deubiquitination activity, in the presence or absence of damaged 
DNA (Figure S4). In addition, while UBP12 DUB activity was previously shown 
to be inhibited by ubiquitin-aldehyde (Zhou et al., 2003), we observed no such 
effect on DNA mediated CRL4DDB2 activation in the presence of 3.9 µM 
ubiquitin-aldehyde (Figure 5e, lanes 1 and 2), a concentration that was 
sufficient to inhibit a control DUB added to the reaction (Figure S5d). The 
CSN inhibitory properties observed in vitro are therefore intrinsic to the 
complex and not due to CSN5 mediated deneddylation, or CSN-associated 
DUB activity. 
In a minimal, recombinant system we have fully reconstituted DNA 
damage-dependent activation of CRL4DDB2 mediated by CSN (see Figure S5 
for mapping of CSN subunits required for protection/release). While the 
CRL4DDB2 complex, as depicted in Figure 3 and 4, is active in the presence of 
E1 and E2 conjugating enzymes, its activity is inhibited by CSN. The 
presence of UV damaged DNA serves to relieve CSN inhibition providing a 
mechanism for DNA-dependent activation of the CRL4DDB2 ligase. 
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The CSA DDB1 complex reveals a common architecture of the DDB1-DCAF 
family 
DDB2 is a member of the large family of DCAFs, functioning as a DNA 
damage specific receptor recruiting CRL4DDB2 to pyrimidine dimer sites. 
Additional DCAFs have been described, the majority of which serve as 
substrate receptors to CRL4 ubiquitin ligases. These receptors likely do not 
bind DNA, but rather recognize proteins. In the CRL4DDB2 structures, DDB2 
emerges as modular unit insulated from the CUL4 ligase. The absence of 
specific interactions between DDB2 and CUL4 would principally allow 
exchange of DDB2 for other WD40 containing substrate adaptors. We thus 
focused on the DDB1-CSA-CUL4-RBX1 (CRL4CSA) ligase, seemingly 
unrelated to DDB2 besides the WD40 repeat in its protein sequence, which 
functions in the transcription-coupled repair (TCR) branch of NER (Fousteri 
and Mullenders, 2008). 
Cockayne syndrome (CS) is a rare congenital disease exhibiting defects in 
the TCR branch of NER. The stalling of RNAPII observed in the presence of 
damaged nucleotides tightens the interaction between the RNAPII and the 
Cockayne syndrome B (CSB) SWI/SNF ATPase. The complex of RNAPII and 
CSB in turn is a prerequisite for the arrival of the Cockayne syndrome A 
protein complex (CRL4CSA) (Fousteri et al., 2006). Both CSA and CSB are 
required for successful repair and transcription restart. CRL4CSA has been 
implicated in the ubiquitination and subsequent degradation of CSB in a UV-
dependent fashion (Groisman et al., 2006).  
We have determined the structure of the human DDB1-CSA complex at 3.3 
Å resolution (Figure 6). The structure was solved by molecular replacement 
as outlined in Supplemental experimental procedures. CSA comprises a 
seven-bladed WD40 propeller (aa 30–365) that attaches to DDB1 through a 
helix-loop-helix motif (aa 1–29). The CSA helix-loop-helix motif (HLH-box) and 
the WD40 propeller were well ordered, whereas no interpretable electron 
density was found for the C-terminus of CSA (aa 364 to 396) and the C-
terminal affinity tag. Irrespective of the limited (20 %) sequence identity 
between DDB2 and CSA, the DDB1-CSA and DDB1-DDB2 complexes show 
high overall structural similarity (backbone rmsd of 3.4 Å for 355 CSA/DDB2 
residues).  
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The location of CSA patient mutations are indicated in Figure 6b. We note 
that CSA mutations resulting in milder forms of CS type III (and UV sensitive 
syndrome UVSS) are point mutations expected to cause only limited structural 
damage. Mutations giving rise to the more severe forms, CS type I and II are 
point mutations, deletions and premature chain termination mutations 
expected to severely compromise the CSA structure (see Table S6 for 
detailed analysis of CSA patient mutations and discussion of structure & 
phenotype correlations). 
 
The CSA-DDB1 interaction is mediated through the HLH-BOX 
DDB1 comprises three WD40 domains (BPA, BPB and BPC) and a C-
terminal α-helical domain (CTD). We found that CSA binds to DDB1 with an 
N-terminal HLH-box segment formed by aa 1–29 (Figure 6a and d). The HLH-
box localizes to a cleft between the DDB1 propellers BPA and BPC. The two 
parallel HLH-box helices, α1 and α2, pack against each other. The HLH-box 
interaction surface with DDB1 encompasses the outer surface of α1 and the 
N-terminal tip of α2 (aa 16–20). The majority of CSA α1 interactions with 
DDB1 are hydrophobic (CSA Met1, Leu5), or contact DDB1 through H-bonds 
(CSA Ser6, Arg8, Gln9). While α1 is buried deeply in the BPC DDB1 
propeller, α2 is further detached from DDB1 pointing towards the DDB1 (BPA) 
propeller. CSA α2, contacts DDB1 largely through H-bonds and long-range 
salt bridges comprising CSA α2 residues Arg17 and Arg20, respectively.  
 
Analysis of helix-loop-helix motifs identified in other WD40 containing DCAFs 
The unexpected structural similarity between DDB2 and CSA prompted us 
to reinvestigate whether the majority of WD40 containing DCAFs bind DDB1 
in a similar fashion. In proteomic studies approximately 50 WD40-containing 
DCAFs proteins were identified as putative substrate receptors (Angers et al., 
2006; Bennett et al., 2010; He et al., 2006; Higa et al., 2006; Jin et al., 2006). 
Out of the 18 WD40 containing DCAFs, identified in at least two proteomic 
studies, 13 contained an HLH-box (Figure S6a). In addition to the conserved 
α1 helix (Fukumoto et al., 2008; Li et al., 2010) (Figure 6d to g), we now also 
detect conservation for helix α2. The beginning of α2 (residues +1 to +3) is 
composed of small and hydrophilic side chains, followed by large hydrophobic 
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residues (Phe, Leu and Tyr) at the +4 position, which pack against α1 (Figure 
6c). A large, often polar, residue is found in the +6 position interacting with 
DDB1 (BPA). The length of the loop between α1 and α2 appears non-
conserved and varies between 2 and 7 residues.  
 Based on these sequence signatures, we identify DDB1-(WD40) DCAF 
family members CDT2, DCAF1, WDR21, WDR23, WDR40, WDR22, WDR32, 
and PHIP among others (Figure S6) as having a HLH-box predicted to bind 
DDB1 in a manner similar to DDB2 and CSA. The resultant CRL4DCAF(WD40) 
complexes are expected to strongly resemble CRL4DDB2 sharing principle 
properties such as ligase mobility (see Figure S6c for a model of CRL4CSA).  
We then tested the functional interplay between CRL4CSA and CSN in vitro. 
We observed that CSA is also autoubiquitinated in vitro (Figure 7a, lane 2) 
and that CSA autoubiquitination is in turn inhibited by the addition of CSN (or 
CSNASM) (Figure 7a, lane 3 and 5). Providing the CRL4CSA substrate CSB 
relieved CSN inhibition, and led to ubiquitination of CSB and CSA (Figure 7a, 
lanes 4, 6 and 7 and Figure 7b). In a fully recombinant in vitro system, 
damage DNA binding to CRL4DDB2, as well as CSB binding to CRL4CSA, 
displaces CSN resulting in activation of the CRL4 ligase complex.  
The overall functional and regulatory constraints following from the 
CRL4DDB2 (and CRL4CSA) architectures thus likely extend to other members of 
the CRL4DCAF family. 
  
Discussion 
The molecular basis of targeting, recruitment and activation of the CRL4DDB2 
ligase in chromatin 
On the basis of our findings, we propose the following working model for 
CRL4DDB2 recruitment and activation in response to UV damage (Figure 7c): 
In the absence of DNA damage, nuclear CRL4DDB2 is complexed to CSN in a 
non-chromatin-bound form (Groisman et al., 2003). Following UV damage, 
CRL4DDB2-CSN is recruited to DNA by its ability to interrogate nucleosomes 
for the presence of 6-4PP and CPD lesions (Figure 2). CRL4DDB2 is 
structurally optimized for recognition of CPDs, which due to their small 
intrinsic helix destabilization frequently escapes detection by other damage 
surveillance factors (Figure 1). XPC-RAD23, alone, has no significant affinity 
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for CPD and is unable to detect 6-4PP lesions in chromatin (Yasuda et al., 
2005). Yet XPC is essential for efficient NER repair. The ability of CRL4DDB2 to 
recognize 6-4PPs, and particularly CPDs, embedded in nucleosomes 
provides a pathway to recruit XPC to lesions in chromatin and activate the 
ligase thus facilitating NER (Sugasawa, 2006). We find that DNA damage 
binding to DDB2 directly displaces CSN from CRL4DDB2 resulting in ligase 
activation (Figure 5). Active CRL4DDB2 targets histones, XPC and possibly 
additional proteins located within ~100 Å around the lesion for ubiquitination. 
The release of CSN additionally allows CRL4DDB2 to autoubiquitinate its DDB2 
subunit on the N-terminus (Figure 4). This results in degradation of DDB2 and 
may function as a timing device delimiting CRL4DDB2 activity following UV. A 
CRL4DDB2 variant defective in DNA binding, as seen in patient XP82TO, 
retains CSN binding and in vivo does not undergo autoubiquitination and 
degradation following UV (Rapid-Otrin et al., 2002; Wittschieben et al., 2005; 
Matsunda et al., 2005; Takedachi et al., 2010) (Figure 5f).  
 
The architecture of the CRL4DCAF family  
The CRL4DDB2 ligase is perceived to be a special case, as it recognizes a 
non-protein substrate. The ligand, in this case DNA, is atypically not the target 
for ubiquitination, but rather proteins in its proximity are the entities 
ubiquitinated.  In order to examine how other CRL4DCAF complexes, 
structurally and functionally, relate to CRL4DDB2, we determined the structure 
of the DDB1-CSA complex. The DDB1-CSA complex, which was shown to 
bind a protein epitope rather than damaged DNA (Groisman et al., 2006) 
revealed a surprising overall architectural similarity to the DDB1-DDB2 
complex. We find that CSN mediated inhibition of CRL4CSA is released 
through addition of CSB, similar to what has been observed for CRL4DDB2. In 
vivo, the disappearance of CSN from the CRL4CSA complex (ca. 4h post UV) 
coincides with ubiquitination and disappearance of CSB (Groisman et al., 
2006). Structure-based sequence analysis identified a common HLH motif 
within the WD40-DCAF family expected to link other WD40 containing DCAFs 
to DDB1 in a manner similar to that of CSA and DDB2. At present, we can not 
exclude that alternative DCAF binding modes exist, or that access of the 
DCAF HLH-box to DDB1 is subject to regulation. Our results demonstrate that 
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CRL4DDB2, CRL4CSA and with it the majority of CRL4DCAF/WD40 complexes are 
predicted, to share a common architectural scaffold. These CRL4 ligases are 
expected to exhibit mobility, and hence, absence of direct crosstalk between 
the DCAF substrate receptor and the ubiquitin ligase, requiring CSN to 
mediate activation.  
 
Substrate dependent crosstalk between CRL4 complexes and the COP9 
signalosome 
CSN is a key regulator of cullin-RING ligase activity. The involvement of 
CSN in ligase regulation poses the following question: how is a specific ligase 
regulated by CSN, without affecting the remainder of cullin-RING ligases. We 
find that the association and inhibition of CRL4DDB2 by CSN is relieved upon 
DNA damage binding to the WD40 propeller of DDB2 (Figure 5). A similar 
behavior is seen for CRL4CSA where CSB binding displaces CSN (Figure 7a 
and b). Indeed, we observe in CRL4DDB2-CSN negative stained EM single 
particle reconstructions that the DDB2 subunit is held in close proximity to 
CSN (data not shown). Other structurally related CRL4DCAF complexes are 
thus expected to bind CSN in a similar fashion. This strongly suggests that 
CSN release and subsequent activation of CRL4DCAF complexes are simply 
triggered by substrate binding to the DCAF within the CRL4DCAF-CSN 
complex. 
Protection of substrate receptors by CSN has previously been described 
for the CRL1 and CRL3 families in vivo (Bornstein et al., 2006; Schmidt et al., 
2009; Zhou et al., 2003) and likely extends to the CRL4 family (Bennett et al., 
2010). The protective effect of CSN on DDB2 autoubiquitination observed in 
this study is independent of deubiquitinating enzymes, and does not require 
CSN5 mediated deneddylation (see Figure S5 for CSN subunits required for 
inhibition). Similar properties have been observed for the CSN-CRL4CSA 
interplay, although the cellular role of CSA autoubiquitination is unclear at 
present. In vivo. (i) the intrinsic CSN deneddylase activity, (ii) CSN-associated 
deubiquitinases and (iii) the non-enzymatic CSN inhibition observed are all 
expected to act in concert inhibiting CRL4 in the absence of an activating cue. 
Further work is needed to define the relative contribution of these three 
strategies (i-iii) to CSN mediated inhibition in vivo. However, all three levels of 
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inhibition are simultaneously relieved once DDB2 (CSA) contacts DNA 
damage (CSB), as the direct contact between receptor and substrate results 
in CSN dissociation and loss of receptor protection. In light of the conserved 
architecture of the majority of CRL4DCAF(WD40) complexes this provides a 
general mechanism for regulating the CRL4 CSN interplay. 
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Experimental Procedures 
Protein expression and purification: All proteins used for structure 
determination were cloned into pFastBac Dual vectors (Invitrogen) and 
expressed and purified from High Five cells (Invitrogen) as outlined in Scrima 
et al., 2008 (see also Supplemental experimental procedures). Purified 
recombinant CSB protein was provided as a kind gift from Regina Groisman. 
Enzymes for neddylation such as NAE1/UBA3 and UbcH12, as well as 
NEDD8, were purified as N-terminal His6 fusion proteins from Escherichia coli 
(Duda et al., 2008). hsUBA1, hsUbcH5A, hsUbcH5B, hsUbiquitin and 
hsUbiquitin-K0 were purchased from Boston Biochem. 
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Oligonucleotides used in this study: Single stranded DNA oligonucleotides 
and oligonucleotides containing tetrahydrofuran (THF) lesion were purchased 
from Sigma Aldrich. Oligonucleotides containing the cis-syn CPD were 
synthesized using phosphor-amidite building blocks (Glenn Research, USA). 
Sequences of oligonucleotides used are provided in the Tables S4 and S5. 
 
Crystallization & Structure solution: Crystallization conditions as well as 
data collection and refinement statistics are given in Table S1.  
 
Cellular assays: HA-tagged DDB2 (wild type or mutant) was stably 
overexpressed in a normal human fibroblast cell line, WI38 VA13, by using 
the pIREShyg vector. The transformed cells were exposed to UVC (10 J/m2) 
and incubated for various times. Whole cell extracts were prepared and 
analyzed by immunoblotting. 
 
In vitro ubiquitination assays: Assays for autoubiquitination were carried out 
as described in Sugasawa, 2006. Antibodies used include α-hsDDB2 
(AF3297, R&D Biosystems), α-XPC (Sugasawa et al., 2005), α-CSA 
(GTX100145, GeneTex), α-CSB (SC10458, Santa Cruz) and horseradish 
peroxidase (HRP)-conjugated secondary antibodies against Goat IgG (R&D 
Biosystems) and rabbit IgG (GeneTex). 
 
Accession Numbers 
CPD#1(pdb:4A08), CPD#2(pdb:4A09), CPD#3(pdb:4A0A), CPD#4(pdb: 
4A0B), CAND1-CUL4B(pdb:4A0C), CRL4ADDB2-DNA(pdb:4A0K), 
CRL4BDDB2-DNA(pdb:4A0L), DDB1-CSA(pdb:4A11) 
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Figure Legends: 
 
Figure 1: DDB1-DDB2 in complex with CPD-containing duplexes 
(A) Cartoon representation of DDB1-DDB2-CPD. DDB2, green; DDB1 
(BPA), red; (BPB), magenta; (BPC), yellow; DDB1-CTD, gray and the DNA in 
black and gray for the damaged and undamaged strand respectively, with 
CPD shown in red. The DDB2 residues involved in DNA binding are shown as 
close-up. (B) Schematic representation of DNA-protein interactions. (C and D) 
Close-up view of the CPD/6-4PP fit to the hydrophobic binding pocket. (D) 
Close-up of the bound CPD lesion, demonstrating that the DDB2 binding 
pocket preferentially accommodates the CPD. See also Figure S1, Tables S2 
and S3. 
 
Figure 2: DDB2 is able to recognize 6-4PP and CPDs embedded in 
nucleosomes 
(A) EMSA of the DDB1-DDB2 complex binding to UV-damaged 
nucleosome core particles (NCP), indicated amounts of DDB1-DDB2 were 
incubated with UV-damaged or undamaged mononucleosomes. (B) EMSA 
analysis of DDB1-DDB2 binding to nucleosomes containing a specific 6-4PP 
lesion, indicated amounts of DDB1-DDB2 were incubated with 0.2 fmol of 
naked DNA (lanes 1-6), mononucleosomes (lanes 7-12) or both (lanes 13-16). 
The non-damaged DNA control is shown as indicated. (C) As in (B) using 
CPD containing nucleosomes. (D) and (E) Quantitative analysis of DDB1-
DDB2 binding to free lesion containing DNA or lesion embedded in the 
nucleosomes 6-4PP (B) or CPD (C). (F) EMSA analysis of DDB1-DDB2 and 
CRL4ADDB2 complex binding to UV-damaged mononucleosomes. 
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Figure 3: The structure of the CRL4ADDB2 complex bound to THF containing 
duplex 
Cartoon representation of the CRL4ADDB2 complex structure: DDB2, green; 
DDB1 (BPA), red; (BPB), magenta; (BPC), orange, DDB1-CTD, gray; CUL4A, 
cullin repeat domains (CRD1-3) and C-terminal domain (CTD) depicted in 
gray to black; RBX1 in cyan. The DNA is shown in black and orange for the 
undamaged and damaged strand respectively. DDB1 and DDB2 are shown 
as surface in the bottom panel. See also Figure S2. 
 
Figure 4: The structures of CRL4BDDB2 bound to DNA damage: rotational 
mobility of the ligase 
(A, B) Overlay of the three experimental CUL4 orientations indicating the 
rotational mobility of CUL4 (in gray) respective to DDB2 (depicted as surface 
in green) and the bound DNA substrate (depicted in orange and black). (C) 
Overlay of medium to high resolution CUL4A and CUL4B structures and 
schematic representation of domain boundaries. (D) Model of CRL4DDB2 
with the CUL4 arm depicted in the most distal DDB1-BPB orientations and the 
resultant ubiquitination hot zone indicated in light orange and gray. (E) Table 
of available medium to high resolution DDB1 structures with the 
corresponding orientation of CUL4 and predicted ePISA solvation energies of 
DDB1 (BPB) to DDB1 (BPA/BPC) interactions. See also Figure S3. 
 
Figure 5: CSN dependent regulation of CRL4DDB2 mediated ubiquitination of 
the DDB2 N-terminus regulates degradation following UV exposure 
(A) In vitro ubiquitination assays using K-less ubiquitin and the CRL4ADDB2 
complex containing either full-length DDB2 (DDB2-FL) or DDB2-ΔN. The 
reaction mixture was subjected to immunoblot analysis with indicated 
antibodies. (B) HA-tagged DDB2-FL or DDB2-7KR was stably overexpressed 
in a normal human fibroblast cell line. Extracts from these cells as well as the 
parental cell line (indicated by -) were subjected to immunoprecipitation with 
anti-HA antibody and immunoblot analysis with indicated antibodies. One 
percent each of the input extracts (I) and unbound fractions (U) were analyzed 
in parallel. (C) The cell line stably expressing HA-DDB2-FL or HA-DDB2-7KR 
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was exposed to UV irradiation 2 h after treatment with 1 mM cycloheximide 
(CHX) in the presence or absence of 5 µM MG132. Cells were further 
incubated for various times in the presence of CHX (± MG132) and whole cell 
extracts were subjected to immunoblotting using indicated antibodies. (D) In 
vitro ubiquitination assays were performed with wild type CRL4ADDB2 complex 
and analyzed by DDB2 immunoblot. Wild type CSN complex (lane 4) or a 
complex containing a CSN5 active site mutant (lane 5) significantly inhibited 
the autoubiquitination of DDB2. This inhibition was relieved by the addition of 
UV-irradiated DNA to the reaction (lanes 5 and 7). (E) Small oligonucleotides 
containing an THF abasic site mimic (lane 3), CPD lesion (lane 4) or 6-4PP 
lesion (lane 5) were sufficient to relieve the inhibition, whereas an undamaged 
oligonucleotide of similar length did not affect the inhibition (lane 6). Ubiquitin-
aldehyde had no effect on the reaction (lane 1 and 2). (F) In vitro 
ubiquitination assays were performed with CRL4ADDB2 complex harboring the 
K244E DDB2 patient mutation. In contrast to wt DDB2, the inhibition by 
CSNASM was not relieved upon damaged DNA addition (lane 4). See also 
Figure S4, S5 and Table S5.  
  
Figure 6:The structure of DDB1-CSA suggests a shared architecture of 
CRL4DCAF complexes 
(A) Overall structure of the DDB1-CSA complex. CSA: blue, DDB1 (BPA): 
red, (BPB): magenta, (BPC): yellow, DDB1-CTD: gray. Schematic overview of 
the CSA organization. (B) CSA mutations linked to different phenotypes of 
Cockayne syndrome (white: CSI, red: CSIII/UVSS). (C) HMM based 
sequence logo and corresponding secondary structure of the helix-loop-helix 
box (see Figure S6a for full alignment). (D) Superposition using DDB1-
BPA/BPC results in a similar orientation of CSA (blue) and DDB2 (green) 
showing the common architecture of the complexes. Close-up view of the 
helix-loop-helix motif in hsCSA (E), drDDB2 (F) and hsDDB2 (G), 
respectively. Residues belonging to the conserved motif are indicated. See 
also Figure S6, S7 and Table S6. 
 
Figure 7: Model for CRL4DDB2 ligase activation and release of CSN upon 
damage binding 
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(A) In vitro ubiquitination assays were performed with CRL4ACSA complex 
and analyzed by CSA immunoblot. Wild type COP9 signalosome (CSN) 
complex (lane 3) or a complex containing a CSN5 active site mutant (lane 5) 
significantly inhibited DDB2 autoubiquitination. This inhibition was relieved by 
the addition of CSB to the reaction (lanes 4, 6 and 7). Unspecific cross-
reactivity of the anti-CSA antibody is indicated with a red asterisk. CSB 
immunoblotting demonstrated that the CSB substrate is also ubiquitinated in 
this reaction (B). (C) In complex with CSN, CRL4DDB2 is held in a ubiquitin 
ligase inactive state. UV irradiation induces lesion formation in chromatin and 
recruitment of the CRL4DDB2-CSN complex to the site of damage. It is 
currently not clear if DDB2 binds on the nucleosome, or to a looped off 
intermediate (Duan and Smerdon, 2010). Binding to chromatin/nucleosome 
results in steric displacement of CSN (involving CSN subunits 1,2,3,4 & 6) 
and ligase activation. This in turn allows for ubiquitination of diverse 
substrates within the zone of ubiquitination including histones, XPC and 
DDB2. 
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Figure 7
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Figure S1: hsDDB1-drDDB2 CPD structures. Related to Figure 1 
(A, B) Surface mutations were introduced in DDB1 in an attempt to favor CPD 
bound DDB1-DDB2 crystallization, relative to the apo-form. As DDB1 does not 
contact the DNA within the DDB1-DDB2 complex (Scrima et al., 2008) mutants were 
introduced to interfere with crystal-packing of symmetry related DDB1 molecules 
(marked DDB1*) in the apo-form. These mutations did not affect the DDB1-DDB2 or 
DDB2-DNA interfaces. The following mutations of DDB1 residues were expressed 
and purified based on analysis of the DNA free (pdb: 3EI3) versus the 6-4PP bound 
DDB1-DDB2 complex (pdb: 3EI1): E127K, E127S, Q174A, A175D, E194A, S196A. 
E224K, E224S and E127K/E224K (Supplemental Figure S1a and b). DDB1 
mutants E194A, E224K and E224S each resulted in diffraction grade CPD co-
crystals.  
(C) Overlay of CPD2, CPD4 and 6-4PP (3EI1) focusing on the lesion and 
opposing bases. The DNA path around the lesions is largely anchored through 
contacts between the phosphate moieties and DDB2 residues Lys280 (binding 
duplex base: D+3 & D+4), Lys168 (D+1 & D+2), Gln372 (D+2), Arg148 (D+1), Arg404 
(U+2), Tyr393 (U+1) and Arg369 (U-1). While the 6-4PP and CPD containing duplexes 
are characterized by different orientations of their ribose moieties and nucleotide ring 
systems, their phosphate groups (positions D+1,D+2,D+3) (Figure 1) are 
indistinguishable within experimental error. This is made possible through 
compensatory rotations around the phosphate backbone torsions linking bases D-
1/D+1 and D+2/D+3 (Figure S1d). Difference in the sequence such as a 
pyrimidine/purine at the U-1 location, the major nucleotide enabling kinking of the 
undamaged strand, are compensated through rolling the base in/out of the duplex 
respectively through the 3’ and 5’ phosphate torsions (Supplementary Figure S1c). 
The phosphate backbone thereby serves as molecular pivot points buffering 
difference in DNA sequence and conformation. The plasticity of the DNA renders 
DDB2 a DNA sequence-independent recognition module, able to accommodate 
different pyrimidine dimer lesions, while being optimized for detecting CPD 
pyrimidine dimers.  
(D) Close-up view of the CPD lesion obtained in the four structures with 2mFobs-
DFcalc contoured at 1σ. A total of four structures of hsDDB1-drDDB2 bound to four 
different CPD containing oligonucleotides (see Table S1, Figure S1d) were 
determined (with CPD #4 containing two molecules/asymmetric unit (ASU)). The five 
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molecules crystallized in different space groups with different packing arrangements. 
The DDB1 (BPB) domain was found to be mobile, and fully disordered in CPD#3. 
DDB1 (BPA+BPC) and DDB2 observed in the four structures share an overall rmsd 
of 0.98 Å (CPD #1 as reference, vs. CPD #2, CPD #3, CPD #4_Mol1, CPD 
#4_Mol2). Overlay of the individual DNA structures using the 7 bp stretch in direct 
contact with DDB2 (damaged bases: D-3 to D+4 and undamaged bases: U-4 to U+3) 
resulted in an average rmsd of 1.36 Å, or 0.95 Å, using all atoms or the phosphate 
atom backbone, respectively. The residues outside the 7 bp core (especially 3’ of the 
CPD) show larger deviations due to lattice contacts and local unwinding. The DNA is 
exclusively bound by DDB2 at the narrow end of the WD40 propeller (Figure 1a) 
where it adopts two B-type stretches spanning 5 bp and 4 bp (Supplemental Figure 
S1e), on the 5’ and 3’ end of the di-nucleotide damage respectively. Three arginine 
and three lysine residues (Arg148, Arg369, Arg404, Lys168, Lys280 and Lys325) 
were found contacting the phosphate backbone. Lys168, in particular, compensates 
the local phosphate backbone negative charge directly at the lesion, where the 
phosphate-phosphate distance (D+1 to D+2) is reduced from about 7 Å (B-DNA) to 5.9 
Å (Supplemental Table S3). 
(E) Schematic representation of the DNA conformation based on 3DNA analysis 
(Lu and Olson, 2008).  
(F) Overlay of the CPD duplex obtained from the CPD1 crystal and the X-ray 
crystallographic structure of a free CPD containing oligonucleotide (1N4A), aligned 
using 4 bp of B-type DNA 5’ to the CPD lesion. The structures of 6-4PP containing 
DNA duplexes in solution showed no similarity with the DDB2-bound duplexes 
(Scrima et al., 2008), whereas the CPD conformation observed in the presence of 
DDB2 closely resembles two protein-free CPD duplex structures previously 
described by Park et al., 2002. The CPD, like other DNA lesions, confers flexibility 
onto the duplex (Yang, 2008). The protein-free DNA structures thereby, depict one 
intermediate out of the populated solution ensemble, which is expected to become 
rigidified upon protein binding. The two cis-syn CPD structures, and that observed in 
the presence of DDB2, share a comparable kink towards the major groove 
(CPDDDB2:~45°; CPDfree:~30°), similar helix unwinding (CPDDDB2:~12.6°; 
CPDfree:~9.3°) and widened minor grooves (CPDDDB2:18 Å; CPDfree:13 Å) resulting in 
an overall rmsd of 1.92 Å over 8 bp (see Supplementary Information 1).  
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(G) CPD containing DNA duplexes bound to DDB2, Photolyase (1TEZ) and T4 
EndonucleaseV (1VAS). Proteins are shown as surface in gray and the DNA as 
cartoon with the CPD highlighted as sticks (black). The approximate helical bend is 
indicated (Mees et al., 2004; Vassylyev et al., 1995).  
(H) Overlay of the DNA overall conformations of an 31 bp THF, 16bp THF (3EI2), 
6-4PP (3EI1) and CPD (CPD1) with DDB2 depicted as surface in gray. 
 
Figure S2: CRL4ADDB2 structure bound to a THF containing duplex. Related to 
Figure 3 
(A) Cartoon representation of the CRL4ADDB2 complex, 2mFobs-DFcalc electron 
density (contoured at 1.0 σ) is shown in blue.  
(B) Ribbon representation of the SeMet labeled CRL4ADDB2 complex highlighting 
predicted Se positions as green balls. Anomalous difference map contoured at 3.0 σ 
is shown in blue.  
(C) Cartoon representation of the CRL4ADDB2 complex, composite omit electron 
density (contoured at 0.8 σ) is shown in blue.  
(D) Summary of observed peaks in the anomalous difference map for the 
CRL4ADDB2 complex.  
(E, F and G) SDS-PAGE analysis of CRL4ADDB2 complexes used in this study.  
(H) Surface representation of the DDB1-BPB domain and close-up of the linker 
region as cartoon between DDB1-(BPA, BPC) and DDB1-(BPB) domains (residues 
384-399 and 702-719) of three different DDB1 conformations (pdb: 2HYE, 2B5L and 
3EI1 (Angers et al., 2006; Li et al., 2006; Scrima et al., 2008)) and DDB1-BPB 
domain of 2B5L in light blue shown as surface.  
 
Figure S3: The CRL4BDDB2-THF and CAND1-CUL4B structures. Related to 
Figure 4 
(A, B) Cartoon representation of the CRL4BDDB2 complex structure with CUL4B in 
gray, RBX1 in cyan, DDB1-BPA in red, DDB1-BPB in magenta, DDB1-BPC in 
orange, DDB2 in green, and the DNA depicted in black and orange for the 
undamaged and damaged strand respectively. Molecule 1 (A) and molecule 2 (B) 
are shown with the corresponding composite omit electron density (contoured at 0.8 
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σ) in blue or the 2mFobs-DFcalc electron density (contoured at 1.0 σ) for molecule 1 
(C) and molecule 2 (D) in blue.  
(E) Cartoon representation of the CAND1-CUL4B structure with CAND1 depicted 
in cyan, blue and purple and CUL4B in gray to black. The overall complex of CAND1 
and CUL4B resembles the previously determined structure of CAND1-CUL1 
(Goldenberg et al., 2004). CAND1 and CUL4B/CUL1 are arranged in a head-to-tail 
fashion, with CAND1 adopting a sinuous super-helical structure wrapping around the 
cullin fold (Supplemental Figure S3e). The two CAND1/CUL4B complex molecules 
observed exhibit the following minor rigid body movements: (i) a ~2-3° hinge motion 
in the N-terminal domain of CUL4B (residues 210-379: preceding cullin repeat 2) 
coupled to a ~3-4° rotation of the CAND1 C-terminal (arm residues 791-1216); (ii) a 
rotation of RBX1 and the CUL4 CTD (residues 637-913) ~1-2.5° in conjunction with 
the CAND1 N-terminus (residues 4-408) (Supplemental Figure S3e). The two 
CAND1 hinge-points (residues 408 and 791) are preceded by an unstructured loop 
region, which likely facilitates the movement around the hinge (Supplemental 
Figure S3f).  
The structures of both CUL4B molecules superimpose well with CUL4A (rmsd of 
1.54 Å over 677 residues). Together with the more than 84 % identity (93 % 
similarity) between CUL4A and CUL4B (residues 192-913) we conclude that both 
CUL4 type cullins share identical overall structures and exhibit limited flexibility in the 
N- & C-terminal domains.  
CAND1 bound CUL4B aligns with CAND1 bound CUL1 with an rmsd of 3.1 Å. 
The main differences among the two cullin folds originated from the orientations of 
the cullin NTD and CTD domains (see above and Angers et al., 2006). Comparison 
of the CUL1, 4A and 4B molecules further supports the notion of a small degree of 
flexibility within these domains (Angers et al., 2006). While relatively small 
differences are detected within the CUL4A/4B branch, more pronounced differences 
are observed between CUL1 and CUL4A/B (Supplemental Figure S3g). 
Between the CAND1-CUL1 and the two CAND1-CUL4B structures, similar 
patches on CAND1 and CUL4B/CUL1 are being used for cullin binding. Conserved 
C-terminal cullin epitopes located on CUL1/4 helix 23 & 29 are recognized through 
conserved interactions with the CAND1 (Supplemental Figure S3e). Additional sites 
of interaction with CUL1/CUL4B cluster in the CAND1 N-terminal (residues 1-208, 
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HEAT repeat helices B1-B5), the C-terminal region (residues 704-1190, HEAT 
repeat helices B20-B22, B24-27) and the beta-hairpin element (residues 1062-1077). 
The less conserved central region of CAND1 (residues 209-703), however, only 
displays few cullin interaction sites (B11-B12, B16-18). While similar residues are 
buried in the two CAND1/CUL4B molecules, detailed hydrogen-bonding and salt 
bridge interaction are often formed in a manner involving neighboring residues N+1/N-
1.  
 (F) Superposition of the CAND1 originating from CAND1/CUL1 structure (1U6G 
(Goldenberg et al., 2004)) and from the CAND1/CUL4B structure.  
(G) Superposition of CUL1 originating from CAND1/CUL1 (1U6G) with CUL4B 
from the CAND1/CUL4B structure. Significant differences between CUL4 and CUL1 
are observed in loop regions CUL4B:509-515 (CUL1: 355-362) and CUL4:277-284 
(CUL1: 109-114). Both these loops constitute substantial interaction surfaces for the 
cullin and CAND1 and push the cullin in a slightly different conformation. These 
conformational changes in the cullin are being compensated through 
expansion/compaction of the CAND1 super-helical U-shaped conformation. The 
overall surface area buried in both proteins upon complex formation is comparable 
CAND1-CUL4B (7327.6 Å2) and CAND1-CUL1 (6683.7 Å2). 
Positional cloning coupled to large scale sequencing efforts revealed multiple 
mutations in the CUL4B gene implicated in X-linked mental retardation (XLMR) 
(Tarpey et al., 2007). In addition to missense mutations, and the presence of 
premature stop codons, a functional CUL4B null patient suffering from XLMR has 
been described (Isidor et al., 2010). Patients show clinical symptoms of mental 
retardation in conjunction with growth retardation, gait ataxia, tremor, hypogonadism 
and gynecomastia (reviewed in Kerzendorfer et al., 2011). The XLMR syndrome 
patients, defective in CUL4B, show very little clinical similarity with those patients 
defective in NER, such as Xeroderma pigmentosum (XP) and Cockayne syndrome 
(CS). The structures of CUL4A and the corresponding cullin moiety of CUL4B 
(residues 192-913) are indistinguishable. In agreement with the structural 
resemblance, we did not observe significant differences in the activity in vitro, and 
observed that both CUL4A and CUL4B bound to DDB1 with comparable affinity upon 
co-expression (data not shown). The structure of CUL4B now provides a molecular 
rationale for mapping of patients mutations: 
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Premature termination mutations: The premature termination mutations (p.308X, 
p.337X, p.388X, p.806X, p.836X) lead all to CUL4B C-terminus truncations, resulting 
in loss of RBX1 binding. The absence of RBX1 in turn, removes the docking site of 
the ubiquitin E2 enzyme, rendering the CUL4B E3 ligase inactive. In cases where 
such CUL4B mutant proteins are produced (see for example Kerzendorfer et al., 
2010), they are expected to function as dominant negatives competing with the 
access of active CUL4 ligases to DDB1. 
Point mutations: p.T213I is located near the interface between CUL4B and DDB1 
in a partially solvent exposed region. Mutation of Thr231 into a hydrophobic Ile is 
expected to influence the conformation of helix (H1), which directly mediates DDB1 
attachment. Two further point mutations have been described: R572C is located in 
close proximity to CAND1 binding. V745A is located in proximity to the RBX1. Both 
mutations are, however, structurally conservative and their mutagenic mode of action 
remains unclear. 
 
Figure S4: The DDB2 N-terminus as target for autoubiquitination. Related to 
Figure 5 
(A) SDS-PAGE analysis of in vitro ubiquitinated CRL4ADDB2 for analysis by mass 
spectrometry, sample positions are indicated by 1, 2 and 3.  
(B) Ubiquitin acceptor lysines mapped by LC-MS/MS with corresponding peptide 
sequence and experimental data.  
(C, D) Two representative MS/MS spectra for peptides harboring ubiquitin 
receptor Lys K40 and K11, corresponding fragmentation for b, b++, y and y++ ions is 
shown.  
(E) SDS-PAGE analysis of proteins used for crystallization and assays.  
(F, G) SDS-PAGE analysis of CUL4A autoubiquitination in the presence and 
absence of CSN or CSNASM, and SDS-PAGE analysis of the deubiquitination activity 
of CSN towards CUL4 (G). Autoubiquitination (Supplementary Figure S4f) and 
neddylation (data not shown) of CUL4A within the CRL4DDB2 complex was unaffected 
by the presence or absence of the CSNASM (Supplementary Figure S4f, lanes 1 
and 4). We further observed that active CSN could remove ubiquitin attached to the 
neddylation site of CUL4 (Supplementary Figure S4g, lane 1) as identified by mass 
spectrometry (data not shown). However, CSN was unable to remove ubiquitin from 
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DDB2 or CSA (Supplementary Figure S4h and i). In addition, the deubiquitination 
of CUL4-ubiquitin was dependant on CSN5, as no such activity was observed with 
CSNASM (Supplementary Figure S4g, lane 2). 
(H, I) Ubiquitinated CSA (H) or DDB2 (I) has been incubated with CSN prior to 
immunoblotting in order to investigate potential deubiquitination activity of CSN, no 
such activity could be observed. 
 
Figure S5: CSN mediates activation between DDB2 and the ubiquitin ligase. 
Related to Figure 5 
(A, B) Inhibition and DNA-dependent relieve of DDB2 autoubiquitination by CSN 
complexes carrying an active site mutation (CSNASM, inactive isopeptidase) lacking 
either the CSN5 subunit or the CSN5 and CSN7 subunit (A), or the CSN8 (B).  
(C) Additional CSN subcomplexes lacking the indicated subunits were tested for 
proficiency in DDB2 protection.  We set out to define which CSN subunits are required to 
confer DNA damage mediated DDB2 protection by CSN. For that purpose we purified a 
number of CSN complexes (see Supplementary Experimental Procedures) using a single 
subunit bearing an N-terminal Strep-II tag. Complexes purified include CSN1*2345678, 
CSN1*2345ASM678, CSN12346*78, CSN12346*8, CSN123*678, CSN123*68, CSN1238*, 
CSN123*, CSN1*2 (* asterisk denotes the subunit carrying the tag) all of which were 
subjected to in vitro autoubiquitination and protection assays. We observed that CSN 5, 7 and 
8 are dispensable to provide DDB2 protection against CUL4-mediated DDB2 
autoubiquitination with complexes lacking these subunits also being as proficient in DNA 
damage dependent loss of DDB2 autoubiquitination protection (Supplementary Figure S5a 
and b). Complexes lacking either CSN4, or CSN6 did no longer protect DDB2 from CUL4 
mediated autoubiquitination. Subunits CSN1, 2 and 3 were required for the structural 
integrity of the complex and could not be deleted in the context of the 8 subunit CSN 
complex. An isolated CSN 1, 2 and 3 complex, however, did not provide protection. Based 
on these findings CSN protection appears to be mediated by CSN 4 & 6, with CSN1, 2 and 3 
playing possible scaffolding roles that by itself are not sufficient to stabilize the complex. 
 (D) Inhibition and DNA-dependent release of DDB2 autoubiquitination by CSNASM 
in the presence of recombinant Usp2 counteracting DDB2 autoubiquitination (lane 2) 
and with Usp2 inhibited by Ub.-Aldehyde (lane 3).  
 
 
79 
(E, F) Cy5 fluorescence (E) or Alexa488 fluorescence (F) scan of a native PAGE EMSA 
titrating CSNASM into a DNA(THF)-CRL4ADDB2-Nedd8 (species I, V) complex. Upon 
increasing CSN concentration the level of free DNA (species IV) increases and the DNA free 
CSN- CRL4ADDB2-NEDD8 complex can be observed in the pocket of the gel. We carried out 
Electrophoretic mobility shift assays (EMSA) to examine the effect of damaged DNA duplex 
addition on the CSN-CRL4ADDB2 complex: The complex of CRL4ADDB2-NEDD8 and a 15 bp 
THF containing duplex was preformed and then subjected to increasing amounts of CSN 
(Supplementary Figure S5e-f). In order to follow the fate of individual components we used 
a synthetic THF oligonucleotide carrying a Cy5 label on the opposing strand, in combination 
with an Alexa488 labeled CRL4ADDB2-NEDD8 complex. Titrations were performed with a 
CSN complex harboring a CSN5 mutant (CSNASM), which is defective in CSN5 mediated 
cullin deneddylation. All complexes are expressed in High Five insect cells (Enchev et al., 
2010). Addition of CSNASM resulted in the dissociation of the CRL4ADDB2-DNA complex 
(Supplementary Figure S5e and f, lane 5-8, species I and V) giving rise to free DNA 
(Supplementary Figure S5e, species IV), CRL4ADDB2-NEDD8 bound CSNASM complex 
(Supplementary Figure S5f in the gel loading pockets) and a protein bound DNATHF species 
(Supplementary Figure S5e, species II & III). Species II & III did not show an Alexa488 
signal, arguing that they are free of CUL4-NEDD8, likely consisting of DDB2 bound 
DNATHF. Importantly, no significant accumulation of novel species was observed containing 
both CUL4-NEDD8 (Alexa488 channel) and DNA (Cy5 channel) (compare Supplementary 
Figure S5e & f, lanes 6-8). The DNA observed upon addition of CSN, in turn, likely 
originates from the displacement of DNA from the free CRL4DDB2-NEDD8-DNA complex 
resulting in CSN-CRL4DDB2-NEDD8 (Supplementary Figure S5f). These findings are 
consistent with DNA mediated dissociation of CRL4DDB2-CSN. 
(G and H) SEC-MALS analysis of a CSN-CRL4ADDB2-Nedd8 complex in the 
absence (G) or presence (H) of a 24bp oligonucleotide harboring a THF site. We 
subsequently tested the effect of DNATHF on CSN-CRL4ADDB2-NEDD8 using size 
exclusion chromatography. We found that CRL4ADDB2-NEDD8 showed tight binding 
to CSNASM under these conditions (see Supplementary Figure S5g). However, no 
binding of CRL4DDB2 to CSN was detected in the absence of neddylation such 
binding between CSN and CRL4ADDB2 was only detectable in pulldown assays, data 
not shown. We carried out gelfiltration experiments using 42 µM CRL4ADDB2-NEDD8 
mixed with 30.45 µM CSNASM in the presence, or absence of 200 µM 24 bp DNATHF 
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(Supplementary Figure S5g and h). The average molecular weight of the CSN-
CRL4ADDB2-NEDD8 peak, in the absence of DNATHF determined by multi-angle light-
scattering (MALS) was 519 kDa (9.39 ml). The apparent molecular weight decreased 
to 467 kDa (9.47 ml) in the presence of DNATHF. DNATHF binding analogously 
resulted in earlier elution of CRL4ADDB2, 10.64 ml (264 kDa) compared to 10.85 ml 
(255 kDa) in the absence of nucleic acid. The loss in apparent molecular weight of 
the CSN containing peak, and concomitant gain in retention time for the CRL4ADDB2 
is consistent with partial dissociation of the CSN-CRL4DDB2-NEDD8 complex. Due to 
the peak overlap of CSN, CSN-CRL4DDB2-NEDD8 and CRL4DDB2-NEDD8-DNATHF 
containing species, different peaks and molecular weights could not be fully 
deconvoluted. (I) SEC-MALS analysis of the CSNASM complex. 
 
Figure S6: Structure of the Cockayne Syndrome A protein (CSA) bound to 
DDB1. Related to Figure 6 
(A) Helix-loop-helix motif in DCAFs: Sequence alignment of 77 sequences N-
terminal of WD40 propellers of DCAFs by T-COFFEE (Notredame et al., 2000).  
(B) Surface conservation of CSA: Identical, strongly similar and weakly similar 
residues as shown in the sequence alignment are highlighted in red, orange and 
yellow, respectively.  
(C) Model of CRL4CSA complex based on two orientations of the DDB1-BPB 
domain.  
(D) Mapping of interaction sites using StrepII-tagged CSA and His-tagged DDB1-
BPB or DDB-BPA/BPC in pulldown experiments. 
(E) SDS-PAGE analysis of the DDB1-CSA complex used for crystallization. 
 
Figure S7: Multiple sequence alignment of CSA. Related to Figure 6 
Sequence alignment and secondary structure assignment of CSA. Sequences 
were aligned with ClustalW (Larkin et al., 2007). Conservation score and secondary 
structure elements are given below and on top of the sequences, respectively 
(Caffrey et al., 2007).  
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Table S1: Crystallographic data and refinement statistics. Related to Experimental Procedures 
Values in parentheses are for the highest resolution shell 
a R!"#$ = !!"# -­‐ !!"#!!"# !!"#!"# ; bRfree is the same as Rwork, but calculated on the reflections set aside from refinement. 
* Subunits from high resolution search models (2HYE, 3EI2 and 4A0C) have been placed by molecular replacement and were rigid body refined. 
Data collection
hsDDB1-drDDB2 CPD 
#1
hsDDB1-drDDB2 CPD 
#2
hsDDB1-drDDB2 CPD 
#3
hsDDB1-drDDB2 CPD 
#4 CRL4ADDB2 SeMet-CRL4ADDB2 #522 SeMet-CRL4ADDB2 #566 SeMet-CRL4ADDB2 #523 CAND1-CUL4B CRL4BDDB2 DDB1-CSA
Beamline SLS X10SA SLS X10SA SLS X06DA SLS X10SA SLS X10SA SLS X06DA SLS X06DA SLS X06DA SLS X10SA SLS X06DA SLS X06DA/X10SA
Wavelength (Å) 1.0000 1.0000 1.0000 1.0000 1.0000 0.9600 0.9600 0.9600 1.0000 1.0015 1.0000
Space Group P212121 P212121 C2221 P22121 C2 C2 C2 C2 P21 P21 P3221
Cell parameters
a, b, c (Å) 114.37, 116.70, 137.58 111.65, 122.94, 154,20 155.64, 227.14, 114.32 113.10, 145.90, 224.44 210.65, 78.02, 276.62 212.20, 77.40, 275.20 215.00, 77.70, 277.30 212.70, 77.20, 275.80 77.09, 152.36, 263.01 130.80, 155.84, 255.39 138.33, 138.33, 244.97
α, β, γ (deg) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 108.5, 90 90, 108, 90 90, 108.7, 90 90, 108.1, 90 90, 89.4, 90 90, 94.2, 90 90, 90, 120
Resolution (Å) 50.0-3.0 (3.1-3.0) 50.0-3.1 (3.2-3.1) 50.0-3.6 (3.7-3.6) 50.0-3.8 (3.9-3.8) 20.0-5.9 (6.08-5.93) 50-5.9 (6.11-5.90) 30.0-7.0 (7.25-7.00) 40.0-6.5 (6.73-6.50) 50.0-3.8 (3.9-3.8) 30.0-7.4 (7.59-7.40) 50-3.3 (3.39-3..31)
Completeness (%) 99.4 (100.0) 99.8 (99.6) 99.4 (99.2) 99.7 (99.7) 98.5 (99.9) 73.2 (35.0) 81.5 (39.1) 85.1 (39.2) 99.7 (99.8) 97.5 (99.1) 92.4 (78.4)
Unique reflections 37332 (3465) 39092 (3471) 23751 (1834) 37310 (2758) 11289 (823) 8396 (392) 5674 (264) 7329 (326) 59850 (4435) 13547 (1013) 38124 (2352)
Redundancy 6.3 (6.3) 7.3 (7.6) 5.3 (5.4) 7.4 (7.6) 4.9 (5.3) 3.0 (2.0) 6.5 (4.8) 6.8 (3.2) 3.8 (3.8) 3.7 (3.7) 2.2 (1.9)
Rsym (%) 11.6 (58.7) 12.9 (57.7) 23.3 (57.2) 14.3 (62.1) 13.9 (55.3) 8.3 (36.9) 13.3 (41.9) 7.3 (41.0) 9.2 (51.1) 9.0 (62.2) 10.4 (43.1)
I/σI 14.2 (4.1)  16.0 (4.5) 8.7 (3.4) 11.9 (3.2) 8.07 (2.41) 19.9 (2.0) 20 (2.5) 24.4 (2.1) 10.2 (2.8) 10.2 (2.3) 7.0 (2.0)
Refinement
PDB code 4A08 4A09 4A0A 4A0B 4A0K 4A0C 4A0L 4A11
Rwork/Rfree 23.4/29.4 24.5/30.7 26.7/34.7 24.3/31.9 26.9/27.0 23.8/31.8 31.8/32.0 17.6/23.3
Reflections (working set) 35444 37137 22561 35416 11036 56857 13523 38079
Reflections (test set) 1866 1955 1188 1864 552 2993 1352 1908
Number of Atoms
Protein 11369 11497 9007 22823 17402 30818 34587 11081
DNA 495 607 648 1135 483 0 966 0
Water 16 22 0 0 0 0 0 0
Ligand 26 1 1 0 0 6 0 0
R.m.s. deviations
Bond lengths (Å) 0.006 0.006 0.007 0.007 * 0.007 * 0.009
Bond Angles (deg) 1.085 0.988 1.076 1.123 * 1.139 * 1.342
Ramachandran
favoured 94.7 93.7 91.4 90.3 * 88.5 * 95.9
disallowed 0.4 0.3 0.3 0.9 * 1.5 * 0
Avg. B-factor (Å2) 48.7 56.7 73.5 126.5 299.0 128.6 253.6 84.2
Crystallization
Reservoir
100 mM MES, 25 mM 
NaOH, 18% PEG 
350MME
100 mM MES, 15 mM 
NaOH, 21% PEG 200
100 mM MES, 28 mM 
NaOH, 16% PEG 
350MME
100 mM MES, 15 mM 
NaOH, 18% PEG 
350MME
100 mM Tris-HCl pH 
8.3, 33% PEG 200
100 mM Tris-HCl pH 
7.9, 35% PEG 200
100 mM Tris-HCl pH 
8.5, 29% PEG 200
100 mM Tris-HCl pH 
8.5, 31% PEG 200
100 mM MES pH6.3, 
30% PEG200, 2% PEG 
8000
100 mM MES pH 6.2, 
3.1% PEG 6000, 4% 
ethyleneglycol
1.4-1.58 M NaKPO4,   
0.1 M NaMalonate,          
0-0.1 M Li2SO4
Protein
DDB1-E194A/DDB2 DDB1-E194A/DDDB2 DDB1-E224K/DDB2 DDB1-E224S/DDB2 DDB1/DDB2/ CUL4A/RBX1
DDB1/DDB2/ 
CUL4A/RBX1
DDB1/DDB2/ 
CUL4A/RBX1
DDB1/DDB2/ 
CUL4A/RBX1
CAND1/CUL4B/    
RBX1
DDB1/DDB2/ 
CUL4B/RBX1 DDB1/CSA
Concentration (mg/ml) 9 9 10 9 16 12 12 12 12 20 5 - 10
Cryoprotectant
100 mM MES, 35 mM 
NaOH, 35% PEG 
350MME, 20mM 
CaAcetate
100 mM MES, 15 mM 
NaOH, 35% PEG 200, 
20mM CaAcetate
Paratone N
100 mM MES, 35 mM 
NaOH, 35% 
PEG350MME, 20mM 
CaAcetate
Reservoir Reservoir Reservoir Reservoir Reservoir
100 mM MES pH 6.5, 
5% PEG 6000, 30% 
ethyleneglycol
2M NaMalonate,      
0.1M Tris-HCl pH 8.0
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Table S2: Minor/major groove width for CPD#1. Related to Figure 1 
Major groove  Minor groove  
Base (DàU+m; 
m=4) 
Width 
(Å) 
Base (DàU+m; m=-
3) 
Width 
(Å) 
C(D-5)àT(U+1) 
G(D-4) àC(U-1) 
C(D-3) àC(U-2) 
G(D-2) àC(U-3) 
A(D-1) àG(U-4) 
CPD(D+1) àC(U-
5) 
CPD(D+2) àG(U-
6) 
G(D+3) àG(U-7) 
C(D+4) àG(U-8) 
17.07 
19.76 
18.51 
18.35 
17.69 
20.02 
16.18 
11.78 
16.60 
G(D-2) àG(U+5) 
A(D-1) àC(U+4) 
CPD(D+1) 
àG(U+3) 
CPD(D+2) 
àC(U+2) 
G(D+3) àT(U+1) 
C(D+4) àC(U-1) 
G(D+5) àC(U-2) 
C(D+6) àC(U-3) 
 
14.70 
15.34 
14.76 
15.21 
18.18 
14.81 
12.89 
14.18 
 
Table S3: Phosphate-Phosphate distance for CPD#1. Related to Figure 1 
Damaged 
Strand 
PP-distance 
(Å) 
PP-distance 
(Å) 
Undamaged 
strand 
D-5 ßàD-4 
D-4 ßàD-3 
D-3 ßàD-2 
D-2 ßàD-1 
D-1 ßàD+1 
D+1 ßàD+2 
D+2 ßàD+3 
D+3 ßàD+4 
D+4 ßàD+5 
D+5 ßàD+6 
 
6.42 
6.24 
6.66 
6.51 
6.18  
5.90  ß 
K168 
5.99 
6.00  ß 
K280 
6.87 
6.35 
6.63 
6.98 
6.22  
6.99 
6.93 
5.95 
6.58 
7.00 
6.72 
6.83 
5.58 
7.58 
U+5 
ßàU+4 
U+4 
ßàU+3 
U+3 
ßàU+2 
U+2 
ßàU+1 
U+1 ßàU-
1 
U-1 ßàU-
2 
U-2 ßàU-
3 
U-3 ßàU-
4 
U-4 ßàU-
5 
U-5 ßàU-
6 
U-6 ßàU-
7 
U-7 ßàU-
8 
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Table S4: Oligonucleotides used for crystallization. Related to Experimental 
Procedures 
DDB1/DDB2-
CPD #1 
damaged strand 5'-ACGCGA(CPD)GCGCCC-3 
 undamaged strand 5'-TGGGCGCCCTCGCG-3' 
DDB1/DDB2-
CPD #2 
damaged strand 5'-GGTGAAA(CPD)AGCAGG -3' 
 undamaged strand 5'-CCTGCTCCTTTCACCC-3' 
DDB1/DDB2-
CPD #3 
damaged strand 5'-GGGTGAAT(CPD)AGCAGG-3' 
 undamaged strand 5'-CCTGCTCCATTCACCC-3' 
DDB1/DDB2-
CPD #4 
damaged strand 5'- GGGTGAAT(CPD)AGCAGG -3 
 undamaged strand 5'-CCTGCTCCATTCACCC-3' 
CRL4ADDB2-THF damaged strand: 5'-GCTACT(THF)ACGCA-3 
 undamaged strand: 5'-TGCGTAAGTAGC-3' 
CRL4ADDB2 (1x 
C3) 
linked strand 5’-TGCGTAAGTAGCT(C3)CGATCT(THF)ACGGAA-3' 
 complementary 1 5’-TCCGTAAGATCG-3' 
 complementary 2 5’-GCTACT(THF)ACGCAA-3' 
CRL4ADDB2 (2x 
C3) 
linked strand 5’-TGCGTAAGTAGCT(C3)(C3)CGATCT(THF)ACGGAA-3' 
 complementary 1 5’-TCCGTAAGATCG-3' 
 complementary 2 5’-GCTACT(THF)ACGCAA-3' 
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Table S5: Oligonucleotides used for EMSA and biochemical assays. Related 
to Figure 5 
15bp DNATHF-
Cy5 
damaged strand 5'-AAATGAAT(THF)AAGCAGG-3 
 undamaged 
strand 
5'-(Cy5)CCTGCTTTATTCATTT-3' 
15bp DNATHF damaged strand 5'-AAATGAAT(THF)AAGCAGG-3 
 undamaged 
strand 
5'-CCTGCTTTATTCATTT-3' 
15bp DNA undamaged 
strand 
5'-AAATGAATAAAGCAGG-3 
 undamaged 
strand 
5'-CCTGCTTTATTCATTT-3' 
24bp DNATHF damaged strand 5'-GTCCTGAATGAAT(THF)ACGCAA -
3' 
 undamaged 
strand 
5'-TTGCGTAATTCATTCAGGAC -3' 
21bp DNA6-4PP damaged strand 5'-TTTCCTAGACT(6-4PP)GCCCAATTA 
-3 
 undamaged 
strand 
5'-ATAATTGGGCAAAGTCTAGGAA -3' 
16bp DNACPD damaged strand 5'- GGGTGAAT(CPD)AGCAGG -3 
 undamaged 
strand 
5'-CCTGCTCCATTCACCC-3' 
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Table S6: Reported CSA mutations in Cockayne Syndrome patients. Related 
to Figure 6 
Mutations Patient CS class Location Expected Effect 
Q106P CS2SE CS I Blade 1 – hydrophobic core, pointing into the 
central cavity of the WD40 propeller 
Integrity of the fold: impaired DDB1 & 
substrate binding 
A160T CS852VI CS III Blade 3 – hydrophobic core of the blade Minor effect on the fold affecting DDB1 
binding and possibly substrate binding 
A160V CS3BE CS I Blade 3 – hydrophobic core of the blade Minor effect on the fold affecting DDB1 
binding and possibly substrate binding 
W194C CS655VI CS I Blade 4 – hydrophobic cavity that appears no 
longer filled by the W > S mutations 
Integrity of the fold: impaired DDB1 & 
substrate binding 
L202S 08STR3 CS I Blade 4 – hydrophobic cavity, in which a 
more polar residues is positioned 
Integrity of the fold: impaired DDB1 & 
substrate binding 
T204K 4_1, 4_2 CS I Blade 4 – hydrogen bonds with Trp214, 
His185 and Lys212. The T > K mutation would be 
expected to result in significant steric clashes 
integrity of the fold: impaired DDB1 & 
substrate binding 
A205P AGO7075 CS I Blade 4 – hydrophobic core of the propeller. 
The A > P mutations likely interferes with the β-
sheet conformation , due to disallowed 
Ramachandran space  
Integrity of the fold: impaired DDB1 & 
substrate binding. Lack of DDB1 binding has been 
demonstrated  
D266G CS861VI, 
08STR2, 
08STR2_2, 3_1, 
3_2 
CS I  Blade 5 – tight turn (Asp is the canonical 
WD40 residues in this position). The change to Gly 
is conservative, however, and expected to have 
mostly local effects  
Likely interfering with substrate binding on 
the narrow side of the WD40 propeller 
Deletion 
A207-S209 
CS794VI CS I Blade: truncates the loop between strands B 
and C. Effect is expected to be local 
Likely interfering with substrate binding on 
the narrow side of the WD40 propeller 
W361C UVSSVI UVSS Blade 7: Cys mutations results in the 
hydrophobic cavity not being properly filled. 
Conservative mutation, however, expected to cause 
only limited damage 
Mildly interfering with the integrity of the 
WD40 fold: impaired DDB1 & substrate binding 
 
Mutations of CSA were identified in 41 CS patients: 8 different point 
mutations, 8 frameshift mutations, 4 deletions and 3 stop codon insertions 
have been described (Laugel et al., 2010). CS has been classified into three 
different sub-groups according to the severity and onset of the disease: the 
most severe form (class 1) has an onset in utero (COFS) or during the first 
years of life; (class 2) manifests itself in the early teens, while class 3 
becomes apparent after the second or third decade of life. The least severe 
phenotype is observed in UV sensitivity syndrome (UVSS), which is also 
associated with mutations in CSA (Laugel et al., 2010) and comes with no 
obvious developmental phenotype, unlike classes I, II and III. 
On the basis of the structure, there are three conceivable ways to impair 
CSA function: (i) point mutations in the structured HLH-WD40 domain 
abolishing DDB1 binding, which has been directly observed in the A205P 
mutation (Jin et al., 2006); (ii) mutations preventing substrate binding on the 
narrow face of the WD40 propeller; (iii) and those interfering with the overall 
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fold expected to affect both substrate binding and DDB1 binding as well as 
protein stability. 
 
Genotype/Phenotype correlations: The structure now provides a molecular 
rationale for the observed Cockayne patient mutations. Deletions of the N-
terminus, residues Δ2-4 or Δ2-7 are expected to impair CSA binding to DDB1. 
Premature chain termination mutants, as seen in patients, on the other hand 
are expected to give rise to misfolded CSA WD40 domains, which likely retain 
binding to DDB1, but are expected to be defective in substrate binding. The 
majority of point mutations concerns the hydrophobic core of the WD40 
propeller and likely exerts their mutagenic effect through WD40 folding 
mutations. Out of eight point mutations, four (and a short deletion) are 
clustered in blade 4 (Figure 6b). The four residues are closely spaced 
occupying position CSA 194, 202, 204 and 205. As this blade is not obviously 
involved in DDB1 interactions, we propose that blade 4 is selected for in 
patient derived mutations due to its involvement in substrate binding. On the 
basis of the patterns of conserved hydrophobic residues (Tyr/Phe100 & 
Phe120) present in all CSA orthologues (Supplementary Figure S6a and 
S7), combined with the patient mutations assigned to blade 4, we speculate 
that the CSA substrate might be bound crossing blade 4/5 & blade 2.  
It is frequently stated that no genotype/phenotype correlation exists for 
patients suffering from CS. Such relationship is principally complicated by the 
fact that both alleles have to be defective or absent for the carrier to develop 
the disease. Analyzing the patient mutations we note, however, that point 
mutations, deletions and frame-shifts give rise to CS type I and II. The 
mutations leading to the milder form of CS type III and UVSS, on the other 
hand, are point mutations. Mutations A160T (CS III) and W361C (UVSS), both 
are predicted to cause only limited damage to the propeller. We therefore 
predict that CSA mutations in type III comprise largely those point mutations 
that only cause limited, localized damage to CSA integrity. 
The three WD40 propellers of DDB1 provide several potential binding sites 
for DCAFs. For initial mapping of the interacting surfaces of CSA/DDB1 
StrepII-tagged CSA was co-expressed with His6-tagged DDB1(ΔBPB) and 
DDB1-BPB (BPB only). DDB1(ΔBPB) did co-purify with CSA, while DDB1-
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BPB was not able to bind (Supplementary Figure S6d). Further a C-terminal 
truncated CSA (1-367) did co-purify with DDB1 similar to full-length CSA. We 
therefore observed no evidence for the involvement of the DDB1-BPB domain 
in CSA binding. This is in agreement with earlier co-precipitation studies (Jin 
et al., 2006): the mutation of a single residue (W953A) on the top face of BPC 
(facing towards the bottom of BPA) of DDB1 resulted in significant reduced 
binding of CSA. In the CSA-DDB1 structure W953 of DDB1 is involved in 
stacking interaction with R19 of CSA.  
The binding mode of CSA with the HLH motif in a cleft formed by BPA and 
BPC of DDB1 was independent confirmed by an additional crystal structure 
obtained at lower resolution (6.0 Å) from crystals in a different space group 
(I23, a=b=c=279.06 Å). The P3221 crystal form was also obtained with a C-
terminally truncated CSA (1-367). Here, as well as in the high resolution 
structure (main text) clear electron density for the HLH motif of CSA was 
observed after a molecular replacement with DDB1 (BPA+BPC, BPB). 
 
 
88 
Supplemental Experimental Procedures 
Protein expression and purification 
hsDDB1 (aa 1-1140) and drDDB2 (aa 94-457) co-complexes were 
expressed and purified as described in Scrima et al., 2008. DDB1-mutants 
were generated using the PIPE mutagenesis protocol (Klock and Lesley, 
2009). The CRL4ADDB2 complex was expressed and purified using 
baculoviruses for hsDDB1 (aa 1-1140), drDDB2 (aa 94-457), hsCUL4A (aa 
38-759), mmRBX1 (aa 12-108) as N-terminal His6 fusion proteins in Hi-5 
insect cells (Scrima et al., 2008). Cells were lysed by sonication (in 50 mM 
Tris pH 8.0, 200 mM NaCl, 5 mM β-ME, 0.1 % Triton X-100, 1 mM PMSF 
and 1 tablet of complete protease inhibitor cocktail Roche Applied Science). 
Following high-speed centrifugation, the supernatant was passed over Ni-NTA 
affinity resin, target protein complex was eluted and subjected to Poros50HQ 
ion exchange chromatography. Purification was completed with size exclusion 
chromatography using a 26/60 Superdex S200 column (GE Healthcare) in 
50 mM HEPES pH 7.4, 200 mM NaCl and 2 mM DTT. CRL4BDDB2 (His6-TEV-
CUL4B aa 192-913) complex purification was performed similar to that of 
CUL4ADDB2, with the exception that CRL4BDDB2 was subjected to overnight 
1 % proteolytic cleavage using TEV protease following affinity purification. N-
terminally StrepII-tagged hsCAND1 (aa 1-1230) and His6-tagged hsCUL4B 
(aa 192-913)/mmRBX1 (aa 12-108) was co-expressed and Ni-NTA affinity 
purified, followed by size exclusion chromatography in 50 mM HEPES pH 7.4, 
200mM NaCl and 5 mM DTT. C-terminally StrepII-tagged hsCSA (aa 1-396) 
and His6-tagged hsDDB1 (aa 1-1140) was co-expressed and StrepII affinity 
purified followed by ion exchange and size exclusion chromatography (see 
above). CRL4ADDB2(K244E)  complex was purified from Hi-5 insect cells as 
described in Sugasawa et al., 2006. 
Recombinant hsCSB was overexpressed in Hi-5 insect cells and purified as 
N-terminal His6 fusion protein as described for DDB1-DDB2 (Scrima et al., 
2008). Untagged recombinant hsCSB overexpressed and purified from insect 
cells was provided as a kind gift from Regina Groisman. While the untagged 
hsCSB was ubiquitinated in our in vitro assay, ubiquitination could not be 
observed with N-terminal tagged hsCSB. 
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The purified complexes were concentrated as indicated in Supplemental 
Table S1, flash frozen in liquid nitrogen and stored at -80°C. 
 
Crystallization 
Crystals of the DDB1/drDDB2–DNA (CPD #1, #2, #3, #4), CRL4ADDB2-
DNA, CRL4BDDB2-DNA and CAND1/CUL4B complexes were grown at 20 °C–
24 °C using the hanging drop diffusion method. In protein-DNA complexes 
typically a 1.20-1.35 molar excess of DNA was added to the protein solution 
and incubated on ice for 20 minutes prior to crystallization by mixing the 
protein solution in a 1:1 ratio with reservoir solution (Supplemental Table 
S1). Crystals of the DDB1-CSA complex were grown using the sitting drop 
vapor diffusion method at 20 °C. Drops contained 5-10 mg/ml protein complex 
and reservoir solution containing 1.4-1.58 M KNaPO4, 0.1 M Na Malonate and 
0-0.1 M Li2SO4 at a 1:1 ratio. 
Crystals were transferred into cryo-solution prior to flash-freezing or were 
directly flash frozen in liquid nitrogen for data collection (Supplemental Table 
S1). Data sets were collected at the Swiss Light Source, Paul Scherrer 
Institut, Villigen, Switzerland, and processed with XDS (Kabsch, 1993). For 
DDB1-CSA three datasets from three crystals were merged to give a 
complete dataset to a resolution of 3.3 Å. 
The CRL4ADDB2-DNA complex revealed packing of the DNA duplex within 
the crystal lattice in a head-to-tail fashion to a symmetry related CRL4ADDB2 
molecule. In an effort to improve crystal-packing, we covalently linked the two 
DNA molecules mimicking a continuous DNA duplex connecting the two 
symmetry related molecules. For this approach we used one, two and three 
flexible methyl group linkers introduced to connect the 3’ end of one 
undamaged strand to the 5’ end of the damaged strand. The sequence of the 
linked damaged strand was slightly modified to prevent self-annealing 
(Supplementary Table S4). A number of these DNA constructs resulted in 
crystals that, however, resulted at best in diffraction quality and resolution 
equal to the parental crystal form (CRL4DDB2-THF, see below). The nominally 
highest resolution data set was collected using CRL4ADDB2-THF. 
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Oligonucleotides used for crystallization 
CPD containing single stranded DNA oligonucleotides were synthesized as 
described in (Iwai et al., 1996) using cis-syn thymine dimer phosphoramidite 
building blocks (Glenn Reasearch, USA). Complementary oligonucleotides 
and oligonucleotides harboring a THF abasic site mimic were synthesized by 
Sigma-Aldrich and purified on a Microsorb 300-5 PureDNA HPLC column 
(Varian, Inc., USA). Oligonucleotides were annealed in 10 mM HEPES 
pH 7.4; 50 mM NaCl and subsequently stored at −20 °C. Unmodified and 
modified oligonucleotides used for biochemistry were also ordered from 
Sigma-Aldrich and HPLC purified by the manufacturer. For a list of 
oligunucleotides used in crystallization see Supplementary Table S4 and S5 
for oligonucleotides used in biochemical assays. 
 
Structure determination and model building 
Structures of DDB1-drDDB2-DNA complexes were solved by molecular 
replacement using DDB1 (BPA+BPC), DDB1 (BPB) and DDB2 (all taken from 
pdb: 3EI1) as search models for Phaser (McCoy et al., 2007).  
The structure of CAND1/CUL4B was determined by molecular replacement 
using the CAND1 model taken from the previously determined structure of 
CUL1-CAND1 (1U6G). For the search, CAND1 was split into an N-terminal 
(aa 4-849) and a C-terminal (aa 850-1216) model. An initial homology model 
for CUL4B (aa 210-913)/RBX1 (aa 19-108) was generated using MODELLER 
(Eswar et al., 2006). The models were used in successive molecular 
replacement rounds in Phaser (McCoy et al., 2007). 
The CRL4ADDB2 complex structure was determined by sequential domain 
placement in step-wise molecular replacement searches. CUL4A attached to 
the BPB domain of DDB1 (obtained from pdb: 2HYE) was successfully 
located using Phaser (McCoy et al., 2007). The solution was fixed and DDB1 
(BPC+BPA) (obtained from pdb: 3EI2) was located using Molrep (Vagin and 
Teplyakov, 1997), followed by localization of DDB2-DNA (pdb: 3EI2). The 
unbiased molecular replacement search reassembled the linker between the 
DDB1 (BPB) and DDB1 (BPA+BPC) domains, resembling the interface 
previously observed in DDB1 structures. 
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The CRL4BDDB2 complex structure was determined by molecular 
replacement with Molrep (Vagin and Teplyakov, 1997) using a strategy similar 
to that outlined for CRL4ADDB2. A search model of CUL4B (obtained from the 
previously solved CUL4B/CAND1 complex structure) was used instead of 
CUL4A and allowed us to locate the two molecules in the ASU. The two 
CUL4B molecules were subsequently fixed and additional rounds of molecular 
replacement allowed the placement of DDB1 (BPA+BPC) (obtained from pdb: 
3EI2) and DDB2-DNA (obtained from pdb: 3EI2). 
The structure of DDB1-CSA was determined by molecular replacement 
using Phaser (McCoy et al., 2007). As search models DDB1 (BPA& BPC, 
BPB from pdb: 3EI1) and a homology model of the WD40 propeller of CSA 
(Kelley and Sternberg, 2009) were used. Phases calculated from the 
placement of DDB1 provided clear electron density for the HLH motif of CSA. 
Rigid body refinement for CRL4ADDB2-DNA and CRL4BDDB2-DNA was 
carried out with Phenix (Adams et al., 2010). DDB1-DDB2-DNA, 
CAND1/CUL4B and DDB1-CSA structures were refined using Refmac5 
(Murshudov et al., 1997) with additional rounds of refinement in Phenix and 
Buster used for DDB1-CSA (Adams et al., 2010; Bricogne et al., 2010). 
Manual model building was performed using Coot (Emsley and Cowtan, 
2004). The final models were verified using composite omit maps as 
implemented in CNS (Brunger et al., 1998). Figures were generated in the 
PyMol package (DeLano Scientific; http://www.pymol.org). 
 
Experimental Structure validation 
The CUL4A-RBX1-DDB1-DDB2 complex was expressed in High Five 
insect cells in the presence of seleno-methionine (SeMet) substituted minimal 
medium (see Cronin et al., 2007 for detailed procedures). The SeMet labeled 
protein crystallized under conditions similar to that of the native protein. The 
resulting crystals belonged to space group C2 sharing identical cell 
parameters to that of the unmodified complex (Supplemental Table S1). 
Single anomalous dispersion (SAD) datasets, with resolutions ranging 
between 5.9 Å and 8 Å, were recorded at beam-line X06DA (Swiss Light 
Source, PSI), which was equipped with a Mar225CCD detector. Data was 
acquired in an inverse beam setup with alternating 1° wedges spaced 180° 
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apart in order to minimize loss of anomalous signal due to radiation damage. 
Reflections were indexed, scaled and integrated using the HKL2000 package 
(Otwinowski and Minor, 1997). The structures were solved by molecular 
replacement with Phaser (McCoy et al., 2007). Anomalous difference maps 
were calculated using FFT from the CCP4 package (Collaborative 
Computational Project, 1994) and averaged in Coot (Emsley and Cowtan, 
2004). Within in the averaged anomalous difference maps (3.0 σ), 50 % of the 
CRL4ADDB2 methionine positions could be located at their predicted position 
(see Supplemental Figure S2b and d). Additional support for the domain 
placement was obtained using composite omit maps (Supplemental Figure 
S2c). 
Attempts to validate the CRL4BDDB2 structure through Se-Met data 
collection were unsuccessful due to the inability to grow crystals despite 
extensive trials. The CRL4BDDB2 crystal form required TEV cleavage, Se-Met 
labeled CRL4B complex, however, is rendered largely insoluble following TEV 
cleavage. The CRL4BDDB2 structure was validated by composite omit maps as 
implemented in CNS (Brunger et al., 1996). Supplemental Figure S3a and b 
show the validation of the individual rigid bodies used in refinement: 
DDB1(BPA+BPC), DDB1(BPB), CUL4B, DNA, RBX1. 
 
Reconstitution of irradiated mononucleosomes 
Mononucleosomes were reconstituted as described (Luger et al., 1997) 
using 134 bp p9HISAT-DNA (Losa et al., 1990) and recombinantly expressed 
and purified histones (H2A, H2B, H3 from X. tropicalis; H4 from S. cerevisiae). 
For UV-damaged nucleosomes, DNA was irradiated prior to reconstitution 
with 2000 J/m2 at 254 nm in a Stratalinker UV Crosslinker 2400. 
Mononucleosome reconstitution and protein binding were analyzed on native 
0.7 % agarose run in 0.2x TB buffer at 100 V for 120 min at 4 °C. Detection 
was performed with a Typhoon Imager (Amersham) using tracer amounts of 
Cy5-labeled DNA. 
 
Electrophoretic mobility shift assays 
EMSA, employing native agarose or polyacrylamide gels, were used to 
analyze nucleosomes and perform binding studies. Non-denaturing poly-
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acrylamide gels (15x25 cm) were poured (5 % acrylamide/Bis-acrylamide 
29/1; 0.5x TBE; 0.1 % APS; 60 µl TEMED) and pre-run for 1 h with 150 V at 
4 °C in 0.5x TBE. Samples were mixed 1:2 with 2x EMSA-buffer (10 mM 
Triethanolamine pH 7.4; 50 mM NaCl, 1 mM DTT, 100 µg/ml BSA). Native 
0.7 % agarose gels were run in 0.2x TB buffer at 100 V for 120 min at 4°C. 
Detection of fluorescently labeled oligonucleoteides and proteins was carried 
out on a Typhoon Imager (Amersham). 
 
DDB1-DDB2 and CRL4DDB2 binding to UV irradiated nucleosomes  
For the analysis of UV-DDB binding to non-irradiated and irradiated 
nucleosome core particles (NCP) (Figure 2a) approximately 70 nM NCP were 
mixed with increasing amounts of UV-DDB and 500 ng dI/dC competitor DNA 
in EMSA-buffer and incubated for 20 min on ice prior to the analysis by 
EMSA. Analysis of CRL4DDB2 binding to irradiated NCP (Figure 2f) was 
performed under similar conditions with 50 nM NCP and increasing amounts 
of protein (no competitor) in EMSA-buffer. 
Reconstitution of NCPs containing a positioned 6-4PP or CPD and EMSAs 
to analyze DDB1-DDB2 binding were performed essentially as described 
previously (Yasuda et al., 2005). Binding reactions were carried out in 15 µl 
including 0.2 fmol 32P-labeled NCP and/or naked DNA and the indicated 
amounts of DDB1-DDB2. A 5% non-denaturing polyacrylamide gel was used 
for electrophoresis. 
 
In vitro ubiquitination assays and CSN protection assay 
In vitro ubiquitination assays were performed as previously described 
(Sugasawa, 2006) with 40 nM E1 (UBA1, Boston Biochem), 1.89 µM E2 
(UbcH5A or UbcH5B, Boston Biochem), 20 nM CRL4DDB2 complex or 
CRL4DDB2-NEDD8 (data not shown), 40 µM ubiquitin (Boston Biochem) or 10 
µM K0-ubiquitin (Boston Biochem). The reaction was incubated for 30 min at 
30 °C and subsequently analyzed by SDS-PAGE coupled to immunoblotting. 
To assess the protection of DDB2 by CSN, an ubiquitin reaction mixture 
lacking the E2 was pre-incubated with the corresponding CSN complex for 
15 min on ice, the assay was subsequently initiated by E2 addition. Loss of 
protection of DDB2 autoubiquitination was tested by adding 1.5 µM of the 
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appropriate DNA oligonucleotide followed by 30 min incubation at 30 °C. To 
exclude the presence of contamination through DNA activated 
deubiquitinating enzymes (DUB), we performed control assays in the 
presence of 3.9 µM ubiquitin-aldehyde, a potent DUB inhibitor (Figure 5e, 
lanes 1-2) (Melandri et al., 1996; Zhou et al., 2003).  We further spiked the 
reaction with recombinant Usp2 and tested the potential of ubiquitin-aldehyde 
to inhibit DUB activity, as expected, DDB2 autoubiquitination was only 
observed in the presence of ubiquitin-aldehyde (Supplementary Figure 
S5d). In vitro ubiquitination assays with CRL4CSA/CSB were carried out under 
similar experimental conditions with 70nM CRL4CSA and between 100nM and 
1uM CSB to test the relieve of CSN inhibition. 
To further exclude potential deubiquitination activity of our CSN 
preparations, ubiquitinated CRL4DDB2 or CRL4CSA complexes were incubated 
with active CSN and subjected to immunoblot (Supplementary Figure S4h 
and i). No deubiquitinating activity could be observed. 
 
Neddylation of CRL4DDB2 and labeling with Alexa488 
In vitro neddylation of CRL4DDB2 complexes was carried out as previously 
described (Duda et al., 2008) followed by purification of neddylated 
complexes by size exclusion chromatography. In order to fluorescently label 
the NEDD8, a thiol-reactive Alexa488-maleimide (Invitrogen) was conjugated 
to a Nedd8(M1C) mutant according to the manufacturer’s instructions with 
TCEP as reductive agent and the Alexa488-NEDD8 conjugate was purified by 
size exclusion chromatography after addition of glutathione to absorb free 
reactive species. The Alexa488-NEDD8 was then conjugated to CRL4ADDB2 
complex by in vitro neddylation (Duda et al., 2008) with subsequent 
purification by size exclusion chromatography. 
 
Mapping of Ubiquitin sites by LC-MS/MS 
The CRL4ADDB2 complex was subjected to in vitro autoubiquitination, and 
subsequently analyzed by SDS-PAGE (Supplementary Figure S4a). Several 
DDB2 bands were excised from the gel, subjected to tryptic digest and 
analyzed by NanoLC-MS/MS with a 1200 HPLC (Agilent) connected to a LTQ 
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Orbitrap Velos (Thremo Scientific). The ubiquitinated peptides were identified 
with Mascot searching Swiss-Prot 2010_09 (Perkins et al., 1999) 
 and manually validated. Peptide fragmentation and spectras are shown for 
two representative peptides harboring the ubiquitin acceptor lysines K11 and 
K40 (Figure S4c and d). 
 
SEC-MALS 
To determine the average mass of protein complexes, size exclusion 
chromatography (SEC) using a Superdex 200 10/300 column (GE Healthcare) 
was coupled to multi angle light scattering (MALS) using an Optilab T-rEX 
refractive index detector and a miniDAWN TREOS 3 angle MALS detector 
(Wyatt Technology). The runs were done in 50 mM HEPES pH7.4, 200 mM 
NaCl and 1mM DTT and 50 µl sample volume were injected. 
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Chapter 3: Detecting UV-lesions in the genome: The 
modular CRL4 ubiquitin ligase does it best!  
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Summary 
The DDB1-DDB2-CUL4-RBX1 complex serves as the primary detection device for UV-
induced lesions in the genome. It simultaneously functions as a CUL4 type E3 ubiquitin 
ligase. We review the current understanding of this dual function ubiquitin ligase and damage 
detection complex. The DDB2 damage binding module is merely one of a large family of 
possible DDB1-CUL4 associated factors (DCAF), most of which are substrate receptors for 
other DDB1-CUL4 complexes. DDB2 and the Cockayne syndrome A protein (CSA) function 
in nucleotide excision repair, whereas the remaining receptors operate in a wide range of 
other biological pathways. We will examine the modular architecture of DDB1-CUL4 in 
complex with DDB2, CSA and CDT2 focusing on shared architectural, targeting and 
regulatory principles. 
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Abstract: 
The DDB1-DDB2-CUL4-RBX1 complex serves as the primary detection 
device for UV-induced lesions in the genome. It simultaneously functions as a 
CUL4 type E3 ubiquitin ligase. We review the current understanding of this 
dual function ubiquitin ligase and damage detection complex. The DDB2 
damage binding module is merely one of a large family of possible DDB1-
CUL4 associated factors (DCAF), most of which are substrate receptors for 
other DDB1-CUL4 complexes. DDB2 and the Cockayne syndrome A protein 
(CSA) function in nucleotide excision repair, whereas the remaining receptors 
operate in a wide range of other biological pathways. We will examine the 
modular architecture of DDB1-CUL4 in complex with DDB2, CSA and CDT2 
focusing on shared architectural, targeting and regulatory principles. 
 
Key words: Genome stability, CUL4, CDT2, DDB2 and CSA 
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Repair of UV-induced DNA lesions is facilitated by CUL4 type E3 
ubiquitin transferases 
The nucleotide excision repair (NER) pathway safeguards the genome 
against bulky DNA adducts and UV-light induced pyrimidine dimers [1-4]. If 
left unrepaired, these lesions interfere with the progression of transcription [5] 
and replication [6], requiring extensive post replicative repair. It only very 
recently emerged that NER requires targeted ubiquitination events in vivo [7]. 
The two major CUL4 E3 ubiquitin ligase substrate receptors in NER are the 
Cockayne syndrome protein A (CSA) and the damage DNA binding protein 2 
(DDB2), both of which are connected to the ligase through the DDB1 adaptor 
subunit. Proteomic studies have revealed that the remainder of the CUL4-
DDB1 RING LIGASE (CRL4) family comprises more than fifty different 
substrate receptor complexes. Additionally, two closely related CUL4 human 
paralogs, CUL4A and CUL4B have been identified which differ mainly in a 
large N-terminal extension present only in CUL4B [8]. By examining three of 
the best characterized CRL4 ubiquitin E3 ligases, all of which function in the 
UV-response to damage (CRL4DDB2, CRL4CSA and CRL4CDT2), we will 
highlight common architectural principles and detail our current understanding 
of CRL4 targeting and regulation. 
 
Nucleotide Excision Repair, an overview 
NER consists of two branches that differ in the mechanism of lesion 
detection: in transcription coupled repair (TCR) damaged DNA bases initiate 
NER through RNA polymerase II stalling [9, 10]; in global genome repair 
(GGR) the non-transcribed genome is continuously interrogated for DNA 
damage through specialized surveillance protein complexes including XPC-
HR23B [11, 12] and DDB1-DDB2 [2]. TCR and GGR are thought to ultimately 
converge into a common pathway comprising: (i) local scanning for the lesion 
and duplex unwinding by the 10 subunit TFIIH complex [7, 13], (ii) 5’ incision 
through the XPF-ERCC1 endonuclease [14], (iii) initiation of DNA gap re-
synthesis and 3’ incision catalysed by XPG, (iv) removal of a 24-32 bp 
damage-containing oligonucleotide, (v) and nick ligation. Overall more than 30 
polypeptides are involved in this process resulting in error free repair [15]. 
NER generally proceeds in a rapid fashion and does not interfere with cell 
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cycle progression. Checkpoint activation is typically only triggered once the 
damage is considered too extensive to be repaired [16]. Mutations in NER 
components result in a number of rare autosomal recessive diseases 
including Xeroderma pigmentosum (XP), Cockayne syndrome (CS & XP-CS), 
UV-sensitive syndrome (UVSS) and Trichothiodystrophie (TTD) [3, 9, 17, 18]. 
These types of DNA repair defects are frequently associated with various 
forms of UV-sensitivity, neurological and development complications, and in 
case of XP pronounced skin cancer predisposition. 
 
First responders: the CRL4DDB2 ligase in pyrimidine dimer detection in 
vivo. 
UV-light transforms adjacent pyrimidine bases into covalent photo-dimers. 
The majority of these cross-links are cyclobutane pyrimidine dimers (CPD), 
and to a lesser extent 6-4 pyrimidine-pyrimidone photoproducts (6-4PP) [19, 
20]. Detecting pyrimidine dimers within a large genome poses an exquisite 
challenge. The DDB1-DDB2 complex plays an important role in the initial 
pyrimidine dimer recognition in vivo [21-25]. Within the DDB1-DDB2 complex, 
the DDB2 subunit is found mutated in patients belonging to Xeroderma 
pigmentosum complementation group E (XP-E) [26]. Cells lacking DDB2 are 
substantially impaired in the repair of CPDs [27-29]. Recent X-ray 
crystallographic studies provided the molecular mechanism of high affinity and 
specificity 6-4PP recognition by DDB1-DDB2 (Figure 1) [30]. DDB1-DDB2 
largely comprises four WD40 propeller domains. The 127 kDa DDB1 protein 
contains three WD40-domains (BPA, BPB & BPC) [31]. The sides of the 
DDB1-BPA and BPC propeller domains are facing each other at an angle of 
~60° and form the binding cavity for DDB2 [30]. DDB2 binding to DDB1 is 
mediated by the N-terminal helix-loop-helix motif preceding the DDB2 WD40 
propeller [30, 32]. The DDB1-DDB2 complex binds damage-containing DNA 
duplexes exclusively through the DDB2 WD40 propeller domain. The DDB1-
BPB domain, which is located on the opposing face of the DDB1-DDB2 
module, provides the attachment site for the cullin4 ubiquitin ligase subunit 
[33] (Figure 1). In vivo, DDB1-DDB2 exists in complex with both CUL4A-RBX1 
and CUL4B-RBX1 paralogs [34-37]. Architecturally, DDB1 acts as an adaptor 
linking the E3 ubiquitin ligase (CUL4) to the UV-damage detection module 
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(DDB2). The protein complex specialised for the recognition of pyrimidine 
dimers in human cells thus doubles as an E3 ubiquitin ligase complex. 
 
The mechanism of pyrimidine dimer recognition: Showing DNA damage 
the damage recognition finger 
DDB2 utilizes a conserved tri-peptide Phe-Gln-His (FQH) hairpin to 
interrogate the duplex for damage. This hairpin forms a surprisingly rigid unit 
that inserts into the minor groove, at the lesion, in a finger like fashion. 
Concomitant with insertion of the damage recognition finger, the lesion is 
flipped out and stabilised in a hydrophobic pocket present at the DDB2 
surface (Figure 1). This pocket serves to restrict the size of the modification 
accommodated, biasing DDB2 towards photo-dimer recognition and 
preventing larger base adducts from being bound. Co-crystallisation of DDB1-
DDB2 with a single-nucleotide abasic site (AP) lesion, embedded in a duplex, 
revealed an almost identical dual base pair flip of the abasic site and the 
adjacent 3´ undamaged base. This is surprising, as unlike in the case of 6-
4PP, only one base is damaged in the AP containing duplex. The damage 
recognition finger, which spans exactly two nucleotides, therefore inherently 
triggers a di-nucleotide flip upon insertion. This flip is independent of whether 
the adjacent 3’ base is modified or not [30]. Contrary to the common notion, it 
was concluded that DDB2 does not appear to recognize the ‘helix distortion of 
the lesions’ per se, as the DDB2 bound DNA conformation differs significantly 
from those of damaged duplexes free in solution. DDB2 rather tests whether 
the damage recognition ‘finger’ can be inserted into the duplex, assessing the 
DNA conformation around the damage, and examines whether the DNA can 
fit to the rigid DDB2 binding ‘mold’. The structural basis of high affinity CPD 
recognition, the biological role of the DDB2 in which it excels above all other 
known human damage detection factors, currently remains elusive. 
 
UV-lesion detection in chromatin: the missing link 
The challenging task of detecting UV-lesions within vast genomes is further 
compounded by the presence of chromatin. In chromatin, the DNA is wrapped 
around an octamer of core histones, with additional linker histones implicated 
in further compaction. In vivo, the position of the photo-dimers respective to 
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the nucleosome core particle depends on the kind of lesion present: the 
strongly duplex distorting 6-4PP is found randomly localized in nucleosomes 
and linkers [38], while the highly mutagenic and difficult to detect CPD 
clusters are found in surface exposed regions of nucleosome [39]. How then 
are these lesions detected and repaired within nucleosomes? While the global 
genome repair branch of NER can be effectively reconstituted on naked DNA, 
the presence of nucleosomes was clearly inhibitory for repair in vitro [40]. 
NER inhibition occurred on multiple levels including damage recognition [41, 
42]. Nucleosome remodeling complexes can function as a principal means to 
remove nucleosomes, providing NER with a DNA substrate that more closely 
resembles the naked DNA. Several chromatin remodeling complexes have 
been implicated in NER. Cells in which chromatin remodelers Ino80 [43] and 
SWI/SNF (Brg1) [44, 45] have been deleted become UV-sensitive. While 
remodelers offer a potential solution to facilitate downstream repair 
processes, they are unlikely to provide a means to directly find the damage. 
How then is damage being read out in chromatin? Recent studies focusing on 
nucleosome dynamics in the presence and absence of damage indicated that 
the DNA around the octamer core unwraps leaving proteins sufficient time 
(and room) to gain access to the lesion [46, 47]. In vivo, DDB2 localizes to 
chromatin in a UV-dependent manner [48, 49] and remains associated with 
mono-nucleosomes upon treatment with micrococcal nuclease [35]. DDB1-
DDB2 is therefore a likely candidate for recognizing pyrimidine dimers 
embedded in nucleosome core particles. The direct interactions between NER 
damage detection factors including DDB1-DDB2, XPC/Rad4 and chromatin 
remodelers has been described [43, 45, 50] offering  a principal means to 
recruit remodelers and facilitate NER in an otherwise repressive chromatin 
environment. 
 
DDB1-DDB2 mediated histone ubiquitination surrounding the sites of 
damage 
Additional evidence implicating DDB1-DDB2-CUL4-RBX1 (CRL4DDB2) in 
damage recognition in chromatin came from studies reporting CRL4DDB2 
dependent ubiquitination of histones H2A, H3 and H4 in response to UV 
irradiation [51-53]. This histone ubiquitination response appeared to be largely 
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mono-ubiquitination. In vitro, CUL4 mediated ubiquitination gives rise to poly-
ubiquitin chains. Whether a deubiquitination enzyme, a specific E2 
transferase, or a regulatory protein serves to restrict the extent of 
ubiquitination in vivo, is currently not known. CRL4DDB2 mediated 
ubiquitination of histones is likely to be local and restricted to the immediate 
~100Å vicinity of the lesion [30, 54]. In vitro histone ubiquitination by 
CRL4DDB2 altered the stability of the nucleosome core driving partial histone 
eviction [53]. Histone ubiquitination with concomitant destabilisation of 
neighboring nucleosomes thus offers an additional mechanism to evict 
histones and drive assembly of the NER machinery in a chromatin 
environment (Figure 2) [30, 55]. Mono-ubiquitination of histones could, in 
addition, function as a recruitment signal for additional auxiliary repair factors 
(see below). 
 
Ubiquitination overseeing damage handover from DDB2 to XPC 
CRL4DDB2 ubiquitination has been implicated in resolving one of the central 
conundrums of NER damage recognition [25]: while DDB1-DDB2 has the 
highest affinity for UV-induced photo-dimers in vitro, and appears to be the 
first protein complex at the lesion in vivo [23, 24, 41], it is dispensable in vitro 
[15]. XPC, in contrast binds 6-4PP with two orders of magnitude lower affinity 
than DDB2 [25, 56, 57] and has no discernable affinity for CPD, yet is 
essential for NER both in vitro and in cells. As DDB1-DDB2 is required for 
efficient XPC recruitment to chromatin [23], the question arises as to how 
damage is handed over from DDB2 to XPC. Recent work demonstrated that 
CRL4DDB2 targets XPC, as well as DDB2 for ubiquitination in a UV-
dependent fashion [25]. Poly-ubiquitination of DDB2 ablates DNA binding by 
DDB1-DDB2 and results in proteasome mediated DDB2 degradation [58, 59]. 
Poly-ubiquitination of XPC, on the other hand, does not appear to affect DNA 
damage binding [25] and XPC is protected from immediate proteasomal 
degradation, likely through association with HR23 [60-62]. This and further 
studies [63] place DDB1-DDB2 in the recruitment of XPC to the sites of 
damage in chromatin, with a subsequent handover of the lesion from DDB2 to 
XPC in an ubiquitin dependent manner [7, 30]. XPC thereby emerges as an 
indispensable core component of NER, which in vivo does, however, require 
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assistance from DDB1-DDB2 in finding specific lesions. The exact molecular 
nature of the damage handover complex from DDB2 to XPC remains elusive. 
The damage probing hairpin of both DDB2 (hsDDB2: 334FQH336) and XPC 
(hsXPC: 799FHGGYS804) cannot simultaneously engage with the lesion 
damage due to large steric clashes [30, 64]. Three, mutually non-exclusive 
possibilities for such a handover complex have been considered: (i) XPC 
binding, via the TGD domain, to the undamaged duplex 3´of the lesion with 
DDB2 engaging the pyrimidine dimer; (ii) XPC attaching to DDB2 through 
protein-protein interaction [25], and (iii) in a more indirect fashion XPC 
recruitment by ubiquitination (for example of the histone or DDB2) as the 
HR23 subunit also carries a UBA domain [65]. In particular in the latter 
mechanism CRL4DDB2 could recruit XPC to lesions such as CPDs, for which 
XPC has no measurable affinity by itself, yet is required for repair in vivo. 
Interpretation of the role of CRL4 mediated ubiquitination in NER has been 
complicated [66], also by the finding that mice carrying a Cul4a deletion in 
skin cells are less likely to develop UV-induced skin cancers [67]. As CUL4A 
is involved in many different cellular pathway regulated in response to UV, 
such as the CRL4CDT2-p21 controlled by UV cell cycle checkpoint, it is 
currently unclear which CRL4 adaptor is responsible for the mouse cancer 
phenotype. 
 
A related DDB1-CSA-CUL4 ligase in Cockayne syndrome 
A general feature of DDB1-CUL4 cullin E3 ligases is their modularity 
(Figure 1). Largely through proteomic studies a number of DDB1-CUL4 
associated proteins have been identified [68]. The family of these proteins is 
known as DCAFs (DDB1-CUL4-associated-factor) [33], DWD-proteins (DDB1-
binding and WD40-repeat) [69] or CDW-proteins (CUL4- and DDB1-
associated WDR proteins) [70]. These DCAFs fall in two potential categories: 
substrate receptors recruiting CRL4 complexes and regulators of CUL4 
function. DDB2 thereby is one out of more than fifty possible substrate 
receptors described. DDB2 recruits the ligase to sites of damages, whereas 
the majority of these CUL4-DDB1 ligase receptors, including CSA [71], are 
likely to recognize protein epitopes, or posttranslational modifications of 
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proteins. In a ‘plug and play’ fashion these receptors can be exchanged, 
customizing CRL4 substrate specificity to different pathways (Figure 1). 
 
The role of the Cockayne syndrome A protein (CSA) in transcription 
coupled repair. 
We will first examine the Cockayne syndrome A CRL4CSA ligase complex 
involved in transcription coupled repair of damages located on the actively 
transcribed strand [4, 9, 72-74]. Cockayne syndrome is a rare autosomal 
disease with mutations in two proteins CSA [75] and CSB [76]. The hallmarks 
of Cockayne syndrome include developmental defects, photosensitivity, 
premature aging and mental retardation [3, 77]. While CSA is integrated in a 
CRL4CSA ubiquitin ligase complex [35], CSB functions as SWI/SNF 
chromatin remodeler [78]. CSA and CSB both appear intertwined with the 
general transcription machinery [13]. Mutations in CSA and CSB are 
indistinguishable on the patient level arguing for a common pathway. Upon 
RNA polymerase II (RNAPII) stalling, both CSA and CSB are required for 
repair and transcription restart. CSB has been implicated in the remodeling of 
stalled RNAPII complexes to which it binds tightly in the presence of damage 
[79, 80]. CSA is translocated to the nucleus, in a CSB-dependent manner, 
and co-localises with CSB at sites of stalled RNAPII [81]. Arrival of CSA is 
required for recruitment of HMGN1 (high mobility group nucleosome-binding 
domain-containing protein 1), XAB2 (XPA-binding protein 2) and transcript 
elongation factor TFIIS [82].  
 Five lines of evidence suggest the involvement of the ubiquitin 
proteasome system in TCR: (i) CSA is constitutively found in complex with 
DDB1 and CUL4 [35], (ii) ubiquitination of CSB was observed under high UV 
conditions, with proteasome dependent CSB degradation during later stages 
of TCR [71], (iii) UV-dependent CSB degradation is absent in cells lacking 
CSA but can be restored by exogenous CSA, and (iv) the DDB1-CSA-CUL4A 
ligase was capable of CSB ubiquitination in vitro; (v) finally, CSB has a 
ubiquitin binding (UBA) domain which was found essential for CSB function in 
TCR [83]. The structure and architecture of the CRL4CSA complex is 
currently unknown. The current data is consistent with CSB functioning as a 
CRL4CSA  recruitment and ubiquitination substrate [71]. Other, as yet 
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unidentified targets cannot be ruled out at present, however. While the 
CRL4DDB2 and CRL4CSA ligase complexes differ substantially in respect to 
their function, there are interesting mechanistic parallels: the respective main 
targets of CRL4DDB2 and CRL4CSA, XPC-HR23 and CSB both carry UBA 
domains believed to play important regulatory roles in NER. What these UBA 
domains recognize and what functional consequences UBA target binding 
has, remains an active area of research. 
 
 
The role of DDB1-CDT2-CUL4 in genomic stability and beyond 
DDB1-CDT2-CUL4 (CRL4CDT2), a third essential CUL4 ligase, oversees the 
S/G2 cell cycle transitions through degradation of the replication licensing 
factor CDT1 [84-86]. Additional human targets include the cell cycle regulator 
p21 [87, 88] and the histone methyltransferase SET8/Pr-SET7 [89-92]. 
Degradation of these substrates proceeds in a DNA replication and UV-
dependent manner. In S. pombe CRL4Cdt2 has been implicated in the 
ubiquitination of Spd1, a ribonucleotide reductase inhibitor [93] and Epe1 [94], 
which  assists in the sculpting of heterochromatic boundaries. In most cases 
examined, CDT2 has been shown to interact with its substrates through a 
conserved, PIP (PCNA-interacting peptide) box containing degron motif in a 
manner dependent on the proliferation cell nuclear antigen (PCNA) [86, 95-
100]. The requirement of two polypeptides (PCNA + PIP containing target) for 
substrate recognition is intriguing, and might suggest that CDT2 uses PCNA 
as an additional level of proofreading in proper substrate selection. 
 
CSN functions as a master regulator of cullin type E3 ligases 
The COP9 signalosome (CSN) has been reported to play a central role in 
the regulation of all cullin E3 ligases (Figure 2) [35, 101]. Similar to other 
cullin-RING E3 ligases [102], the CUL4 E3 ligase is activated through 
attachment of NEDD8, a small ubiquitin-like modifier [35, 54]. The removal of 
NEDD8 from cullins is catalysed through the metallo-isopeptidase activity of 
the COP9 signalosome (CSN) [103, 104]. CSN is an eight subunit, ~350 kDa 
protein complex conserved in all eukaryotes [35, 105-107]. CSN shares 
significant sequence and structural homology with the components of the 19S 
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proteosome lid. The first three-dimensional EM structure of the CSN complex 
at 25 Å resolution shows a central cleft along with two CSN segments 
corresponding to CSN1/2/3/8 and CSN4/5/6/7 [108-110]. The exact mode of 
cullin binding to CSN is currently not known. 
 
CSN a master regulator of ubiquitin ligase, challenges for regulation. 
Detailed understanding of CSN regulation is complicated by the observed 
discrepancies between biochemical and genetic properties of the complex. 
Gene deletion studies, for example, demonstrated that S. pombe csn1- and 
csn2- strains are sensitive to UV and ionizing radiation, along with a slow 
DNA replication phenotype [111, 112]. The catalytic csn5 deletion mutant, in 
contrast, did not display this pronounced phenotype [111], suggesting that the 
CSN function extends beyond catalytic cullin de-neddylation through the 
CSN5 isopeptidase. Intriguingly, despite being a master regulator of all cullins, 
CSN appears nevertheless able to differentially regulate CRL4 ligases in 
response to a common stimulus, such as UV: in the absence of UV-damage, 
CSN is associated with the un-neddylated CRL4DDB2 and CRL4CSA complexes. 
Upon UV-damage, CSN dissociates from CRL4DDB2 [35, 49] allowing its 
neddylation. At later time points, CSN de-neddylates and re-associates with 
the CRL4DDB2 complex [113]. In TCR, on the other hand, CRL4CSA complexed 
to CSN rapidly locates to the damage site upon UV irradiation [35], and only 
dissociates at a much later time point. The PCNA-dependent ubiquitin-
mediated proteolysis of CDT1 by CRL4CDT2 for example also proceeds in 
response to UV, similarly mediated by CSN [100, 114]. The open question 
currently is whether CSN can selectively regulate defined CRL4-substrate 
receptor complexes in response to a given stimulus, while not interfering with 
the remainder of cullin-CSN complexes, and if so how it does achieve this 
kind of mechanistic specificity? Specialized CSN release CRL4 factors may 
exist regulating CSN release in response to cellular signals [49]. 
 
General principles of DDB1-DCAF-CUL4 architecture and regulation 
What general architectural, targeting and regulatory principles can we 
deduce from these CRL4 complexes?  
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1. Architecture 
All structurally characterized DDB1-DCAF complexes [32] utilize a helical 
motif in binding DDB1. This motif structurally resembles DDB2 helix1. Helix1 
equivalents, although only moderately conserved, have been identified in the 
protein sequence of several DCAF proteins and are referred to as DDB-box 
(devoted to DDB1 binding) [115]. A number of WD40 containing DCAFs, 
however, do not appear to contain recognizable helical domains. It is currently 
unclear if those helices simply escape detection or whether fundamentally 
different DDB1 binding modes exist (Figure 1). When comparing different 
proteomic studies identifying DCAFs a common set of about 10 to 20 WD40 
containing DCAFs have been consistently identified in most studies [33, 68-
70, 99, 116], most of those appear to have helical motifs that could be used 
for DDB1 binding. Currently, there is no direct evidence for DDB1 binding 
mediated by WDXR motifs equivalent to the WDXR motif present in DDB2, 
which, as seen in the DDB1-DDB2 structure, is not part of the DDB1 interface 
or the DNA binding interface [30]. Yet mutation of the WDXR motif (R273H) in 
DDB2 gives rise to a mutant protein that is no longer able to bind to DNA 
damage, likely due to local unfolding of the propeller [57]. By analogy, it 
should thus be considered that mutation of the corresponding WDXR in other 
DCAFs could also indirectly ablate DDB1 binding through interference with 
WD40 folding, leaving the possibility that WDXR is not necessarily part of the 
DDB1-DCAF interface. Additional DDB1-DCAF structures are required to 
resolve this issue. 
2. WD40 containing and non-WD40 containing DCAFs 
The majority of DCAFs comprise WD40 propeller domains. We propose 
that those DCAFs who have helical elements preceding the WD40 propeller 
bind DDB1 in a manner resembling the DDB1-DDB2 complex. Other proteins 
have been classified as DCAFs that do not contain WD40 propeller domains. 
They often do have helical elements, nevertheless, and likely bind DDB1 
using those motifs (Figure 1). Their mode of DDB1 attachment is likely to be 
equivalent to that seen in the SV5V-DDB1 [31] and DDB2 (helix1)-DDB1 
structures.  
3. Substrate recognition and ubiquitination 
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In case of WD40 containing DCAFs, the WD40 propeller is used for 
recruiting the CRL4 complex to the ubiquitination target. The ligand binding 
site of this WD40 propeller is expected to be located at the narrow face of the 
WD40 propeller cone, pointing away from DDB1 [30] (Figure 1). This ligand, 
which recruits the CRL4 complex via the WD40 of the substrate receptor, 
however, does not necessarily have to be the target that undergoes 
ubiquitination (see DDB2). As the ligase is able to span distances up to 100Å, 
the recruiting ligand and the ubiquitination target might therefore also be 
separate proteins/ligands (Figure 2). 
4. Regulation  
As outlined above, the CRL4 family is likely to be under the control of the 
signalosome (Figure 2). Substrate binding to the WD40 DCAF could also be 
regulated through posttranslational modification, as is commonly observed in 
the CUL1 family of targets [117]. For example, substrates might require 
phosphorylation prior to CRL4DCAF binding [118], with phosphorylation being 
the key determinant for binding/regulation. As is already evident in case of 
CRL4CDT2, more complicated substrate binding schemes appear in operation, 
ensuring tight regulation of the ligase function. Additionally, a number of 
DDB1 binding proteins have been identified, for example DET1 [119] and 
DDA1 [116], which might have a regulatory role rather than serving as a 
substrate receptor.  
 
Within the large CUL4 family [36], the CRL4DDB2 ligase is currently the best 
understood representative in respect to its structure, function and regulation. 
While DDB2 recognizes damaged DNA as a recruiting substrate, the majority 
of the remaining receptors likely recognizes protein epitopes (or 
posttranslational modification thereof). More work will be needed to define 
what these epitopes are and how ubiquitination is regulated in these 
CRL4DCAF ligases. Furthermore, we will need to understand the functional role 
of the plethora of DDB1-CUL4 associated factors, which do not function as 
substrate receptors. Understanding CRL4 targeting and regulation is expected 
to significantly improve our understanding of the various biological pathways 
these proteins operate in. 
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Figure legend: 
Figure 1: Modular architecture of CRL4DCAF complexes 
Tentative model of the CRL4DDB2 complex by overlaying the DDB1-DDB2 
complex bound to a 6-4 PP containing oligonucleotide [30] and the DDB1-
CUL4/RBX1 complex [33], assuming no overall conformational changes. The 
architecture of DDB1-DDB2 serves as a structural archetype for complex 
formation between WD40-type DCAF receptor proteins and DDB1. The 
overall assembly of CRL4DCAF complexes and putative modes of association 
of (I) helix-containing WD40-type DCAF receptors (as seen in DDB1-DDB2), 
(II) hypothetical assembly of non-helix WD40 DCAFs and (III) non-WD40 
DCAFs (as seen in DDB1-SV5V) are depicted. 
Inlet panel: Structural details of UV-lesion recognition. The DDB2 (green) 
FQH-hairpin ‘finger’ (yellow) inserts into the damaged DNA duplex (grey and 
black) and concomitantly extrudes the 6-4 PP lesion (red) into a hydrophobic 
surface pocket. 
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Figure 2: Regulation of CRL4DCAF complexes 
a) DDB2 specific NER pathway: (1) Recruitment of inactive CSN-CRL4DDB2 
to the nucleosome embedded lesion. (2) Ubiquitin ligase activation by CSN 
release and CUL4 neddylation; subsequent ubiquitination of nearby proteins, 
including DDB2 auto-ubiquitination, XPC and histones. (3) Ubiquitination 
induced eviction of the histone octamer facilitating recruitment of the NER-
repairosome and initiation of damage repair. Proteasomal degradation of 
ubiquitinated DDB2 is implicated in CRL4DDB2 release and damage 
handover to downstream NER factors.     
b) General model for CRL4DCAF regulation: (1) Recruitment of inactive 
CSN-CRL4DCAF through DCAF receptor proteins. (2) Release of CSN with 
subsequent CUL4 neddylation and ligase activation resulting in substrate 
ubiquitination. (3) Pathway specific induction of coordinated cellular events, 
such as proteasomal degradation of the substrate protein, relocalisation or 
recruitment of interaction partners.  
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Chapter 4: Structural basis of CRL4CRBN inhibition by 
Thalidomide and its derivatives 
 
Materials and methods 
 
Cloning and protein expression 
Homo sapiens DDB1 (residues 1-1140) (Scrima et al., 2008) and gallus 
gallus CRBN (residues 1-445) were cloned into pAC derived vectors (BD 
biosciences PharMingen, San Jose, CA USA) and recombinant baculoviruses 
were prepared according to the manufacturers protocol. Proteins were 
expressed as N-terminal His6 (DDB1) and N-terminal StrepII (CRBN) tagged 
fusion proteins in Hi-Five insect cells (Invitrogen). 
For purification, cells were resuspended in lysis buffer (50mM Tris-HCl 
pH8.0, 200mM NaCl, 0.1% Triton X-100, 5mM TCEP (tris(2-
carboxyethyl)phosphine), 1mM PMSF and 1 tablet/100ml Sigma protease 
inhibitor cocktail) and lysed by sonification. The lysate was clarified by 
ultracentrifugation and proteins were then purified using Strep-Tactin affinity 
purification. Proteins were further purified by anion exchange chromatography 
(Poros 50HQ) using a 0-800mM NaCl gradient. Size exclusion 
chromatography (SEC) (HiLoad 16/60 Superdex 200; GE Healthcare) in 
50mM HEPES pH 7.4, 200mM NaCl and 0.25mM TCEP yielded protein 
without visible contamination (coomasie stained SDS-PAGE). The purified 
protein was concentrated using “Amicon Ultra” spin concentration devices, 
flash frozen in liquid nitrogen and stored at -80°C until further use. 
 
Compounds, enzymes and antibodies used 
(S)-Thalidomide, (R)-Thalidomide and lenalidomide (revlimid) used for 
crystallization were kind gifts from NIBR Cambridge (USA). (S)-Thalidomide 
for biochemistry was purchased from Sigma Aldrich (USA) (T150-100MG) and 
lenalidomide (S1029) for biochemistry and pomalidomide (S1567) for 
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crystallization and biochemistry were purchased from Selleckchem (USA). All 
compounds were dissolved in DMSO at various concentrations. 
Ubiquitin activating enzyme E1 (UBA1), ubiquitin conjugating enzyme E2 
(UbcH5a, UbcH5b), ubiquitin and “K-0 ubiquitin” were purchased from Boston 
Biochem (USA). Anti-Flag M2 Antibody was provided by the lab of S. Gasser 
(Friedrich Miescher Institute, Basel, Switzerland) and initially purchased from 
Sigma Aldrich. Horseradish peroxidase (HRP)-conjugated secondary 
antibodies against mouse IgG were purchased from Abcam (ab6728). 
 
Crystallization of hsDDB1-ggCRBN 
Protein-thalidomide/lenalidomide co-crystals were obtained by mixing of 
thalidomide or lenalidomide with purified hsDDB1-ggCRBN protein complex in 
a 2-3:1 molar ratio. Initial screening was carried out using a phoenix liquid 
handling robot (Art Robbins, CA, USA) using commercially available screens 
(Hampton, USA; Quiagen, DE), initial hits were refined in a 24 well hanging 
drop vapour diffusion setup by mixing 1µl of protein solution with 1µl of 
reservoir solution (100mM Na-Cacodylate, 80mM NaH2PO4, 120mM K2HPO4, 
700mM-1200mM tri-NaCitrate). Diffraction grade hsDDB1-ggCRBN-
pomalidomide co-crystals were obtained under similar conditions.  
Data collection was carried out at beamlines X10SA and X06DA of the 
Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland) with a 
Pilatus 2M or Pilatus 6M detector, respectively. Collected data sets were 
processed using XDS (Kabsch, 1993). 
 
Structure solution and Model building 
The crystals contained one molecule in the asymmetric unit (AU). The 
structure was solved by molecular replacement using Phaser (Mccoy et al., 
2007) with the BPA/BPC/CTD of DDB1 (3EI1) as search model. The 
BPA/BPC/CTD domains of DDB1 were fixed and the BPB domain searched 
with Molrep (Vagin and Teplyakov, 1997). Rigid body refinement on DDB1 
domains was done with Phenix (Adams et al., 2010). 
De novo model building for the CRBN subunit was carried out with Coot 
(Emsley and Cowtan, 2004), all structures were refined using phenix.refine 
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(Adams et al., 2010) and Buster (Smart et al., 2012). Figures were generated 
with PyMol (DeLano Scientific, http://www.pymol.org). 
 
In vitro ubiquitination assays 
In vitro ubiquitination assays and CSN protection assays were carried out 
as described in Fischer et al., 2011. Final enzyme concentrations in the 
reaction mix were 15-20 µM ubiquitin, 0.04 µM E1, 0.07 µM CRL4CRBN 
complex, 1 µM E2 (UbcH5a or UbcH5b) in 1x Ubiquitin Assay Buffer 
(Sugasawa, 2006). CSN concentrations user for CRL4CRBN inhibition varied 
between 100nM-400nM as indicated in Figure 4.3. 
Table 1: X-ray data collection and refinement statistics.  
Data collection
hsDDB1-ggCRBN 
Thalidomide
hsDDB1-ggCRBN 
Lenalidomide
hsDDB1-ggCRBN 
Pomalidomide
Beamline SLS X06DA SLS X10SA SLS X10SA
Wavelength (Å) 0.9999 1.0000 1.0000
Space Group P32221 P32221 P32221
a, b, c (Å) 172.27, 172.27, 140.16 172.27, 172.27, 139.90 170.89, 170.89, 138.58
α, β, γ (deg) 90, 90, 120 90, 90, 120 90, 90, 120
Resolution (Å) 30.0-3.07 (3.15-3.07) 30.0-3.16 (3.24-3.16) 50.0-3.70 (3.92-3.70)
Completeness (%) 99.9 (99.9) 99.8 (100) 99.4 (97.0)
Unique reflections 45138 (3289) 41312 (3022) 48596 (7639)
Redundancy 8.4 (7.5) 5.4 (5.1) 5.3 (5.1)
Rsym (%) 12.6 (116.5) 12.7 (105.4) 26.0 (120.5)
I/σI 16.85 (1.85) 13.74 (1.62) 7.42 (1.43)
CC(1/2) 99.8* (63.9*) 99.7* (57.9*) 98.4* (46.5*)
PDB code not deposited not deposited not deposited
Rwork/Rfree 19.3/25.4 20.3/23.6 20.6/21.8
Reflections (working set) 42865 45679 24213
Reflections (test set) 2273 2434 1274
Protein 11715 11627 11753
DNA 0 0 0
Water 348 252 0
Ligand 20 20 22
Bond lengths (Å) 0.01 0.01 0.009
Bond Angles (deg) 1.45 1.40 1.32
favoured 96.64 94.99 96
disallowed 3.36 5.01 4
Avg. B-factor (Å2) 84.8 93.2 94.3
Cell parameters
Refinement
Number of Atoms
R.m.s. deviations
Ramachandran
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Results 
DDB2 and CSA are two members of the DCAF family involved in 
nucleotide excision repair, which our studies have shown to share striking 
structural similarity between these WD40 β-propeller substrate receptors. 
While a majority of DCAFs identified by proteomic studies (Angers et al., 
2006; Groisman et al., 2006; He et al., 2006; Jin et al., 2006; Bennett et al., 
2010) are predicted to contain a WD40 repeat domain, others have been 
identified as DCAFs that likely do not share these domains. To investigate 
how a putative non-WD40 DCAF would look like, and how it would bind to 
DDB1 and recruit it’s substrate to the ligase, we determined the structure of 
DDB1-CRBN. 
 
Overall structure of the DDB1-CRBN complex 
To facilitate crystallization, a number of orthologues (homo sapiens, danio 
rerio, gallus gallus) previously known to bind thalidomide (Ito et al., 2010) 
were cloned, expressed in “Hi-Five” insect cells and screened for 
crystallization conditions in the presence or absence of the two drugs, 
thalidomide and lenalidomide. Only a chimeric complex of homo sapiens 
DDB1 and gallus gallus CRBN yielded crystals of sufficient quality for 
structure determination. hsDDB1-ggCRBN in complex with thalidomide and 
lenalidomide crystallized in space group P 32 2 1 (154), and structures were 
determined at 3.07 Å and 3.16 Å resolution, respectively. A 3.7 Å refined 
structure of hsDDB1-ggCRBN bound to pomalidomide was obtained under 
similar conditions (see Table 1 for a summary of data collection and 
refinement statistics). The overall sequence conservation of chicken CRBN 
versus human CRBN (91% similarity and 84% sequence identity), make it 
likely that the results observed will also hold true for the human CRBN 
orthologue. DDB1 is a highly conserved protein with an overall sequence 
conservation between chicken and human DDB1 of 98% similarity (97% 
identity), moreover all residues involved in CRBN interaction are conserved 
from chicken to human. 
The DDB1 subunit predominantly consists of three seven-bladed WD40 β-
propellers arranged in a triangle-like shape (BPA, BPB and BPC), and a 
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helical C-terminal domain (CTD) (Li et al., 2006; Scrima et al., 2008) (see 
Figure 4.2a). The structure of CRBN consists of three domains, a 9β-sheet 
containing N-terminal domain (NTD, residues 1-185), a 7 α-helices containing 
helical insertion domain (HID, residues 186-317) that mediates the interaction 
with DDB1, and another 9 β-sheet containing C-terminal domain (CTD, 
residues 318-445) that harbors the thalidomide binding pocket and a zinc 
coordination site (Figure 4.2a). The region preceding Asn46 and following 
Arg427 are not well defined in the electron density map and were omitted 
from model building. In addition, a segment spanning from Arg205 to Phe222 
could not be assigned with sufficient confidence and was omitted from the 
model. 
Comparison of the CRBN structure with other known structures reveals that 
the region aa46-aa317 (NTD and HID) largely resembles the structure of a 
bacterial Lon protease N-terminal domain (PDB: 3LJC), while the CTD 
(residues aa318-aa427) displays similarity to a methionine sulfoxide 
reductase fold (PDB: 3MAO). Structural comparison using DALI server (Holm 
and Rosenström, 2010) reported a Z-score of 16.2 with an RMSD of 2.7 Å for 
CRBN(46-317) with 3LJC over 178 residues aligned. The structure alignment 
of CRBN(318-427) with 3MAO also reported a Z-score of 9.5 with an RMSD 
of 2.0 Å over 79 residues. 
Although NTD and HID generally align well with the Lon protease (3LJC), a 
significant difference arises from the DDB1-interacting motif located C-
terminal to the NTD. The NTD consists mainly of β-strands and aligns with 
an overall C-α RMSD of 2.06 Å (SSM superposition, Coot) (Emsley and 
Cowtan, 2004) to the N-terminal subdomain of 3LJC. While the helices H4, 
H5, H6 and H7 again show striking similarity with the helices in the Lon 
protease fold, a 63 amino acid insertion after residue 185 and before H4 
(aa252-aa263) forms the DDB1-interacting motif and does not show 
recognizable similarity with any known structures. It is also different to the 
canonical HLH motif seen, such as in DDB2 or CSA. 
The interaction with DDB1 is mediated through a long loop (aa189-aa223), 
followed by a helix-loop-helix (aa223-249). This CRBN region occupies a 
cavity between the DDB1-BPC and BPA domains similar to that seen in other 
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known DCAFs. DDB2 in contrast employs, in addition to the HLH motif 
engulfed in the DDB1 cavity, also a large hydrophobic patch to interact with 
DDB1. The buried surface area of the CRBN-DDB1 complex is 2194 Å2 
(EPPIC Server, Duarte et al., 2012), with major binding contributions made by 
the loop region spanning CRBN residues Glu188 to Phe222, and a helical 
arrangement including helices H3 and H4 (residues Arg223 to Tyr250) 
(Figure 4.2a). Additional contacts are formed by residues within helix H7 (aa 
306-319), with Gln308 and Arg311 being involved in hydrogen-bonding 
interactions. 
Figure 4.1: Superposition of chicken CRBN with mouse MsrB2 active site. The CTD of 
CRBN and MsrB2 are depicted as cartoon representation in green and cyan, respectively. 
Thalidomide bound to CRBN is depicted as sticks representation in magenta. Catalytic 
residues of MsrB2 and corresponding residues in CRBN are highlighted in yellow and orange, 
respectively. 
The CTD of CRBN is defined by an overall β -strand and globular 
arrangement, consisting of nine all antiparallel β-sheets. Comparison with 
two published structures of Methionine-R-Sulfoxide reductases (human 
MsrB1, PDB: 3MAO and mouse MsrB2, PDB: 2L1U) revealed 
superimposable structures (rmsd of 2.1 Å over 78 residues and rmsd of 3.1 Å 
over 62 residues for 3MAO and 2L1U, respectively) (Figure 4.1). While a iron 
ion is coordinated in MsrB1, a zink ion is found in the structures of CRBN and 
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MsrB2, within the structurally conserved coordination site provided by four 
cysteins (Cys325, 328, 393 and 396 in ggCRBN). The residues involved in the 
catalytic activity of MsrB2 (Trp103, His148, Phe150, Arg160, Cys162 and 
Arg162), and the catalytic cysteine 162, in particular, are not conserved in 
CRBN. The corresponding residues in CRBN include (Trp402, Phe404, 
Lys415, Trp417 and Thr420) (Figure 4.1), of which residues Trp402 and 
Phe404 localize to the thalidomide binding pocket. 
Thalidomide is the ancestor of a class of molecules called IMiDs (Cellgene, 
Summit NJ, USA), which exhibit different pharmacological properties despite 
being highly similar in structure. In order to understand the molecular basis of 
IMiD binding to CRBN, we determined the structures of DDB1-CRBN bound 
to all three clinical relevant IMiD compounds, thalidomide (Thalomid), 
lenalidomide (Revlimid) and pomalidomide. 
 
Thalidomide occupies a pocket in the C-terminal domain of CRBN 
The small molecule inhibitor thalidomide binds to a hydrophobic pocket 
mainly composed of Tryptophan W382, W388 and W402 in conjunction with 
residues N353, P354, H355 and F404 (Figure 4.2a, c). The presented X-ray 
structures revealed that lenalidomide and pomalidomide bind to the same 
pocket of CRBN in a comparable fashion (Figure 4.2b). 
The glutarimide group of thalidomide (Figure 4.3a) faces inwards toward the 
hydrophobic pocket and is buried within a hydrophobic cage provided by 
W382, W388 and W402 (Figure 4.2c), while the phtalimide group is oriented 
towards the outside in a solvent exposed manner. This binding mode is 
compatible with the reported linkage of a carboxyl-derivative of thalidomide 
(Figure 1.8) to magnetic beads used in the affinity-based identification of 
CRBN as target to thalidomide (Ito et al., 2010). The binding of thalidomide to 
CRBN is mainly mediated through van der Waals forces and two hydrogen 
bonds formed by the glutarimide oxygens of CRBN and His380 and Trp382. 
The overall shape of the binding pocket suggests that the S-enantiomer of 
thalidomide is preferentially bound (Figure 4.2d). This is in line with the 
observation that it is the S- as opposed to R-enantiomer of pomalidomide that 
shows pharmacologic activity (Lopez-Girona et al., 2012). 
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Figure 4.2: Structure of DDB1-CRBN bound to thalidomide. (A) Overall structure of the 
DDB1-CRBN complex. CRBN (NTD): blue, CRBN (HID): cyan, CRBN (CTD): green, DDB1 
(BPA): red, DDB1 (BPB): magenta, DDB1 (BPC): orange, DDB1 (CTD): grey. Schematic 
overview of the CRBN organization. Thalidomide, in magenta, and the residues involved in 
thalidomide binding are highlighted. (B) Overlay of Thalidomide, Lenalidomide and 
Pomalidomide bound to CRBN, with CRBN depicted as surface representation in green. (C) 
Close-up view of the Thalidomide interacting residues, depicted as yellow sticks. Thalidomide 
is shown as sticks in magenta, together with its positive Fo-Fc electron density calculated and 
contoured at 2.5 σ before it was build into the complex. (D) Close-up view on the thalidomide 
binding pocket in CRBN shown as green surface. 
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The differences between the three derivatives thalidomide, lenalidomide 
and pomalidomide are minor (Figure 4.3a-c) and, in consequence, the overall 
binding mode is very similar (Figure 4.2b). Minor differences are observed for 
the aniline of lenalidomide and pomalidomide, absent in thalidomide, which 
potentially forms a hydrogen bond with the Glu379 side chain (Figure 4.3e). 
This is interaction is not predicted to significantly contribute to binding due to 
its solvent exposed binding mode. In thalidomide, one of the phthalimide 
carbonyl oxygens lies within 4 Å of the backbone carbonyl oxygen of Glu379 
or may be lodged against the electron-rich face of the indole of the Trp388. In 
lenalidomide, the lactam analog, the carbonyl is absent. This would relieve 
these potential, unfavorable interactions. 
Figure 4.3: Autoubiquitination of CRBN. Skeletal formula of (A) Thalidomide, (B) 
Lenalidomide and (C) Pomalidomide. Stereisomers are not drawn in this representation. (D) 
In vitro ubiquitination assays were performed with FLAG-CRBN containing CRL4CRBN 
complex and subjected to anti-FLAG immunoblot analysis. The decrease in signal for CRBN 
corresponds to increasing amounts of ubiquitinated CRBN. CSN inhibition was achieved with 
100nM of CSN5 active site mutant containing CSN complex (CSN(ASM)), compounds were 
used 10µM final concentration. (E) CRBN and Thalidomide are depicted as sticks in green 
and red, respectively. 2mFo-Fc electron density is shown in blue calculated and contoured at 
1.5 σ.   
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Ito and colleagues have found that thalidomide inhibits the ubiquitin ligase 
activity of CRL4CRBN in vivo and in vitro (Ito et al., 2010), moreover, it has 
been reported that thalidomide, lenalidomide and pomalidomide exhibit 
different pharmacological properties that could not be anticipated by our 
structural studies. In order to better understand the effect of thalidomide on 
CRBN and the CRL4CRBN ubiquitin ligase, we set out to characterize the effect 
of thalidomide to CRL4CRBN in a fully recombinant system. 
 
Autoubiquitination of CRL4CRBN is inhibited by CSN in vitro 
The CRBN subunit of the CRL4CRBN ubiquitin ligase undergoes 
autoubiquitination in vivo and in vitro (Ito et al., 2010). This autoubiquitination 
activity depends on the DDB1 interaction and thereby on CRL4CRBN assembly. 
Ito and colleagues were further able to demonstrate that CRBN 
autoubiquitination in vivo is inhibited by thalidomide and that a Y384A and 
W386A mutant abolishes thalidomide binding but not CRL4CRBN assembly. As 
a consequence, the mutant also resists the inhibitory effect of thalidomide. We 
focused on characterizing the effect of thalidomide on CRL4CRBN function in 
vitro and the role of CSN in regulating CRL4CRBN.  
We examined whether recombinant CRL4CRBN complex exhibits E3 
ubiquitin ligase activity, in vitro ubiquitination assays were performed using 
recombinant CRL4CRBN comprising a CRBN as N-terminal FLAG fusion 
protein. Likely due to the promiscuity of the ubiquitination reaction, we were 
unable to detect poly-ubiquitinated CRBN in anti-FLAG immunoblots. Instead, 
we observed a decrease of the signal for unmodified FLAG-tag CRBN that we 
anticipate to be due to polyubiquitination of CRBN including the lysines of the 
FLAG-tag (Figure 4.3d lane 1 and 2). CRBN is autoubiquitinated in vitro, 
irrespective of the presence or absence of thalidomide, lenalidomide or 
pomalidomide (Figure 4.3d, lanes 1-5), while in vivo CRBN ubiquitination is 
sensitive to thalidomide treatment (Ito et al., 2010). We have previously 
demonstrated that CSN inhibits DDB2 and CSA autoubiquitination (Fischer et 
al., 2011) and we thus examined the effect of CSN on CRBN 
autoubiquitination in vitro. Within a CRL4CRBN complex, CRBN was 
ubiquitinated in the presence of an E1 (Uba1) and E2 (UbcH5a), as previously 
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observed (Ito et al., 2010). CRBN autoubiquitination, however, was inhibited 
in the presence of CSN (Figure 4.3d, lane 6). Moreover, the CSN mediated 
inhibition of CRL4CRBN was not relieved upon addition of either thalidomide, 
lenalidomide or pomalidomide (Figure 4.3d lanes 7-9).  
Figure 4.4: Alignment of human CRBN versus chicken CRBN. The alignment was 
generated with CLCbio (clcbio inc, Aarhus, DK) using the ClustalW algorithm (Larkin et al., 
2007). 
 
Discussion and outlook 
Structure of DDB1-CRBN; New diversity in the CRL4 ligase family 
Cullin4-type CRL E3 ubiquitin ligases are assembled in a modular fashion 
consisting of the scaffolding cullin subunit, which binds the globular Rbx1 
protein at the C-terminus, thereby assembling the active center. On the N-
terminus, the cullin is anchored to the BPB domain of DDB1, where DDB1 
forms the adaptor that binds the substrate recruiting DCAFs. Previous 
structures of DDB1-DCAF complexes (Scrima et al., 2008; Li. et al. 2006; 
Angers et al. 2006; Fischer et al., 2011) have highlighted the importance of a 
conserved helix-loop-helix motif (HLH) that anchors the DCAF to DDB1. 
Similar helical binding motifs have been identified for viral proteins SV5v (Li et 
al., 2006) and the HBx protein (Li et al., 2010). Based on these structures, a 
bipartite binding mode has been established as the canonical form of DDB1-
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DCAF interaction, where the HLH motif (DDB2, CSA) in conjunction with 
hydrophobic patches, on the surface of the WD40 repeat domain, contribute 
to DDB1 binding. 
Here we present the structure of hsDDB1-ggCRBN, the first structure of an 
endogenous non-WD40 β-propeller DCAF found to bind DDB1 in a way that 
differs significantly from the previously observed binding modes. CRBN forms 
a tripartite structure (Figure 4.2a) in which the NTD and HID share structural 
similarities to the N-terminal domain of a bacterial Lon protease (PDB: 3LJC) 
and in which the CTD largely resembles the structure of the mammalian 
Methionine-R-Sulfoxide reductase (MsrB1, PDB: 3MAO). The DDB1 
interacting region consists of two helices with long interconnecting loop 
regions, and has evolved at the junction between the NTD and HID domains. 
The overall buried surface area of the DDB1-CRBN interaction is 2194 Å2, 
calculated using the Eppic web server (Duarte et al., 2012) and comparable to 
the buried surface area of 1895 Å2 seen for the DDB1-DDB2 interaction. 
Figure 4.5: comparison of DDB1-DDB2, DDB1-CSA and DDB1-CRBN structures. 
 
Despite the lack of structural conservation between known WD40 DCAF 
receptors and the structure presented for CRBN, the overall spatial 
dimensions of the CRL4CRBN arrangement are likely to be similar to that of 
CRL4DDB2 (Fischer et al., 2011) (Figure 4.5). CRBN binds to DDB1 in a 
similar position and the overall arrangement is, to some extent, similar to what 
has been observed for DDB2 and CSA. It is therefore likely that CRBN binds 
40 Å 40 Å 40 Å
40 Å40 Å 40 Å
hsDDB1-drDDB2 hsDDB1-hsCSA hsDDB1-ggCRBN
 
 
146 
its (as yet unknown) substrate through the surface opposing the DDB1 
binding site and thereby allows for ubiquitination through the Cul4/Rbx1 ligase 
arm (see General discussion and perspectives for a more detailed 
discussion of CRL4 architectural constraints).  
Figure 4.6: Superposition of CRBN with a MSS4-Rab8 complex. (A) A superposition of 
the CRBN-CTD with MSS4 of 2FU5 in complex with Rab8 is depicted as cartoon 
representation in green, magenta and cyan, respectively. (B) Surface conservation of CRBN, 
highlighting the residues absent in the Arg419* mental retardation patient mutation. (C) 
Surface conservation of CRBN together with Rab8 from the MSS4-Rab8 complex aligned via 
MSS4 to the CTD of CRBN. The N-terminal helix of Rab8 occupies a surface in MSS4 that is 
equivalent to a conserved patch in CRBN in proximity to the thalidomide binding pocket.  
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The CTD of CRBN aligns with MSS4 in the published X-ray structure of a 
MSS4-Rab8 complex (PDB: 2FU5), CRBN-CTD and MSS4 superimpose with 
a rmsd of 3.47 Å over 107 residues (Itzen et al., 2006) (Figure 4.6a). 
Moreover, evolutionary conservation of surface residues is a common 
determinant of functional protein surface residues. We note that the highly 
conserved areas on the CRBN surface correlate with the position of the 
thalidomide binding pocket (Figure 4.6b), suggesting a functional role of 
these residues in addition to thalidomide binding. Strikingly, residues in 
CRBN, equivalent to those involved in protein-protein interactions between 
MSS4 and Rab8, contribute to the thalidomide binding site or are in close 
proximity (Figure 4.6c). These observations suggest that the thalidomide 
binding pocket might also be involved in substrate binding and that 
thalidomide could act as a substrate competitive inhibitor.  
 
Thalidomide binding and activity 
Since general inhibitors of the proteasome (bortezomib) and the Nedd8 E1 
enzyme (MLN4924) (Adams et al., 1998; Soucy et al., 2009) have shown 
promise in clinical trials, approaches to develop drugs with potentially higher 
efficacy and safety for specific indications have been initiated. In the 
sequential ubiquitin proteasome system, in which the proteasome represents 
the most general target, the E3 ligases and therefore also the cullin-RING E3 
ligases are the most selective targets. While CRLs have long been considered 
“undruggable”, recent studies have identified a number of tool compounds, 
including inhibitors to the S. cerevisae CRLs SCFCdc4 (Orlicky et al., 2010) and 
SCFMet30 (Aghajan et al., 2010). And to other targets in the UPS, such as the 
E2 enzyme Cdc34 (Ceccarelli et al., 2011). More recently thalidomide and the 
closely related lenalidomide and pomalidomide have been identified as a 
compound targeting specifically the CRL4CRBN E3 ubiquitin ligase (Ito et al., 
2010), thereby being the first in class FDA approved inhibitor of a CRL. The 
identification of CRBN as the primary cellular target of thalidomide (Ito et al., 
2010) and moreover the finding that CRBN is also mediating the anti-
myeloma effects of thalidomide and lenalidomide (Lopez-Girona et al., 2012) 
have shed light on the cellular action of thalidomide. However, without 
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knowledge of downstream targets, and without ruling out other off-target 
effects, the precise “mode of action” remains elusive (see also Chapter 5 
General discussion). 
The derivatives of thalidomide, lenalidomide and pomalidomide, have been 
shown to be more potent and have also been proposed to harbor less severe 
side effects (Quach et al., 2010). Potency, in this case, has mainly been 
addressed based on the degree of TNFα inhibition. Structurally, the three 
analogs are closely related. Lenalidomide has an additional amino group on 
the forth carbon of the phthaloyl ring, but lacks the carbonyl oxygen at position 
three. Pomalidomide, the latest derivative to have gone into clinical trials, is 
essentially a combination of both (Figure 4.3a to c). The additional amino 
group in lenalidomide and pomalidomide is expected to contribute to 
hydrogen-bonding with Glu379 without adding significant binding energy due 
to being solvent exposed. In order to fully address the differences in CRBN 
binding, precise binding studies will be required.  
Our structural and biochemical data demonstrates that thalidomide directly 
binds to a hydrophobic pocket within the CRBN subunit of CRL4CRBN without 
abolishing the interaction with DDB1. It also does not impair the overall 
structural integrity of the multi-protein CRL complex; and does not inhibit the 
ubiquitin ligase activity per se (Figure 4.3d). Rather, our data suggests that 
thalidomide binding to CRBN impairs substrate recruitment to the ligase and 
thereby the CSN mediated activation of the CRL4CRBN ubiquitin ligase. This is 
in line with the observation that thalidomide treatment inhibits CRBN 
autoubiquitination in vivo (Ito et al., 2010) but not in vitro (see General 
discussion and perspectives for a more detailed discussion of CRL4 
inhibition). However, to fully understand the mode of action and to confirm the 
proposed mechanism of inhibition, knowledge of a cellular target of the 
CRL4CRBN ligase will be required.  
 
Conservation in chicken versus human CRBN 
In order to obtain a high resolution structure of DDB1-CRBN bound to 
thalidomide and its derivatives, a large number of different deletion constructs 
of zebrafish, chicken and human CRBN were tested for solubility and, if 
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applicable, were pursued in presence or absence of thalidomide and 
lenalidomide in crystallization trials. 
 Diffraction grade crystals were only obtained for the chicken CRBN 
construct in a chimeric assembly with human DDB1. The overall conservation 
of chicken CRBN versus its human orthologue are 91% (similarity) / 84% 
(sequence identity) for the full-length constructs used; and 95% (similarity) / 
88% (sequence identity) for the boundaries that were modeled according to 
the electron density (see Figure 4.4). All of the residues involved in 
interactions with thalidomide, lenalidomide and pomalidomide are conserved 
between chicken and human CRBN. A region of little conservation is located 
between ggCRBN residues aa 201-224 corresponding to a loop region absent 
in the electron density and are therefore likely to be unstructured. 
The general high level of sequence conservation between human versus 
zebrafish CRBN, the identity of residues involved in thalidomide binding and 
the previously observed CRBN dependent thalidomide teratogenicity in 
chicken embryos (Ito et al., 2010), indicate that the conclusions drawn from 
the chicken CRBN structure will apply to the human orthologue. 
 
Mapping of patient mutations on CRBN 
CRBN was first identified as a new gene mutated in a mild form of mental 
retardation (Higgins et al., 2004). The identified nonsense mutation causes a 
premature stop codon after residue Arg419, resulting in a truncated form of 
CRBN (Figure 4.6b). Arginine 419 is located within the C-terminal domain 
and in proximity to the thalidomide binding pocket. 
In the treatment of multiple myeloma with revlimid (lenalidomide), 
resistance to the drug has been reported in certain patient groups (Lopez-
Girona et al., 2012), and cell culture experiments demonstrated that acquired 
resistance to the drug correlates with a loss of CRBN (Zhu et al., 2011; 
Lopez-Girona et al., 2012). Another potential source of drug resistance could 
be acquired mutations of the CRBN gene; the COSMIC database (Forbes et 
al., 2010) reports a number of somatic patient mutations in the CRBN gene 
(see Table 2), one nonsense mutation (p.E106*), and seven missense 
substitutions. The structure presented now provides a molecular rationale for 
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the reported mutations. The premature stop codon after E106 likely leads to 
an unfolded protein, or at least abolishes the interaction with DDB1, resulting 
in a phenotype similar to a total loss of CRBN expression. W224L and N236T 
are surface exposed residues involved in DDB1 binding, likely weakening this 
interaction. The T119A and D249N mutations affect the core of the protein 
and likely impair correct folding. Mutations E132K, L168P and T403M are 
surface mutations and could be involved in substrate binding. 
Table 2: Reported somatic patient mutations in the CRBN gene. (Forbes et al., 2010) 
 
 
  
Position Mutation*(Amino*Acid) Location Expected*Effect
106 p.E106* N)terminal2of2DDB12
interacting2motif
Missfolded2protein2and2
deficient2in2DDB12binding
119 p.T119A NTD:2Hydrophobic2core Minor:2Possibly2impaired2
fold
132 p.E132K NTD:2Surface2exposed2
charged2residue
Charge2reversal:2Possibly2
substrate2binding
168 p.L168P NTD:2Surface2exposed Minor:2Possibly2substrate2
binding
224 p.W224L HID:2CRBN)DDB12
interface
Possibly2impaired2DDB12
binding
236 p.N236T HID:2CRBN)DDB12
interface
Minor:2Possibly2impaired2
DDB12binding
249 p.D249N HID2core Possibly2impaired2fold2&2
DDB12binding
403 p.T403M CTD:2Surface2exposed Minor:2Possibly2impaired2
fold
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Chapter 5: General Discussion and Perspectives 
 
The structural, biochemical and in vivo data presented here provide (i) the 
molecular basis of CRL4DDB2 architecture, targeting to chromatin and 
regulation by the COP9 signalosome. (ii) Evidence that similar regulatory 
principles apply to the remainder of the CRL4 ligase family, and (iii) the 
structural basis of CRL4CRBN inhibition by the small molecule inhibitors 
thalidomide, lenalidomide and pomalidomide. Based on the work presented 
and in light of current knowledge, I will discuss how these findings integrate 
into the present understanding of CRL4 architecture and regulation, and will 
propose a model how thalidomide inhibits the CRL4CRBN ligase. 
 
Molecular architecture of CRL4 E3 ubiquitin ligases  
The structures of CRL4ADDB2 and CRL4BDDB2 presented in this work are 
the first X-ray structures of a fully assembled Cullin RING ligase (CRL) bound 
to its substrate. The structures reveal that the mobility of the ligase arm 
creates a ubiquitination hot zone around the site of damage and thereby 
insulates the substrate receptor from the E2 binding site (see Chapter 2). 
Together with the structures of the DDB1-CSA and DDB1-CRBN complexes 
(see Chapter 2 and 3) and previously available structural information on the 
CRL4 family (Li et al., 2006; Li et al., 2010; Angers et al., 2006; Scrima et al., 
2008), a architectural consensus is now emerging amongst CRL4 ligases. 
 
Structural and functional homology between CUL4A and CUL4B 
Mammalian cells express two CUL4 isoforms, CUL4A and CUL4B 
(Jackson and Xiong, 2009), which are believed to be, to a large extent, 
functionally redundant. Cul4a-/- mice are viable and show only mild 
phenotypes, while knockdown of Cul4b in Cul4a-/- MEFs results in a growth 
arrest, suggesting that the Cul4b gene is able to largely compensate for the 
loss of Cul4a (Liu et al., 2009). The CUL4A and CUL4B proteins share a high 
degree of sequence homology (83% sequence identity over 752 residues), 
and exhibit high structural similarity within the cullin fold (rmsd of 1.54 Å over 
677 residues) (see also Chapter 2 for further details). While, the major 
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difference between the two isoforms arises from a ≈190 residue N-terminal 
extension in CUL4B (Ota et al., 2004). Within the crystallized boundaries, 
CUL4A and CUL4B assemble into CRL4DDB2 ligase complexes, which are 
structurally indistinguishable from each other (Fischer et al., 2011). 
Biochemical assessment of ligase activity towards DDB2 and XPC 
ubiquitination, CSN mediated inhibition, and DNA damaged induced release 
suggests that the CUL4B protein can compensate for CUL4A in vitro (Fischer 
et al., 2011; and data not shown). Therefore, the discussion of CSN mediated 
CRL4 activation will not address specific differences between the two 
isoforms. 
Despite these similarities, the two isoforms are not entirely redundant, 
which becomes apparent in a number of human pathologies that are 
specifically associated with either CUL4A or CUL4B. For example, although 
having a functional Cul4a, X-linked mental retardation (XLMR) has been 
associated with several familial mutations in the Cul4b gene (Tarpey et al., 
2007). It was proposed that the unique N-terminus of CUL4B may be 
responsible for recruitment and CUL4B dependent degradation of a number of 
substrates involved in XLMR (Lee and Zhou, 2012). Accordingly, the CUL4B 
N-terminal domain has been shown to bind the arylhydrocarbon receptor 
(AhR), a putative substrate receptor, which recruits estrogen and androgen 
receptors for degradation (Ohtake et al., 2007). While a specific role of the 
CUL4B N-terminus can be anticipated, the structure of CRL4BDDB2 does not 
provide a rationale how a substrate could be directly recruited through the N-
terminus as a target for ubiquitination in cis. However, as dimerization has 
been described for DCAF substrate receptors (Ahn et al., 2011), more 
complex CRL4 assemblies resulting in a substrate binding mode that involves 
the N-terminus and ubiquitination in trans can not be ruled out at present. 
Further evidence for distinct roles of the two isoforms arises from mouse 
genetics: Cul4a-/- mice show increased stability in several CRL4 substrates, 
including components of the NER pathway and p21 (Liu et al., 2009). Whether 
this is due to functional differences or due to a reduction in available Cul4 
protein is currently unresolved. For example in 293T cells, cellular 
concentrations of DDB1 (323 nM) are below the combined concentrations of 
CUL4A (158 nM) and CUL4B (307 nM) (Bennett et al., 2010). In turn, in a 
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Cul4a-/- background DDB1 cellular concentrations would be expected to be 
equal or above the global pool of available Cul4 proteins and this may result 
in altered CRL4-DCAF homeostasis. In order to fully understand the 
differential roles played by Cul4a and Cul4b, further structural characterization 
of the N-terminal domain of CUL4B, as well as biochemical and functional 
studies will be required. 
Common architectural features emerge for CRL4DCAF(WD40) 
The CRL4ADDB2 ubiquitin ligase is believed to be a “special” ubiquitin 
ligase, as it does not directly recognize a protein substrate. Instead, the DDB2 
substrate receptor binds to damaged DNA and thereby recruits proteins to the 
vicinity of the ligase arm, targeting them for ubiquitination. It has been shown 
by Angers and colleagues (Angers et al., 2006) that CUL4A folds into an 
elongated, largely helical shape, forming the scaffold of the CRL4DDB2 ligase 
complex. The E2 binding protein RBX1 is located at the C-terminus of CUL4, 
while the N-terminus (aa 39-96), in conjunction with the BPB domain of DDB1, 
bridges the cullin and the adaptor protein DDB1. DDB1 then recruits the 
DCAFs (DDB1 CUL4 associated factors), which form the substrate receptors 
within the CRL4 family and confer substrate specificity to the system (see also 
Chapter 2 for more details). The available multitude of DDB1 containing 
crystal structures showed the BPB domain in a number of distinct 
conformations, leading to the hypothesis that the mobility inherent in the BPB 
domain directly translating into rotational freedom of the ligase arm (Scrima et 
al., 2008). Using the crystal structure of CRL4ADDB2 and CRL4BDDB2, we were 
able to experimentally trap the ligase arm in 3 different conformations, 
spanning an angle of 60° around an axis defined by the DDB1-BPA/BPC and 
the DDB2 domains. Moreover, using the information derived from the 11 
available medium/high resolution structures of DDB1 (Li et al., 2006; Li et al., 
2010; Angers et al., 2006; Scrima et al., 2008; Fischer et al., 2011), we were 
able to deduce that the ligase arm can rotate around 150°, creating a large 
“ubiquitination hot zone” around the site of damage. We propose that the 
overall U-shaped CRL4 assembly together with mobility of the ligase arm 
observed in the CRL4DDB2 structures as well as in the CRL4SV5v structure 
(Angers at al., 2006), is a common feature for all CRL4DCAF complexes and 
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that the structural variability within the CRL4 family originates from the 
DCAFs, which confer substrate specificity to the system.  
The structure of DDB1-CSA revealed that despite little sequence 
homology, the DDB2 and CSA proteins share striking similarities in their 
overall structural arrangement (backbone rmsd of 3.4 Å for 355 CSA/DDB2 
residues) (Fischer et al., 2011). Similar to DDB2, CSA is anchored to the 
DDB1 protein via its helix-loop-helix (HLH) motif bound to a groove between 
the BPA/BPC domains of DDB1. The majority of identified DCAFs (Higa et al., 
2006; Scrima et al., 2008; Li et al., 2010; Fischer et al., 2011) are predicted to 
comprise a WD40 propeller domain and for at least 13 of them we were able 
to identify the putative helix-loop-helix (HLH) motif preceding the propeller 
(Fischer et al., 2011) and we propose that other WD40-DCAFs will display an 
overall structural arrangement similar to that of CRL4DDB2. A helical binding 
motif has also been observed in the structure of CRL4SV5v (Angers et al., 
2006) and a helical peptide stemming from the hepatitis B protein X (HBx) 
crystallized in complex with DDB1 (Li et al., 2010). Both DCAF DDB1 binding 
epitopes attach to the same BPA/BPC groove also used by DDB2 and CSA. 
This suggests that helical binding motifs are not only common determinants of 
DCAF proteins, but are also employed by viral proteins to take control of a 
CRL4 ligase (Li et al., 2005). While the structures of DDB2 and CSA provide a 
structural rationale for understanding the architecture of WD40-DCAFs, a 
number of endogenous proteins have been predicted to be DCAFs, which do 
not fall in the WD40 β-propeller class. In order to examine how other putative 
DCAFs relate to the WD40-DCAFs DDB2 and CSA, we determined the 
structure of the DDB1-CRBN complex bound to thalidomide. 
 
Substrate receptor plasticity goes beyond WD40 β-propeller DCAFs 
The structure of DDB1-CRBN presented in this work provides the first 
atomic structure of an endogenous “non-WD40” DCAF, which shares virtually 
no homology to a WD40 β-propeller (Figure 4.2a). The crystal structure of 
CRBN has revealed significant topological similarities between the N-terminal 
domain (NTD) and the helical insertion domain (HID) of CRBN and the N-
terminal domain of a Lon protease (PDB: 3LJC), as well as between the C-
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terminal domain (CTD) of CRBN and the human Methionine-R-Sulfoxide 
reductase MsrB1 (PDB: 3MAO), despite low amino acid sequence similarity. 
Although there are structural similarities, the active site of MsrB1 is not 
conserved and at present there is no evidence for any catalytic activity of the 
CRBN protein. The DDB1 interacting motif of CRBN, while still comprising two 
helices, differs from the canonical HLH motif observed for DDB2 or CSA, 
despite also binding to the cavity between the DDB1 BPA and BPC domains. 
While the structural hallmark of endogenous DCAF proteins has so far been a 
WD40 propeller preceded by a HLH motif, with CRBN we find that other folds 
have evolved to interact with DDB1 and serve as substrate receptors to form 
functional CRL4 ligases.  
These results allow us to refine our view of DCAFs: all structurally 
characterized DDB1-DCAF complexes employ a helix-containing motif to 
mediate the DDB1-DCAF interaction (Li et al., 2006; Li et al., 2010; Scrima et 
al., 2008; Fischer et al., 2011), whether an endogenous WD40 β-propeller 
containing DCAF, a non-WD40 DCAF, or a viral protein hijacking a CRL4 
ligase. We propose the canonical HLH motif to be mainly present in WD40 
propeller containing DCAFs and likely preceding the propeller domain. As 
seen in the case of CRBN, non-canonical helices can occupy the same cavity 
in the DDB1 protein and mediate a DDB1-DCAF interaction, and further viral 
proteins can donate a helix similar to helix1 in DDB2 in order to recruit DDB1 
for a function beneficial to the virus (Li et al., 2010). The overall shape and 
form of DCAFs can vary, and while CRBN displays some similarity in size and 
overall shape to DDB2 and CSA, with dimensions of ≈ 40 Å x 40 Å length 
(Figure 4.5), other endogenous DCAFs have been predicted to be of much 
smaller size (Ifrg15), or be comprised of extended structures with additional 
domains (Cdt2, DCAF1). 
Despite architectural varieties within the known DCAFs, the overall 
assembly of the ligase complex likely maintains its U-shaped architecture as 
Rbx1, Cul4 and DDB1 contribute the scaffold. While the mobility of the ligase 
arm will help to accommodate the different DCAF architectures and 
compensate for differences in substrate positioning, it will result in spatial 
separation of substrate recognition and the ligase “active site” and thereby 
 
 
156 
does not allow for direct crosstalk between the substrate receptor and the 
ligase, thus requiring CSN to mediate CRL4 activation.  
 
Substrate dictated CSN release and CRL4 ligase activation 
CRL4 ligase complexes are linked to many cellular pathways and tight 
control of ligase activity is therefore a crucial property. As reported for other 
cullins (Morimoto et al., 2000; Podust et al., 2000; Read et al., 2000; Wu et 
al., 2000), neddylation, a modification of cullins with the small ubiquitin-like 
protein Nedd8 at a conserved lysine residue, serves as activator of CRL4 
ligases. The activation is counteracted by the COP9 signalosome (CSN), an 
8-subunit isopeptidase complex that specifically removes the Nedd8 
modification from cullins, thus rendering them inactive (Deng et al., 2000). As 
detailed in this study, CSN also inhibits the ligase and protects the substrate 
receptor from autoubiquitination in a non-enzymatic, CSN5 independent 
fashion (See Chapter 2 for more details). With CSN being a key regulator of 
cullin ligase activity, the question arises how a single complex regulates 
hundreds of specific CRLs?  
 
Substrate triggered dissociation of CSN relieves CRL4 inhibition 
A number of regulatory events have been associated with CSN, including 
posttranslational modifications and differential gene expression. 
Phosphorylation of CSN subunits has been reported (Bech-Otschir et al., 
2002; Matsuoka et al., 2007), potentially affecting CSN activity or the 
assembly of the CSN holocomplex. Furthermore, CSN6 is cleaved by 
caspases during apoptosis, although the precise role of this event remains 
elusive (da Silva Correia et al., 2007; Hetfeld et al., 2008). Despite these 
potential effects on CSN activity, the conundrum of the differential regulation 
of specific CRLs by CSN cannot be explained by a modification or regulation 
of the global CSN pool, and to our knowledge, no cullin specific CSN 
modification has been reported. Another route to achieve CRL specific 
regulation is by modulating the association of CSN with a specific ligase. It 
has been proposed that the presence of a substrate reduces or circumvents 
the association of CSN with SCFSkp2 and thereby increases the level of 
 
 
157 
neddylation (Bornstein et al., 2006). Further evidence that substrate binding is 
involved in regulating CRLs is given by similar findings with CRL2VHL (Chew 
and Hagen, 2007) and work on SCF ligase complexes (Schmidt et al., 2009). 
Our work established that for CRL4DDB2, the binding of the damaged substrate 
DNA to the substrate receptor DDB2 leads to the release of CSN and 
activation of the ligase in vitro.  We also found CSN to be physically 
dissociated from the ligase, and hence escape of CSN5 mediated 
deneddylation, non-enzymatic CRL inhibition, and Ubp12 mediated 
deubiquitinating activity (Zhou et al., 2003) in the presence of substrate. We 
were able to observe similar behavior for the CRL4CSA ligase in which the 
binding of CSB (a protein substrate rather than damaged DNA) induces CSN 
displacement and ligase activation. Therefore, we propose that this regulatory 
principle will likely extend to the remainder of the CRL4DCAF family. Supporting 
our proposition, single particle EM reconstructions of CRL4DDB2, CRL4Cdt2 and 
CRL4Ifrg15 (data not shown) indicate that substrate binding to the DCAF and 
CSN binding are mutually exclusive, all of which provides a molecular 
rationale for the observed substrate induced CSN release and CRL activation. 
 
Do similar principles apply to other CRLs? 
CSN not only regulates CRL4 ligases, but also has been associated with 
the regulation of canonical cullin ligases in general (Cul1, Cul2, Cul3, Cul4, 
and Cul5). Again, we propose that non-catalytic inhibition in conjunction with 
substrate induced CSN release is likely also a hallmark of a large number of 
other cullin ligases.  In fact, a detailed kinetic study of the CSN mediated 
deneddylation of Cul1 ligase complexes SCFFbw7 and SCFSkp2 has lead to 
very similar observations (Emberley et al., 2012). The authors show that the 
deneddylation of SCFFbw7 and SCFSkp2 is inhibited by up to 2.5fold in the 
presence of an appropriate substrate to the ligase. Further, they provide 
evidence that CSN inhibits SCF ligases independent of CSN5 mediated 
deneddylation activity, similar to our findings for CRL4. These findings are 
underlined by EM and biochemical studies of the CSN-SCFSkp2 and CSN-
SCFFbw7 complexes (Enchev et al., 2012), which not only show striking 
similarity to the overall assembly of our CSN-CRL4DDB2 EM reconstructions 
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(data not shown), but also provide additional evidence that the substrate 
triggered dissociation of CSN expands to the SCF ligase family. Together, 
these findings support a model in which CSN, employing deneddylation in 
conjunction with passive protection, inhibits Cullin RING ligases and where 
the binding of a substrate can trigger relief of this inhibition through physical 
dissociation of CSN from the ligase. In this model, the substrate dictates the 
state of CSN mediated inhibition, implying that the presence of a substrate 
would be necessary and sufficient to specifically activate the appropriate CRL 
ligase. A frequently observed feature of CRL protein substrates is the 
necessity of a posttranslational modification in order to be recognized by a 
CRL for degradation (Hon et al., 2002; Min, 2002; Wu et al., 2003; Mizushima 
et al., 2004; Hao et al., 2005; Mizushima et al., 2007). This provides another 
layer of control to the timed activation of a ligase and thereby the degradation 
of a substrate. 
 
Does CSN play a non-enzymatic role in vivo? 
While the in vitro data presented deepens our mechanistic understanding 
of CRL regulation, the situation is arguably more complex in vivo. More than 
200 CRLs have been implicated in a multitude of processes (Cardozo and 
Pagano, 2004) and their activity is likely affected by binding partners and 
posttranslational modifications (Goldenberg et al., 2004; Wertz et al., 2004; 
Matsuoka et al., 2007; Olma et al., 2009). Despite these complexities, 
genetics have provided evidence for the importance of the observed 
mechanisms in vivo. In the yeast Schizosaccharomyces pombe, csn1- and 
csn2- strains exhibit pronounced sensitivity to ionizing radiation and exhibit 
slow DNA replication, with csn5- strains having a less severe phenotype 
(Mundt et al., 1999; 2002), indicating that in addition to deneddylation a CSN 
“non-enzymatic” role also exists in S. pombe. Work in Neurospora crassa 
identified active site mutations in the csn5 JAMM domain, which assemble 
into a CSN holocomplex deficient in cullin deneddylation activity (Zhou et al., 
2012), which exhibit a less severe phenotype than a total loss of csn5. The 
authors could further demonstrate that the csn5 active site mutant not only 
rescues the CRL1FWD-1 mediated degradation of FRQ but also partially 
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rescues the stability of a number of substrate receptors, likely through the 
inhibition of autoubiquitination. These findings from plants and yeast indicate 
the potential in vivo relevance of the observed non-catalytic CSN activity in 
inhibiting CRL ligase activity. 
 
Can substrate binding trigger CSN release in vivo? 
We have shown that binding of damaged DNA to the DDB2 subunit of 
CRL4DDB2 triggers the release of CSN and the activation of the ligase in vitro. 
Furthermore, the patient mutation DDB2 (K244E) deficient in DNA binding 
does not trigger the release of CSN in vitro (Fischer et al., 2011) and in vivo 
(Takedachi et al., 2010), indicating that a mutant deficient in DNA substrate 
binding is, following UV exposure, not activated in vivo. Similar evidence for 
the role of substrate binding in relieving CSN mediated CRL inhibition has 
been found for CRL1 and CRL2 (Chew and Hagen, 2007). The authors could 
show that mutants of the substrate receptors Skp2 and VHL are defective in 
substrate binding and preferentially associate with unneddylated cullin. Our 
findings together with the in vivo results and additional in vitro experiments 
(Emberley et al., 2012; Enchev et al., 2012), support a model in which the 
binding of a substrate to a CRL ligase complex triggers dissociation of CSN 
and thereby relieve of deneddylation activity and passive non-enzymatic 
protection.  
Recent advances in proteomics (Bennett et al., 2010; Kim et al., 2011), 
biophysical and biochemical assays (Kleiger et al., 2009; Emberley et al., 
2012), and structural methods (Duda et al., 2011; Fischer et al., 2011; Enchev 
et al., 2012) have began to shed light on the complexities that govern the CRL 
ligase networks and the regulatory mechanisms involved. Despite these new 
and detailed insights, further studies will be needed to elucidate how the 
complex CRL machinery works on a cellular level and specifically to pinpoint 
how the multitude of regulatory principles contribute to tight CRL regulation in 
vivo, and how this relates to specific physiological mechanisms. 
Thorough mechanistic insights into CRL ligase architecture, function and 
regulation will also deepen our understanding of their role in human diseases 
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such as cancer and will enable researchers to ultimately design novel CRL 
targeting medications. 
 
The UPS and CRL4 as targets for therapeutic intervention 
Over the past decades tremendous efforts have been made to understand 
the critical role that posttranslational modifications (PTM) play in pathways 
driving neoplastic transformation. PTMs offer a plethora of candidates to 
pharmacologically impede tumor growth not to mention other human disease. 
While kinase inhibitors are still the largest group within PTM directed 
therapeutics, the ubiquitin proteasome system (UPS) has raised interest since 
the successful clinical evaluations of the proteasome inhibitor bortezomib 
(velcade), which was approved by the FDA for the treatment of multiple 
myeoloma in 2003 (Adams et al., 1998). Bortezomib acts at the end of the 
UPS by non-specifically blocking the degradation of poly-ubiquitinated 
substrates and thereby sensitizing rapidly dividing cells to apoptosis (Adams, 
2004). MLN4924, another UPS directed small molecule inhibitor, presently in 
clinical trials, inhibits the Nedd8 specific E1 enzyme (NAE/UBA3) preventing 
neddylation and thereby activation of the global Cullin RING ligase pool 
(Soucy et al., 2009; Bennett et al., 2010). Both compounds have limited 
specificity for biological pathways; they rather affect the overall protein 
homeostasis through accumulation of a vast number of ubiquitin ligase 
substrates. However, more precise targeting of CRLs or other components of 
the UPS would allow specifically to address a pathway involved in 
carcinogenesis or other diseases, increase efficacy while providing more 
control over adverse site effects. While the common protein-protein 
interactions involved in CRL substrate recognition have long been though to 
be undruggable, a number of groups have recently reported success in finding 
specific inhibitors to SCFCdc4, SCFMet30 and Cdc34 (Aghajan et al., 2010; 
Orlicky et al., 2010; Ceccarelli et al., 2011). Although these inhibitors are of 
still experimental nature and in the case of SCFCdc4 and SCFMet30 directed to a 
yeast protein, they serve as prototypes for specific downstream targeting 
inhibitors of the UPS. On the other hand, a proven compound in clinical 
development is thalidomide, another specific CRL inhibitor that has been 
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around for decades and was recently rediscovered as anti-cancer agent 
resulting in FDA approval for the treatment of multiple myeloma in 2006. 
Through the discovery that thalidomide targets the CRL4CRBN ligase (Ito et al., 
2010), thalidomide and its also FDA approved derivative lenalidomide 
(revlimid) became the prototype of a specific CRL4 ligase inhibitor effective in 
the treatment of human cancer. In this study we present the first atomic 
structure of the DDB1-CRBN complex, the cellular target of thalidomide, 
bound to thalidomide, lenalidomide and pomalidomide (see Chapter 4 and 
Figure 4.2). 
 
Is Thalidomide the first in class CRL inhibitor used in cancer therapy? 
Thalidomide (α-N-phtalimido-glutarimide), is a synthetic derivative of 
glutamic acid and the ancestor of a class of anti-myeloma compounds termed 
IMiDs (immunomodulatory drugs) by Cellgene corporation (Summit, NJ, USA) 
(Shortt et al., 2012) (Figure 4.3a to c). Thalidomide, despite its adverse side 
effect in causing multiple birth defects, has been rediscovered for the 
treatment of multiple myeloma (Galustian et al., 2004) and the amino 
substituted derivatives lenalidomide (revlimid, cc-5013) and pomalidomide 
(CC-4047, Actimid) were synthesized with the aim of optimizing anti-TNFα 
and anti-angiogenic properties. Clinical trials displayed a significant efficacy 
against multiple myeloma and resulted in FDA approval of thalidomide and 
lenalidomide. However, both are limited by strict prescription regulations due 
to the lack of knowledge on the mode of action and the teratogenic nature of 
IMiDs. The discovery of CRBN as the primary target of thalidomide binding 
(Ito et al., 2010) has been a milestone in understanding thalidomides 
teratogenic effects. Further, a comprehensive biophysical, biochemical and 
cellular study confirmed CRBN as a cellular target of thalidomide in anti-
myeloma treatment (Lopez-Girona et al., 2012). These structures now provide 
a detailed molecular understanding of how these compounds bind with high 
affinity to the CRBN substrate receptor of CRL4CRBN. They also represent the 
first structure of an FDA approved compound with evident inhibitory function 
that targets a specific CRL ligase and provide the grounds to explore how this 
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inhibition is achieved on a molecular basis, and what its underlying cellular 
mode of action may be.  	
  	
  
Structure-function analysis of thalidomide derivatives 
Despite minor differences between the compounds thalidomide and its 
derivatives lenalidomide (one additional amino group at the C4 position of the 
phtaloyl ring, without the carbonyl oxygen at C3) and pomalidomide (a 
combination of thalidomide and lenalidomide), cellular and clinical data 
suggest a significantly increased potency of lenalidomide (Lopez-Girona et al., 
2012 and references within) over thalidomide. Pomalidomide has further been 
assigned a 10-fold increase in potency over lenalidomide through a number of 
cellular assays (Lopez-Girona et al., 2012). Competition assays of 
lenalidomide, or pomalidomide, for CRBN binding to thalidomide analog 
affinity beads (Ito et al., 2010; Lopez-Girona et al., 2012) revealed similar 
affinities of lenalidomide and pomalidomide to CRBN, but found an increased 
affinity compared to thalidomide, potentially explaining the efficacy gain for the 
two derivatives over thalidomide. However, even when incorporating our own 
structural data we could not find any explanations for the difference in potency 
between lenalidomide and pomalidomide. To fully resolve the types of 
chemical interactions and their contributions we require more precise binding 
studies and higher resolution crystal structures in the future. 
Differences in efficacy could also arise from off-target effects; the specific 
linkage off the affinity beads used by Ito and colleagues (Ito et al., 2010), 
although compatible with CRBN binding, would not resolve any binding 
mediated by the phtaloyl ring due to steric clashes. In light of the minor 
variations among the compounds and the similar overall binding mode, the 
following discussion will focus on our high resolution structure of DDB1-CRBN 
bound to thalidomide. 
 
Stereoselectivity of the CRBN-Thalidomide interaction 
All three compounds are chiral molecules and although enantioselective 
synthesis has been achieved, the compounds rapidly racemize in vivo (Bosch 
et al., 2008) preventing stereoselective administration. The thalidomide R-
 
 
163 
form has often been considered as the “good” enantiomer responsible for 
sedative effects (Höglund et al., 1998; Eriksson et al., 2000), while the S-
enantiomer has commonly been associated with teratogenicity (Heger et al., 
1994). The presented structures provide a rational of stereoselective 
thalidomide binding to CRBN, the shape of the binding pocket accommodates 
the S-enantiomer of thalidomide, while binding of a R-enantiomer would be 
disfavored and rather unlikely (Figure 4.2). Further evidence for the selectivity 
is provided by the observation that initial crystallization screens with 
enantioselective synthesized S-thalidomide and R-thalidomide only yielded 
crystals for the S-enantiomer and the electron density maps suggest the 
presence of the S-enantiomer of thalidomide, lenalidomide and pomalidomide, 
despite the fact that the later were provided as a racemate. Through the use 
of a non-racemic pomalidomide derivative Lopez-Girona and colleagues 
(Lopez-Girona et al., 2012), could demonstrate that a S-enantiomer of methyl-
pomalidomide stimulates Interleukin-2 (IL2) production in activated T cells 
compared to a R-methyl-pomalidomide (IC50 values of 0.02 µM compared to 
>10 µM) and that this corresponds to a similar rank order in binding to CRBN. 
These results provide strong evidence that only the S-enantiomer of 
thalidomide and derivatives can bind to CRBN and as such, is inducing 
teratogenicity and anti-myeloma effects. 
 
Does thalidomide employ CSN to inhibit CRL4CRBN? 
It has been observed that thalidomide inhibits autoubiquitination of CRBN 
in vivo (Ito et al., 2010; Lopez-Girona et al., 2012) and that CRBN 
autoubiquitination is DDB1 dependent. Despite reported differences in 
efficacy, our structures, biochemical assays and the published cellular CRBN 
autoubiquitination assays suggest that thalidomide, lenalidomide and 
pomalidomide have similar mechanistic effects on CRBN. In this discussion I 
will therefore be focusing on thalidomide alone. The inhibition of DDB1 
dependent CRBN autoubiquitination has been a commonly observed effect of 
thalidomide administration in vivo (Ito et al., 2010; Lopez-Girona et al., 2012). 
This raises the question, however, how this small molecule effectively inhibits 
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the activity of a CRL4 ubiquitin ligase when binding to the substrate receptor 
even though the receptor itself is insulated from the ligase active site?  
Our work shows that in vitro thalidomide does not inhibit the CRL4CRBN 
ligase activity per se. Accordingly, the structures determined do not provide 
any evidence for a conformational change induced by thalidomide binding that 
could translate into ligase inhibition. Instead, we find that CRL4CRBN is, similar 
to CRL4DDB2/CSA, inhibited through binding of the COP9 signalosome (CSN) to 
CRL4CRBN and that this inhibition is not relieved upon binding of thalidomide. 
The observed substrate dependent activation of other CRL ligases (Chew and 
Hagen, 2007; Fischer et al., 2011; Emberley et al., 2012; Enchev et al., 2012) 
suggests that binding of an as yet unknown substrate to the CRBN substrate 
receptor could lead to dissociation of CSN from CRL4CRBN, thereby activating 
the ubiquitin ligase. Based on these observations, we propose that 
thalidomide binding to CRBN, rather then inhibiting the ligase activity per se, 
blocks binding of the unknown substrate to the CRBN substrate receptor and 
thereby prevents CSN mediated CRL4CRBN activation. This results in a 
multilayered CRL4CRBN inhibition, where the substrate recruitment to the 
ligase is inhibited and, in turn, CSN is not dissociated from the ligase. The 
observed discrepancy between thalidomide-induced CRL4CRBN inhibition in 
vivo (Ito et al., 2010; Lopez-Girona et al., 2012) and the absence of such an 
effect of thalidomide on ligase activity in vitro, is fully anticipated by the 
proposed model. To validate the proposed mechanism of CRL4CRBN inhibition 
by thalidomide, lenalidomide and pomalidomide knowledge of the missing 
cellular substrate will be crucial.  
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Conclusions and future work 
In this thesis I have elucidated the molecular architecture and function of 
the CRL4DDB2 ligase and the mechanism of substrate induced CSN 
dissociation and CRL ligase activation. Moreover, the crystal structures of 
DDB1-CSA and DDB1-CRBN expand our architectural understanding of 
CRL4DCAF ligase complexes beyond WD40 comprising DCAFs, and refine the 
view on general principles that govern CRL4 architecture. Structural and 
biochemical studies on the CRL4CRBN inhibitors thalidomide, lenalidomide and 
pomalidomide, demonstrate how these FDA approved small molecules target 
a specific CRL4 ubiquitin ligase. On the basis of our findings, we propose the 
following model for CSN mediated CRL4 ligase activation: the interplay with 
the substrate and a proposed mode of inhibition by small molecules. We 
further envision that our model expands to other CRL ligase complexes, which 
is supported by recent literature and unpublished data. 
In complex with CSN (Figure 5.1), a CRL4 ubiquitin ligase is held in an 
inactive state, whereat CSN enzymatically deneddylates the cullin and 
physically blocks access of Rbx1 to an ubiquitin charged E2 (Fischer et al., 
2011; Enchev et al., 2012). Binding of a substrate to the DCAF induces the 
physical displacement of CSN from the CRL4 ligase (see also Chapter 3 for 
more details) and, together with subsequent neddylation of the cullin will result 
in an active CRL4 ligase complex. The active ligase will in turn readily 
ubiquitinate substrates recruited to the ubiquitination zone and ultimately the 
DCAF itself. Thalidomide acts as a substrate competitive inhibitor to the 
DCAF CRBN and while blocking binding of a putative substrate, will 
simultaneously inhibit the dissociation of CSN, neddylation and therefore 
activation of the CRL ligase. The thalidomide bound CRL4 complex will be 
locked in a CSN bound, inactive state. 
 The substrate triggered relieve of CSN inhibition has become evident not 
only for CRL4 but also for cullins in general (Fischer et al., 2011; Emberley et 
al., 2012; Enchev et al., 2012) and provides an elegant mechanism to explain 
how a single regulatory enzyme can (differentially) control the multitude of 
CRL ligase complexes present in a cell. An important question, which goes 
beyond the scope of my thesis, concerns the contributions of the observed 
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inhibitory principles and the relevance of substrate triggered CSN release in 
vivo. To better understand how CSN interacts with and acts on specific CRL 
ligase complexes, detailed kinetic studies on CSN mediated CRL regulation 
for a large set of CRL complexes are needed. Correlation of CRL-CSN 
kinetics with cellular concentrations of CRL components (Bennett et al., 
2010), would provide insights into the dynamics of CRL regulation by CSN. 
High resolution structural information on CSN and CSN-CRL complexes of 
sufficient resolution would further provide insights on how this large multi-
protein complex is able to interact with and specifically regulate the large 
number CRLs. 
In order to collect evidence for the proposed model of thalidomide action, it 
would be necessary to find the substrate of CRBN, which in return could be 
used to show CSN displacement in vitro. A profound knowledge of cellular 
ligase substrates will also be required to unravel the pleiotropic effects that 
have been associated with thalidomide in cancer therapy and development. 
Despite the description of a number of putative substrates or proteins affected 
by thalidomide treatment, including Fgf8 (Ito et al., 2010), PRKAA1 (Lee et al., 
2013), or BKCα (Jo et al., 2005), to our knowledge no evidence for a direct 
CRL4CRBN ligase substrate has been obtained. Finally, I suggest to use 
proteome wide screens to discover protein substrates of CRL4CRBN and to 
decipher the network involved in thalidomide action.  
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Figure 5.1: Proposed model of CSN mediated CRL4 regulation and thalidomide 
mediated CRL4CRBN inhibition. CRL4 is held in an CSN bound, inactive state. Binding of a 
substrate will physically dissociate CSN from the ligase and allow for neddylation of the cullin, 
which will result in an active CRL4 ligase complex. Thalidomide will bind to CRBN in an 
substrate competitive manner, thereby blocking the binding of a substrate and subsequent 
CSN dissociation and ligase activation. 
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